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Neutrophils are the most abundant leukocyte in mammals and represent one of the first lines 
of defence against invading microorganisms. In recent years, it has become clear that 
neutrophils are not only responsible for the killing of pathogens, but that they also play an 
important role in shaping adaptive immune responses. The aim of this project was to 
determine the role of the neutrophil-derived host defence peptide, cathelicidin, in the 
generation of Th17 responses during inflammation. Following inoculation with heat-killed 
Salmonella typhimurium, cathelicidin knockout mice cannot produce IL-17 and show 
increased IFNγ, whereas other cytokines are produced normally. Ex vivo, I show that 
cathelicidin is a novel Th17/Tc17 differentiation enhancing factor, which acts directly on both 
CD4+ and CD8+ T cells to increase their activation status, protect them from death and 
concentration-dependently upregulate IL-17 production. Gene expression analysis revealed 
that cathelicidin downregulates the expression of several Th1-related genes and upregulates 
the aryl hydrocarbon receptor (AHR), a known regulator of Th17 differentiation. The addition 
of an AHR antagonist to our in vitro cultures abolishes the boost to IL-17 production normally 
induced by cathelicidin. I provide further evidence that suggests lymph node neutrophils are 
the cellular source of cathelicidin, which are responsible for amplifying type-17 responses 
during inflammation. These data contribute to our understanding of how lymph node 























The immune system is typically divided into two categories: the innate and adaptive. The 
innate response consists of non-specific defence mechanisms that occur immediately after 
immune challenge, whereas the adaptive response occurs slightly later and displays great 
specificity. Cross talk between the two systems is critical for protecting the host against 
infection. The aim of this project was to determine how two different immune cells, 
neutrophils and T cells, interact and influence each other’s behaviour. Neutrophils are the 
most abundant white blood cell type and constitute one of the first lines of defence as part 
of the innate immune response, whereas T cells are major players of adaptive immunity. 
More specifically, I sought to determine how a host defence peptide produced by 
neutrophils, called cathelicidin, is involved in driving the generation of a particularly 
damaging subset of T cells (Th17). Th17 cells are characterized by the production of IL-17, 
which has been shown to have many harmful effects, particularly during autoimmune 
disease. Mice that lack cathelicidin cannot produce IL-17 during inflammation. Here, I show 
that cathelicidin acts directly on the T cells, inducing several changes that lead to the 
development of Th17 features. Furthermore, I provide evidence that suggests neutrophil-
derived cathelicidin acts on T cells and exerts its effects in a particular location: the lymph 
nodes. This data contributes to our understanding of how neutrophils influence the 
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The immune system is typically divided into two branches: innate (non-specific) and adaptive 
(acquired) immunity, both of which efficiently cooperate to protect the host from infection1. 
The innate immune system dates back to the first multicellular organisms and is the most 
evolutionary conserved2. It refers to non-specific physical, chemical and cellular defence 
mechanisms, which contribute to the generation of a rapid inflammatory response 
immediately after immune challenge1,3. These include physical barriers (e.g. skin, epithelial 
and mucosal linings of respiratory and gastrointestinal tracts), phagocytic cells (e.g. 
macrophages), the complement system and soluble proteins1,3. The innate immune system 
is activated following recognition of highly conserved molecular structures, or pathogen 
associated molecular patterns (PAMPs), by pathogen recognition receptors (PRRs), such as 
Toll-like receptors (TLRs)1,4. 
 
On the other hand, adaptive immunity refers to the more complex, antigen-specific immune 
response and can only be found in jawed fish and vertebrates5. The hallmarks of the adaptive 
immune system are the clonal expansion of B and T lymphocytes bearing antigen-specific 
receptors and the development of immunological memory1,6. Receptor specificity is 
generated by the somatic recombination and hypermutation of gene segments that encode 
B and T cell receptors7. B lymphocytes secrete antibodies that bind to antigens displayed by 
pathogens or extracellularly on infected cells, triggering the activation of mechanisms that 
attack and destroy them1. T lymphocytes help activate B cells, secrete cytokines and trigger 
programmed cell death pathways1. Unlike the innate immune system, adaptive immunity 
requires several days to mount an efficient response following its first pathogen encounter1. 
However, the effects of the adaptive immune system are long-lasting, highly specific and 





1.1 T Cells   
 
1.1.1 T cell development  
 
T cells are derived from haematopoietic stem cells that develop in the bone marrow and 
migrate to the thymus, where they undergo a series of maturation steps dependent on a 
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number of signalling events and molecular interactions with the local stromal cell 
compartment9. Receptor specificity is generated by somatic rearrangement of the gene loci 
encoding the T cell receptor (TCR) a, b, g and d chains, which give rise to either αβ or γδ 
lineages7.  
 
Double negative (DN) cells represent the earliest developing thymocytes; they lack the co-
receptors CD4 and CD8, but can be subdivided based on their expression of CD44 and CD259. 
CD44-CD25+ cells undergo b-selection, which selects cells that have successfully rearranged 
their TCR b chain locus9. Formation of a pre-TCR (pairing of the b chain with a surrogate a 
chain) promotes their survival and proliferation9. This induces the upregulation and 
expression of both CD4 and CD89. These double positive (DP) cells then rearrange their TCR 
a chain to produce an ab TCR9.  
 
Positive selection of maturing T cells results in the survival of those capable of recognising 
and engaging with MHC-peptide complexes with appropriate affinity10. Conversely, negative 
selection ensures the elimination of thymocytes that bind self-peptide-MHC (major 
histocompatibility complex) complexes so strongly as to be potentially autoreactive10. The 
vast majority of developing T cells die by apoptosis during this process9. Following selection, 
the down-regulation of either co-receptor produces naïve CD4+ or CD8+ lymphocytes that 
exit the thymus and circulate the periphery9.  
 
Naïve T cells constantly circulate between secondary lymphoid organs via the blood and 
lymph in search of their cognate antigens11. However, they have also been shown to routinely 
traffic through non-lymphoid organs as well, including the liver, lungs and intestine11,12.  
Migration of T cells from the blood to these sites follows the general adhesion and signalling 
steps of cell trafficking: selectin-mediated rolling, chemokine-triggered activation and 
integrin-dependent arrest13.  
 
 
1.1.2 T cell activation  
 
T cell activation results in the proliferation and differentiation of naïve lymphocytes, and is 
critical for the initiation and regulation of the immune response (Figure 1.1)8. Antigen-
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presenting cells (APCs) such as dendritic cells (DCs), patrol the periphery to capture and 
process antigen8. Once captured, they then migrate to the lymphoid organs where they 
present antigen peptides in complex with MHC molecules to naïve T cells8. Interactions 
between the TCR, CD4/CD8 co-receptor and antigen-MHC complex results in the activation 
of downstream signalling pathways that promote T cell activation and differentiation8.  
 
In addition to antigen, a second co-stimulatory signal is also required to protect against 
premature or excessive T cell activation8. CD28 is expressed on all naïve T helper cells and its 
ligands, CD80 and CD86, are upregulated upon DC activation14. Furthermore, T cells that 
recognise antigen strongly specifically upregulate the expression of 4-1BB (CD137) and 
OX408,15. Their respective ligands are typically found on APCs following pathogen recognition 
and provide survival signals to primed T cells8,15. These TCR and co-stimulatory signals induce 






Antigen dose, the type of APC and time of differentiation have all been shown to contribute 
to the polarization of naive T cells16. For example, DCs are more potent inducers of IL-2 
production and therefore stimulate the proliferation of T cells better than macrophages17. 












Figure 1.1: T cell activation by a dendritic cell. DCs present antigen peptides in complex with MHC 
molecules to naïve T cells. Interactions between the TCR, CD4/CD8 co-receptor and the antigen-
MHC complex activate the T cell. A co-stimulatory signal mediated by CD28 is also required. CTLA4 
is an inhibitory receptor that competes for CD28 and negatively regulates T cell activation. Binding 
of OX40 and 4-1BB to their respective ligands provide survival signals.  
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1.1.3 CD4+ T helper and CD8+ cytotoxic T cells  
 
T lymphocytes can be broadly subdivided into CD4+ T helper cells and cytotoxic CD8+ T cells1,8. 
CD4+ T helper cells are essential for the development of adaptive immunity: they orchestrate 
a coordinated response from multiple other cell types via the production of diverse, 
pleiotropic soluble mediators18. For example, T helper cells play a key role in the maturation 
of B cells into antibody-producing plasma cells, as well as the recruitment of other immune 
leukocytes to sites of infection/inflammation1,8. CD4+ T cells recognise antigen peptides 
presented on MHC class II molecules by APCs and upon activation, can differentiate into 
several distinct subsets that produce different panels of cytokines1,8.   
 
Conversely, cytotoxic CD8+ T lymphocytes recognise antigen peptides presented by MHC 
class I molecules, which is expressed by all nucleated cells1,8. They are critical for immune 
defence against intracellular pathogens and tumour surveillance and employ multiple 
mechanisms to kill infected or malignant cells1,19. For instance, they produce TNFa and IFNg, 
which exhibit anti-tumour and anti-viral activity respectively20,21. CD8+ T cells can also form 
an immunological synapse with infected cells, into which they release the contents of 
cytotoxic granules (perforin and granzymes)19. Perforin forms a pore in the membrane of the 
target cell, which allows serine proteases to enter and induce apoptosis19,22. Activated CD8+ 
T lymphocytes can also promote apoptosis via interactions between Fas ligand (FasL) and 
Fas19. Ligation of CD8+ FasL and target cell Fas induces the recruitment of the adaptor protein 
FADD (Fas-associated death domain) and binding of procaspase-8, resulting in the formation 
of the death-inducing signalling complex (DISC)23. This leads to the activation of effector 
caspase-3 by active caspase-8 and programmed cell death23.  
 
 
1.1.4 T helper cell subsets 
 
In 1986, Coffman and Mossman suggested that different subpopulations of CD4+ T helper 
cells possessed distinct cytokine signatures that could differentially shape immune 
responses24. Two subsets were initially identified: Th1 and Th224. Furthermore, they 
postulated that naïve T helper cells are not pre-determined to be either Th1 or Th224. Instead, 
the environment in which they encounter antigen dictates their subsequent fate24. Since 
then, it has been established that the effector CD4+ T cell population is highly heterogenous25. 
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A number of other T helper cell subsets have subsequently been identified based on the 
cytokines and transcription factors required for differentiation, the cytokines they produce, 
as well as their physiological function (Figure 1.2)25.  
 
Th1 lymphocytes are the primary producers of IFNg and are critical for host immunity against 
replicating intracellular pathogens, such as Salmonella typhimurium and Mycobacterium 
tuberculosis26. Naïve CD4+ T cells are driven to differentiate towards the Th1 lineage by IL-12 
and IFNg27. IFNg activates the STAT1 (signal transducer and activator of transcription 1) 
signalling pathway and induces the expression of T-bet, the master transcription factor 
required for Th1 polarization28. IL-12 activates STAT4, which together with T-bet, promotes 
the production of IFNg and suppresses Th2 development by downregulating GATA329,30. Th1-
derived IFNg creates a positive feedback loop that promotes further Th1 responses, as well 
as activates and enhances the microbicidal activity of macrophages to combat infection31.   
 
Th2 cells are important for the eradication of helminths and extracellular parasites, but have 
also been implicated in the pathogenesis of asthma and allergy26. Th2 differentiation requires 
IL-432. IL-4 activates STAT6, which upregulates the expression GATA333. GATA3 is 
indispensable for Th2 development; differentiation of naïve T cells is diverted towards the 
Th1 lineage in GATA3-deficient mice34. GATA3 suppresses Th1 differentiation by 
downregulating STAT4 and inhibiting IFNg, but together with STAT6, plays additional roles in 
the transcription of Th2-specific genes, including the type 2 cytokines IL-4, IL-5 and IL-1335,36. 
IL-4 and IL-13 promote B-cell proliferation and stimulate antibody production and class-
switching to IgE37. IL-5 stimulates bone marrow production of eosinophils, as well as their 
activation and chemotaxis to affected tissues38. IL-13 enhances mucus production and is 
responsible for helminth expulsion and airway hypersensitivity26.  
 
The Th1/Th2 paradigm was re-evaluated and extended in light of the identification of the 
Th17 subset in 200539. Th17 cells protect the host at mucosal surfaces against extracellular 
bacteria and fungi26. As their name suggests, Th17 lymphocytes produce large quantities of 
the pro-inflammatory cytokine IL-17, which has also been shown to drive immunopathology 
in various autoimmune conditions such as multiple sclerosis (MS), rheumatoid arthritis (RA) 
and psoriasis39,40. In mice, early commitment to the Th17 lineage requires TGFb and IL-6, 
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which activates STAT341. STAT3 upregulates IL-23R and the Th17 master transcriptional 
regulator, RORgt, which in turn induces the expression of IL-1742,43. Differentiation of human 
Th17 cells also requires IL-1b44. Despite minor differences in cytokine requirements, the 
molecular mechanisms responsible for inducing IL-17 production in human CD4+ T cells are 
similar to those in mice. 
 
Regulatory T cells (Tregs) are critical for maintaining immune homeostasis and promoting 
tolerance26. More specifically, Tregs secrete a number of immunomodulatory proteins (IL-10 
and TGFb) that downregulate the activity of other pro-inflammatory effector cells by 
suppressing their activation, proliferation and cytokine production26. For example, Treg-
derived IL-10 inhibits intestinal inflammation in a T cell transfer model of colitis45. Tregs 
constitutively express CD25 (IL-2Ra chain) and CTLA4, which serve both as markers for this 
subset, as well their regulatory function46,47. Natural Tregs (nTreg) develop in the thymus and 
require the engagement of CD28 and expression of the transcription factor FOXP3 (Forkhead 
Box P3) for their development26,48. However, strong TCR signalling, suboptimal co-stimulation 
and high concentrations of TGFb have been shown to induce the expression of FOXP3 in naïve 
T cells in vitro, as well as in the periphery49,50. These induced Tregs (iTreg) are phenotypically 
and functionally similar to thymic-derived nTreg, in that they are anergic, suppressive and 
capable of inhibiting disease in vivo: Chen et al. demonstrated that TGFb-induced Tregs 
prevented the development of pathogenesis in a mouse model of allergic asthma, as well as 
suppressed antigen-specific CD4+ T cell proliferation in an ovalbumin (OVA) peptide TCR 
transgenic adoptive transfer model49.   
 
Several other T helper cell subsets have been identified, including Th9, Th22 and T follicular 
helper (Tfh) cells26. Th9 lymphocytes are one of the most recently discovered and secrete 
large quantities of IL-9, a growth factor historically associated with the Th2 phenotype51. 
Differentiated Th2 lymphocytes can undergo Th9 polarization when stimulated with TGFβ, 
however, naïve CD4+ T cells can also be driven towards the Th9 lineage by TGFβ and IL-452. 
Th22 lymphocytes produce IL-22, which acts on non-haematopoietic cells such as epithelial 
cells and keratinocytes to promote wound healing and maintain barrier integrity53,54. The aryl 
hydrocarbon receptor (AHR) drives Th22 differentiation, but the polarizing cytokines 
required by this lineage remain unknown53. Finally, T follicular helper (Tfh) cells can be found 
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in the secondary lymphoid organs and play essential roles in the formation of germinal 
centres and B cell antibody production55. Tfh lymphocytes require IL-21 and IL-6 for their 
differentiation, which induces the expression of the Bcl6 (B Cell Lymphoma 6) transcription 
factor56. 
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Figure 1.2: CD4+ T helper and regulatory subsets. Naive CD4+ T cells can differentiate into distinct 
subsets depending on the cytokine environment. These are characterized by their expression of 
lineage-specific transcriptional regulators, as well as the secretion of key cytokines. GC: germinal 
centre 
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1.2 Th17 Cells 
 
1.2.1 Th17 differentiation 
 
Th17 polarization can be split into three phases: 1) differentiation, mediated by IL-6 and/or 
TGFb and IL-1b 2) IL-21-induced self-amplification, 3) and stabilisation, which is driven by IL-
23 (Figure 1.3)26.  
 
IL-6 plays an indispensable role in initiating Th17 differentiation by activating STAT3, which 
drives the transcription of RORγt26. Humans with STAT3 mutations have lower numbers of IL-
17-producing T cells and as a result, are prone to recurrent opportunistic pulmonary 
infections57. Furthermore, STAT3 ablation in CD4+ T cells results in increased expression of T-
bet and FOXP3, as well as protection against several autoimmune pathologies, such as EAE 
(experimental autoimmune encephalomyelitis, the mouse model of MS)58,59. In addition to 
driving RORγt expression, STAT3 can also bind to the IL-17A and IL-17F promoters, thereby 
directly promoting their expression60.  
 
RORgt is the master regulator of Th17 differentiation: ectopic expression of RORC2 in primary 
human T cells induces a cytokine and chemokine receptor profile consistent with bona fide 
human Th17 cells61. Unlike STAT3, RORγt-deficiency leads to restricted, but not complete 
interruption, of Th17 cytokine expression62.  
 
TGFb is also critical for Th17 development: mice over-expressing TGFb generate more Th17 
cells, whereas those with defective TGFb signalling display profoundly impaired Th17 
differentiation in vivo63,64. TGFβ plays an important but indirect role by suppressing T-bet and 
GATA3, thereby inhibiting CD4+ T cells from adopting alternate Th1 or Th2 cell fates65. 
Moreover, one study has shown that TGFβ inhibits SOCS3, a negative regulator of STAT3 
signalling and therefore Th17 differentiation66. However, this cytokine also plays critical roles 
in Treg polarization67. More specifically, TGFβ alone and at high concentrations induces 
FOXP3 expression, whereas low concentrations of TGFβ and the presence of IL-6 enhance 
STAT3 activation and upregulates RORgt67. 
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There has been some debate as to the absolute requirement for TGFb during human Th17 
development. For example, one group has shown that TGFβ inhibited IL-17 production in 
memory T cells when added alone or in combination with another Th17-polarizing cytokine 
(IL-1β, IL-23 or IL-6)68. Furthermore, Chen et al. demonstrated that naïve human T cells failed 
to differentiate in response to TGFb and IL-6, despite the fact that they promoted RORgt 
expression69. Some studies suggest that IL-1β can substitute the effect of TGF-β in driving 
Th17 differentiation: Acosta Rodriguez and colleagues demonstrated that IL-1β and IL-6 were 
essential for inducing IL-17 production in cell-sorted naïve human T cells70. However, Manel 
et al. found that TGFb, together with IL-23 and IL-1b induced human Th17 differentiation 
under serum-free conditions71. They postulated that culture medium contained serum-
derived TGFb or AHR ligands, which was responsible for previously inaccurate findings that 
led some to conclude that this cytokine was not required71. 
 
The second, self-amplification phase of Th17 differentiation is crucial for mounting a robust 
immune response26. This is driven by IL-21, which is produced in significant amounts by the 
Th17 cells themselves72. Unlike IFNg and IL-4, which are capable of creating positive feedback 
loops during Th1 and Th2 differentiation respectively, IL-17 does not amplify Th17 
polarization73. This is because IL-17 is neither a growth nor a differentiation factor, and its 
receptor is not expressed on T cells73. IL-21 is induced by IL-6 in activated T cells in a STAT3-
dependent process and has been shown to suppress FOXP3 expression and inhibit IFNγ 
production in naïve CD4+ T cells, thereby promoting Th17 development whilst simultaneously 
antagonising differentiation of other cell lineages72. IL-21 deficiency impairs Th17 
differentiation and protects against EAE72. However, some studies suggest that IL-21 is not 
an absolute requirement for Th17 development: Sondereggar and colleagues demonstrated 
that the differentiation of IL-17-producing CD4+ T cells, their recruitment to inflamed organs 
and the development of autoimmune disease was not affected in Il21R–/– and Il21–/– mice74.  
 
The final stage of Th17 development is driven by IL-23, which is produced predominantly by 
activated APCs in response to exogenous or endogenous stress signals26. IL-23 is unable to 
induce Th17 differentiation on its own; naïve CD4+ T cells are not responsive to IL-23 because 
they do not express the IL-23 receptor (IL-23R), which is induced by IL-6 and IL-2175. However, 
several reports have shown that IL-23 synergizes with other Th17 differentiation factors to 
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stabilize the population by activating or maintaining effector function genes (Rorc, Il17 and 
Il23r), whilst repressing those that destabilize the Th17 lineage (Il2, Il27)76. Indeed, IL-23R-
deficient Th17 cells become arrested at an early activation stage, are unable to downregulate 
IL-2 and fail to maintain their IL-17 expression77. In addition, Sun and colleagues recently 
demonstrated that RORγt also contributes to the maintenance of pathogenicity of Th17 cells 
by suppressing IL-10 production78.    
 
Several other transcription factors have been implicated in Th17 development26. RORa is 
induced by IL-6/TGFb, and together with RORgt, synergistically enhances Th17 differentiation 
by promoting the expression of IL-1762. It has been suggested that the residual IL-17 
production observed in RORγt-deficient cells is dependent on the activity of RORα62. 
Interestingly, mice deficient for both RORa and RORgt show complete inhibition of Th17 
differentiation62.  
 
AHR, a ligand-activated transcription factor that integrates environmental, dietary , microbial 
and metabolic cues, has also been shown to promote Th17 polarization26. Treatment of 
mouse CD4+ T cells cultured under Th17-driving conditions with AHR ligands such as FICZ, 
increased the percentage of IL-17+ lymphocytes and enhanced autoimmune pathology 
during EAE79. Furthermore, Veldhoen et al. demonstrated that culturing T cells in Iscove's 
modified Dulbecco's medium (IMDM), which is richer in aromatic amino acids that give rise 
to natural AHR agonists, resulted in higher Th17 expansion compared to RPMI80. However, 
loss of AHR does not cause complete abortion of Th17 differentiation, although this has been 
associated with a loss of IL-22 expression79. Kimura and colleagues suggested that AHR acts 
indirectly to inhibit the activity of STAT1 by acting as an E3 ubiquitin ligase, targeting it for 
degradation and consequently suppressing Th1 development81.  
 
BATF is also thought to play an important role during Th17 polarization: T cells from BATF 
knockout mice are incapable of inducing the expression of RORgt and IL-21 and are resistant 
to EAE82. Similarly, IRF4-deficiency in CD4+ T helper cells leads to the downregulation of IL-
23R and RORgt, which characterises a profound intrinsic defect in IL-17 production and in the 
autocrine IL-21 loop83. Mudter and colleagues demonstrated that IRF4 directly binds to the 
IL-17 promoter and induces the mucosal expression of this cytokine, which subsequently 
drives Th17-dependent colitis84.   





1.2.2 Negative regulation of Th17 differentiation 
 
Numerous factors associated with the development of other T helper cell subsets are potent 
inhibitors of Th17 differentiation. IFNg increases T-bet expression, which subsequently 
prevents IL-23-mediated expansion of Th17 lymphocytes in the intestine85. IL-27 is another 
classical Th1-associated cytokine produced by macrophages and DCs, that blocks the initial 
stages of Th17 differentiation by directly suppressing RORγt and RORα in a STAT1-dependent 
manner86. However, committed IL-23R+ Th17 cells downregulate IL-27R and are therefore 
resistant to IL-27-mediated suppression87. In addition, IL-2 signalling induces STAT5, which 
can displace STAT3 from the IL-17 promoter and subsequently repress its transcription88. 
Cytokines associated with the Th2 lineage also inhibit Th17 polarization. For instance, IL-4 
selectively suppresses the transcription and secretion of Th17-polarizing cytokines such as 


















Figure 1.3: Mouse Th17 differentiation. Th17 polarization in mice can be split into three phases. 
Differentiation is mediated by IL-6 and TGFb, which activate STAT3 and induce the expression of 
RORɣt. The self-amplification phase is driven by IL-21. IL-23 is responsible for the expansion and 
stabilisation of the Th17 phenotype.  
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1.2.3 Microbiome-dependent regulation of Th17 cells 
 
During homeostasis, Th17 cells are predominantly located at barrier sites, such as in the skin 
and gastrointestinal tract43. The frequency of these barrier-resident Th17 lymphocytes is 
dramatically reduced in germ-free (GF) mice, suggesting that their development is 
dependent on commensal bacterial colonization90. Specific species have been shown to drive 
Th17 differentiation90. For example, Ivanov et al. established that segmented filamentous 
bacteria (SFB) are sufficient to reconstitute the Th17 population, which homed to the lamina 
propria of both the small and large intestines in GF mice following colonization91. SFB are 
Gram-positive, spore-forming microorganisms that are closely related to Clostridia and 
Bacteroides species91. SFB induce the upregulation of several genes in epithelial cells, 
including serum amyloid antigen (SAA), which promotes the development of Th17 
lymphocytes by promoting the production of IL-1b by dendritic cells92,93. Commensal 
dysbiosis and decreased levels of SFB have been observed in mice fed a high-fat diet, which 
correlates with a reduced number of Th17 cells92,94. Furthermore, SFB-induced Th17 
lymphocytes were shown to exacerbate disease in a mouse model of arthritis92,95. However, 
SFB can only be detected in humans during the first 36 months after birth and as such, the 
role this bacterial species plays in inducing the generation of intestinal Th17 cells is 
controversial92.  
 
Adenosine 5’-triphosphate (ATP)-producing bacteria have also been shown to promote the 
accumulation of Th17 cells within the lamina propria96. Atarashi and colleagues 
demonstrated that systemic or rectal administration of ATP into GF mice activated a unique 
subset of CD70high CD11clow cells that enhanced Th17 differentiation, resulting in the 
exacerbation of T cell-mediated colitis97.  
 
 




As their name suggests, Th17 cells produce IL-1739. IL-17 is part of a family of six related 
cytokines (IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17-F), all of which possess conserved 
residues in their C-terminal region98. CD4+ T cells can express IL-17A and IL-17F, which are 
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highly homologous and can form three different disulphide-linked dimers (IL-17F/F, IL-17A/A, 
IL-17F/A)98. All three dimeric forms of IL-17 trigger qualitatively similar signalling pathways98. 
However, IL-17A homodimers are considered more potent than IL-17F99.  
 
The IL-17 receptor family consists of five members (IL-17RA, IL-17RB, IL-17RC, IL-17RD and 
IL-17RE)100. IL-17A and IL-17F signal through a heteromeric receptor complex consisting of 
the IL-17RA and IL-17RC chains, both of which are single transmembrane proteins and 
ubiquitously expressed in various cell types100. The absence of either chain has been shown 
to prevent IL-17-driven pro-inflammatory cytokine secretion101. Other receptors including IL-
17RB and IL-17RE have been identified as specific receptors for IL-17B and IL-17C, 
respectively100.  
 
Binding of IL-17 to its receptor induces the activation of the adaptor protein ACT1, which is 
required for the recruitment of TNFR-associated factor 6 (TRAF6)100. TRAF6 is an essential 
upstream activator of the canonical nuclear factor–κB (NFκB) and mitogen-activated protein 
kinase (MAPK) intracellular pathways100. Collectively, these factors trigger the stabilization 
and transcriptional induction of IL-17-induced genes (Figure 1.4)100.  
 
IL-17 has pleiotropic effects and is an important mediator in tissue inflammation. Its main 
effect is the recruitment and activation of neutrophils102. For instance, it has been shown to 
increase neutrophil survival by directly inhibiting apoptosis in inflamed tissues103. Laan and 
colleagues demonstrated that subcutaneous injection of IL-17A into mice accelerates 
neutrophil development102. More specifically, IL-17A promotes granulopoiesis by inducing 
the secretion of granulocyte-colony stimulating factor (G-CSF) in bone marrow stromal cells, 
which synergizes with the transmembrane form of stem cell factor (SCF) to induce the 
differentiation of CD34+ progenitors into neutrophil precursors in vitro104,105. In addition, IL-
17 induces the expression of chemokines such as CXC-chemokine ligand 1 (CXCL1), CXCL2 
and CXCL5, all of which are neutrophil chemoattractants and promote neutrophil 
recruitment98. Both neutrophil recruitment and granulopoiesis are impaired in Il17ra−/− mice, 
rendering them susceptible to microbial infection106. Furthermore, Liang et al. showed that 
neutralization of IL-17A homodimers strongly blocked neutrophilic airway inflammation 
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induced by the adoptive transfer of ovalbumin (OVA)-specific Th17 lymphocytes and 
subsequent airway challenge with antigen107.  
 
Various other cytokines and inflammatory mediators are induced by IL-17, including IL-6, IL-
1b and antimicrobial peptides (AMPs)98. For example, IL-17 enhances the expression of b-

















NFκB Target gene  
transcription 
Figure 1.4: Simplified IL-17 signalling. IL-17A and IL-17F dimers, as well as IL-17A/F heterodimers 
bind to the IL-17 receptor complex, composed of IL-17RA and IL-17RC chains. Receptor signaling 
activates ACT1, which recruits TRAF6. This results in the activation of the NFκB and MAPK signalling 
pathways that induce the transcription of target genes.  
MAPKs 
CHAPTER 1: INTRODUCTION 
 17 
1.2.4.2 Other Th17-related cytokines 
 
Mature Th17 cells produce several other cytokines besides IL-17. For instance, the 
encephalitogenicity of Th17 cells has been shown to be dependent on IL-1b- and IL-23-
induced production of granulocyte-macrophage-colony stimulating factor (GM-CSF)109. Th17-
derived GM-CSF induces the activation, maturation and differentiation of pro-inflammatory 
myeloid cells, which contribute to demyelination in EAE109. GM-CSF is also essential for the 
secretion of Th17-stimulating cytokines, such as IL-23 and IL-6, by dendritic cells and 
macrophages, thereby further amplifying IL-17-driven pathology110.  
 
Th17 cells also produce IL-22, a member of the IL-10 family of cytokines108. IL-21 triggers IL-
22 production in CD4+ T cells by activating STAT3, which controls the epigenetic status of the 
Il22 promoter and its interaction with AHR111. Conversely, the transcriptional repressor c-Maf 
can also bind to the Il22 promoter and mediate TGFb-dependent suppression of IL-22 
production in Th17 cells112. The IL-22 receptor is a heterodimer composed of the IL-10R2 and 
IL-22R1 subunits and is almost exclusively expressed on cells of non-haematopoietic origin113. 
IL-22 provides tissue-protective effects and is primarily involved in the preservation of 
mucosal barriers113. For instance, IL-22 exhibits anti-apoptotic properties that, together with 
its capability to promote cellular proliferation, aid in wound healing and tissue repair114. Yeste 
et al. demonstrated that IL-21 and AHR signalling limit mucosal inflammation during DSS-
induced colitis through the production of IL-22111. IL-22 can also promote the expression of 
several antimicrobial peptides at mucosal surfaces to protect the host from microbial 
infections108. Aujla and colleagues observed that IL-22-knockout mice displayed increased 
mortality in response to infection with Klebsiella pneumoniae and that this was due to 
increased bacterial adhesion and invasion115. However, IL-22 can be pathogenic in settings of 
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1.2.5 Th17 Cells in health and disease 
 
1.2.5.1 Th17 cells in bacterial infection 
 
The Th1 lineage is typically considered the main defence against intracellular pathogens26. 
However, Th17 lymphocytes are critical for the recruitment and early activation of 
neutrophils and therefore play important roles in host protection against numerous bacterial 
species117. For instance, TLR4 expression in the lungs following K. pneumoniae infection 
promotes IL-23 production by DCs, leading to the release of IL-17 from both CD4+ and CD8+ 
T cells and subsequent neutrophil chemotaxis118. Furthermore, IL-17RA-deficient mice 
display impaired protective responses against Streptococcus pneumoniae, which is 
associated with subdued pneumococcal killing by polymorphonuclear cells119. Similarly, 
during M. tuberculosis infection, IL-17A promotes the formation of mature granulomas and 
induces the expression of CXCL9, CXCL10 and CXCL11, which recruit IFNγ-producing cells and 
promote the development of a protective Th1 response120.  
 
On the other hand, Th17 cells can also promote inflammation and subsequently induce 
harmful tissue damage during bacterial infection117. For example, Chung et al. demonstrated 
that the formation of abscesses that contribute to morbidity following intraperitoneal 




1.2.5.2 Th17 cells in viral infection 
 
Th17 cells are generally considered detrimental to the host during viral infection122. 
Hypercytokinemia of specific chemokines and cytokines has been associated with severe and 
often fatal cases of human influenza infection (e.g. H5N1)123. Bermejo-Martin and colleagues 
demonstrated that severe disease with respiratory involvement following infection with 
nvH1N1, a pandemic variant of the influenza virus, is characterized by early secretion of Th17 
(and Th1) cytokines123. Furthermore, IL-17 suppresses the Th1 response by preventing Th1 
differentiation and inhibiting the production of IL-2 and IFNγ, both of which induce cytotoxic 
T lymphocyte activity and anti-viral functions122. For example, Hou et al. demonstrated that 
Th17 cells enhance the persistence of Theiler’s murine encephalomyelitis virus (TMEV) by 
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inhibiting target cell destruction by cytotoxic T lymphocytes124. In addition, Th17 cells were 
found to inhibit type 1 immunity and drive immunopathology in the liver during murine 
hepatitis125.  
 
However, IL-17+ lymphocytes also play beneficial, if indirect roles, during viral infection. For 
instance, CD8+ IL-17+ (Tc17) cells induce an influx of neutrophils that protect the host after 
lethal influenza challenge126.  
 
 
1.2.5.3 Th17 cells in fungal infection 
 
Th17 cells play an important role in host defence against fungal pathogens98. For instance, IL-
17 is essential for protective immunity against Candida albicans, a commensal 
microorganism of the human oral cavity, gastrointestinal tract and reproductive mucosa127. 
Genetic polymorphisms leading to defects in Th17 differentiation and proliferation or IL-17 
receptor signalling are associated with chronic mucocutaneous Candida infections127. For 
example, this occurs with autosomal recessive deficiency of the IL-17RA receptor128. IL-17 
acts on epithelial and mesenchymal cells to upregulate the expression of pro-inflammatory 
cytokines such as IL-6, the neutrophil-recruiting chemokines CXCL1 and CXCL5, as well as 
antimicrobial peptides, all of which limit fungal growth and burden127,129. Conti and 
colleagues demonstrated that Th17-deficient and IL-17R-deficient mice experienced severe 
oropharyngeal candidiasis compared to Th1-deficient animals, which was associated with 
impaired neutrophil recruitment and AMP (S100A8, S100A9 and β-defensin 3) production129.  
 
 
1.2.5.4 Th17 cells in autoimmune disease 
 
IL-17-secreting cells have been implicated in a number of autoimmune and chronic 
inflammatory conditions98. Psoriasis is a disease of the skin, characterized by epidermal 
hyperplasia due to abnormal differentiation of basal keratinocytes and leukocyte 
infiltration130. The expression of classical Th17-related genes, such as RORC, IL17A and IL22 
is upregulated in patients with psoriasis compared to healthy controls130. Psoriatic epidermal 
Th17 cells produce IL-17 and IL-22, which directly stimulate keratinocyte proliferation and 
inhibit epidermal differentiation, respectively131,132. Furthermore, DC-derived IL-23 has been 
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shown to drive psoriatic plaque formation in mice via activation of innate IL-17/IL-22–
producing lymphocytes133. IL-17 also helps create a chronic inflammatory environment by 
inducing the release of neutrophilic chemoattractants by keratinocytes, which promotes 
granulocytic skin infiltration134. Interestingly, Chiricozzi et al. identified a complex interplay 
between IL-17 and TNF-α, in which they synergistically contributed to many of the key 
inflammatory pathways in psoriasis135.  
 
Th17 cells have been shown to play a critical role in driving pathology in rheumatoid arthritis 
(RA)136. For example, Nakae et al. showed that IL-17-deficient mice are resistant to collagen-
induced arthritis and that IL-17 was responsible for the priming of collagen-specific T cells 
and collagen-specific IgG2a antibody production137. Furthermore, human patients with early 
inflammatory arthritis display enhanced and persistent levels of IL-17 in the peripheral blood, 
as well as increased numbers of Th17 cells compared to healthy human controls, which 
positively correlate with increased disease activity138. IL-17 stimulates the recruitment of 
neutrophils and monocytes, which in turn promotes joint inflammation and articular 
cartilage breakdown136,139. For instance, IL-17 is chemotactic for monocytes at concentrations 
typically detected in RA synovial fluid and Lubberts et al. determined that the ectopic 
expression of IL-17 intra-articularly enhanced neutrophil migration into the joints of 
mice140,141. Moreover, several studies have shown that IL-17 plays a major role in amplifying 
the effects of macrophage-derived cytokines140. IL-17 enhances TNFa-induced synthesis of 
IL-1b ,IL-6, and IL-8 in skin and synovial fibroblasts, thereby promoting inflammation142.  
 
There is a strong association between multiple sclerosis (MS), Th17 cells and IL-17143. IL-17 
knockout mice show delayed onset, decreased severity scores and early recovery of EAE (the 
mouse model of MS)144. Furthermore, IL-23-deficient animals are resistant to EAE induction: 
Th17 cells from these mice cannot infiltrate the CNS and remain in the lymph nodes77. In 
humans, high levels of IL-17 can be detected in the lesions and CSF of MS patients143. 
Hedegaard and colleagues suggested that autoantigen-driven Th17 proliferation and levels 
of IL-17 were associated with disease activity, as determined by the number of active plaques 
detectable by magnetic resonance imaging (MRI)145. It has been postulated that Th17 cells 
play a more relevant role in the initial phases of EAE and MS, by mediating the breakdown of 
the blood brain barrier (BBB) and the recruitment of other pathogenic immune cells143. IL-17 
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promotes the formation of reactive oxygen species (ROS) within endothelial cells, enhances 
the activation of matrix metalloproteinase-3 (MMP-3), attracts neutrophils and induces the 
production of other pro-inflammatory cytokines such as  IL-1b and TNFa146. This results in 
the impaired integrity of the BBB, the recruitment of large numbers of neutrophils, 
monocytes and macrophages, sustained myelin and axonal damage and neuronal 
apoptosis146. In addition, ROS generation leads to the upregulation of endothelial adhesion 
molecules and increased transmigration of inflammatory cells via the BBB, thereby allowing 
easier access of myelin-specific T cells from systemic circulation to a usually immune-
privileged site147.  
 
Th17 cells play an important role in inflammatory bowel disease (IBD)148. Multiple genome-
wide association studies have demonstrated that polymorphisms within several Th17-related 
genes are associated with IBD, including IL23R and STAT3148. The gastrointestinal mucosa of 
patients with Crohn’s disease (CD) and ulcerative colitis (UC) is infiltrated with high numbers 
of Th17 cells149. In line with this, tissue biopsies from inflamed colons show elevated levels 
of Th17-associated cytokines compared to healthy controls149. Raza and Shata found that the 
levels of IL-17 secreted by PBMCs from UC patients correlated with disease activity150. IL-17 
has been shown to trigger and amplify inflammation, by stimulating colonic epithelial cells to 
produce pro-inflammatory cytokines and chemokines such as IL-6, IL-8 and MCP-1 (monocyte 
chemoattractant protein) via NF-kB and MAPK pathways151. This is supported by the fact that 
IL-17R knockout mice are protected from TNBS-induced colitis152. However, IL-17 has also 
been reported to have tissue-protective effects in the gut: Ogawa et al. demonstrated that 
IL-17 neutralization lead to exacerbated intestinal inflammation in response to dextran 
sodium sulphate (DSS)153. Similarly, Th17-derived IL-22 has also been shown to play a 
protective role during IBD148. For example, IL-22-deficency is associated with worsening 
inflammation in mouse models of DSS-induced acute and chronic colitis154. The local 
protective effects of IL-17 and IL-22 are mediated by the induction of mucin production and 











Neutrophils are the most abundant innate immune cell in the human peripheral blood and 
comprise 60-70% of all leukocytes155. Previously, these short-lived effector cells were thought 
to have a half-life of less than a day (1.5 hours in mice, 8 hours in humans)156. However, a 
recent study by Pillay and colleagues demonstrated that neutrophils can have a circulatory 
lifespan of up to 12.5 hours in mice and an incredible 5.4 days in humans157. However, the 
methodological approach employed almost certainly also labelled bone marrow neutrophils 
and it is therefore possible that this is a considerable overestimate158. Nonetheless, 
neutrophil longevity increases several fold during inflammation and after migrating to the 
tissues, where they receive enhanced survival signals in the form of various cytokines, growth 
factors and bacterial products156. 
 
 
1.3.1 Neutrophil development 
 
Neutrophils are produced in the bone marrow from hematopoietic stem cells159. In humans, 
around 1011 neutrophils are produced each day155. Common myeloid progenitors (CMPs) 
undergo a series of transformations in a highly regulated process that is mediated by 
different combinations of transcription factors expressed at specific stages of neutrophil 
development (Figure 1.5)159. The first neutrophil-committed progenitor, the promyelocyte, 
arises from the myeloblast state159. Promyelocytes are capable of dividing and can be 
recognised by their round nucleus and dark cytoplasm160. Myelocytes represent the last cell 
in the mitotic pool; the inhibition of proliferative genes and the upregulation of anti-
proliferative factors induces the generation of metamyelocytes, marking the beginning of 
terminal differentiation159. These can be identified by their kidney-shaped nucleus and clear 
cytoplasm160. Banded neutrophils, in which the nucleus adopts a horseshoe shape, are the 
penultimate developmental stage160. These immature cells cannot be found in the peripheral 
blood during homeostasis but have been identified in the circulation during periods of acute 
infection or inflammation160. 
 
Mature neutrophils contain granules and secretory vesicles that store specific proteins 
relevant to their function, including antimicrobial peptides, proteases, membrane-bound 
receptors and extracellular matrix proteins to name but a few161. Neutrophil granule 
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formation is hierarchical and their distinct composition is dependent upon the timing at 







Azurophilic (primary) granules develop in myeloblasts and early promyelocytes159. These 
early-appearing granules were originally defined by their high myeloperoxidase (MPO) 
content, which accounts for almost 5% of the neutrophil’s total dry weight159. However, they 
also contain a number of acidic hydrolases (elastase) and antimicrobial proteins 
(defensins)159. Secondary, or specific, granules are produced in myelocytes and are rich in 
antibiotic substances, including cathelicidin and lactoferrin159. Gelatinase (or tertiary) 
granules form during the transition of metamyelocytes to banded neutrophils159. As their 
name suggests, this subset possess high levels of gelatinase, as well as matrix 
metalloproteinases, which are important for the degradation of the vascular basement 
membrane and neutrophil extravasation into inflamed tissues159. Secretory vesicles can only 
be found in mature, segmented cells159. They contain an important reservoir of membrane-
associated receptors, including CD10, CD11b and CD16, which are required for firm adhesion 
to the activated endothelium and migration into tissues159. The newly-discovered ficolin-1 
granules are enriched for the microbial lectin, ficolin-1, and constitute the fourth and final 
subset159. Ficolin-1 is a very complex protein that is synthesized during the transition from 
















Figure 1.5: Neutrophil development. Modified from Brianna et al., 2019. Neutrophil progenitors 
undergo a series of transformations which coincide with granule formation. Their distinct 
composition is dependent upon the timing at which they are formed.     
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myelocytes to metamyelocytes, but localizes in granules that form in segmented cells during 
the final stages of neutrophil development159. The exact role of these ficolin-1 granules 
remains to be determined but it is possible that they provide rapid release of pattern 
recognition molecules that activate the lectin complement pathway163.  
 
 
1.3.2 Neutrophil recruitment  
 
Fully mature neutrophils exhibit low expression of CXCR4 and increased CXCR2164. CXCR4 
promotes the retention of neutrophils in the bone marrow where bone marrow stromal cells 
produce its ligand, CXCL12165. Mice with a myeloid lineage-restricted deletion of CXCR4 
display neutrophilia in the peripheral blood166. The downregulation of this receptor therefore 
allows the release of mature neutrophils into circulation164. G-CSF also promotes neutrophil 
exit from the bone marrow by upregulating CXCR2 ligands (e.g. CXCL2) expressed by 
endothelial cells and downregulating CXCL12 in the bone marrow165.  
 
Circulating neutrophils are recruited from the blood and mobilized to sites of infection or 
inflammation through the leukocyte adhesion cascade, which consists of the following steps: 
tethering, rolling, adhesion, crawling and transmigration156. More specifically, direct 
activation of pattern-recognition receptors and the release of inflammatory mediators from 
tissue-resident sentinels induce the upregulation of adhesion molecules by endothelial 
cells156. These include P- and E-selectins, which bind to their glycosylated ligands with 
relatively low affinity, promoting the tethering and rolling of free-flowing neutrophils156. The 
activated and inflamed endothelium is also decorated with chemokines; activation of 
neutrophil G-protein-coupled chemokine receptors stimulates conformational unfolding of 
β1 and β2 integrins (e.g. MAC-1, LFA-1), which increases the affinity for their ligands (ICAM-
1) and mediates firm adhesion156. Neutrophils finally leave the vasculature and gain access 
to the peripheral tissues via transmigration, which requires the release of specific proteases 
that possess enzymatic activity against the extracellular matrix (e.g. MMP9)156. Once 
extravasated, neutrophils follow chemotactic gradients to reach the site of inflammation and 
complete their functions156.  
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Neutrophils can also be recruited to the lymph nodes via the afferent lymphatics or by exiting 
the circulation through high endothelial venules (HEVs)167–169. For instance, Hampton and 
colleagues demonstrated that neutrophils re-localized to the subcapsular sinus of draining 
lymph nodes following bacterial injury, indicating they entered via the lymphatics168. This was 
mediated by CD11b and CXCR4 and induced lymphocyte proliferation168. Similarly, HEVs are 
the major route of entry of blood-borne neutrophils into tumour-draining lymph nodes, 
which is dependent on interactions between neutrophil L-selectin/CXCR2 with 
addressin/CXCL2167. Beauvillain et al. also found that the recruitment of neutrophils to lymph 
nodes via this pathway requires CCR7: injection of complete Freund’s adjuvant (CFA) failed 
to induce the rapid recruitment of neutrophils to the lymph nodes in CCR7-deficient mice169.  
 
 
1.3.3 Neutrophil Activation  
 
Neutrophils are activated in response to a number of different stimuli, which promote 
prototypical neutrophil functions170. For instance, bacterial-derived formylated peptides, 
such as fMLF (N-formylmethionine-leucyl-phenylalanine), act via formyl peptide receptor 1 
(FPR1) to trigger a range of intracellular kinase pathways that induce superoxide production, 
degranulation and chemotaxis171. Leukotrienes, which are generated by the metabolism of 
arachidonic acid through the 5-lipoxygenase pathway, act primarily on myeloid leukocytes to 
induce activation of integrins, adhesion to endothelial cell walls and chemotaxis172. Oyoshi 
and colleagues demonstrated that leukotriene B4-driven neutrophil recruitment to the skin 
is essential for allergic skin inflammation172. Platelet-activating factor (PAF) is another pro-
inflammatory agent that activates neutrophils; PAF receptor antagonists were shown to 
prevent neutrophil migration across cytokine pre-treated endothelial cells173. Moreover, PAF 
primes neutrophils to respond to a secondary stimulus with increased ROS production174. The 
complement fragment C5a also induces actin-cytoskeleton polymerization and 
reorganization, thereby adjusting the mechanical properties of neutrophils and transforming 
them into migratory cells capable of being recruited to sites of inflammation175. Indeed, Sadik 
et al. determined that C5a plays a critical role in the initiation of neutrophil-mediated 
autoimmune inflammation in the arthritic joint176.  
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1.3.4 The multifaceted functions of neutrophils  
 
Neutrophils provide one of the first lines of defence against invading microorganisms155. They 
are highly mobile cells and quickly respond to inflammatory cues from infectious or damaged 
areas by trapping and killing invading pathogens177. Neutrophils are therefore traditionally 
known for their antimicrobial and phagocytic capabilities177. However, they possess a much 
more diverse repertoire of functional responses and display immunomodulatory properties 
as well178.  
 
 
1.3.4.1 Pathogen killing 
 
Phagocytosis and the Respiratory Burst: Neutrophils rely upon several mechanisms for the 
eradication of invading microorganisms177. Phagocytosis refers to the uptake of a pathogen 
into a vacuole upon ligation of opsonic receptors179. This is followed by fusion with 
intracellular granules, the release of hydrolytic enzymes and the assembly of the NADPH 
oxidase complex within the membrane179. Activation of NADPH oxidase results in a dramatic 
increase in oxygen consumption (respiratory burst) and the production of superoxide anions 
(O2-), which are further metabolized into hydrogen peroxide (H2O2) and other reactive 
oxygen species (ROS)179. These free radicals can induce damage to bacterial DNA and directly 
attack polyunsaturated fatty acids in membranes, resulting in decreased membrane fluidity 
and permeabilization180. However, neutrophils must precisely control the location and timing 
of NADPH oxidase activity because excessive ROS production can cause collateral tissue 
damage163.  
 
Degranulation: Neutrophil granules can also fuse with the plasma membrane, leading to the 
exocytosis of antimicrobial and cytotoxic molecules into the extracellular environment181. 
Degranulation is a highly regulated process that occurs in the reverse but ordered sequence 
of synthesis (formed-first-released-last model)159,181. Secretory granules require minimal 
cellular stimulation for release, whereas azurophilic granules require a very powerful agonist 
(e.g. fMLF) to promote degranulation and largely confine their release of proteolytic enzymes 
to the phagosome159,182.  
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Degranulation of cationic host defence peptides, such as defensins and cathelicidins, plays 
an important role in antimicrobial responses183. These positively charged molecules interact 
with negatively charged cellular membranes, creating pores that can lead to permeabilization 
and the disruption of DNA/RNA biosynthesis183. However, neutrophil granule contents are 
also highly cytotoxic and can be detrimental to the surrounding tissue if secreted in an 
uncontrolled fashion163. For example, IL-6 has been shown to increase PMN cytotoxic 
potential through the selective enhancement of neutrophil elastase release in critically ill 
patients at risk for inflammatory organ injury184. 
 
NETosis: Another mechanism that neutrophils employ for pathogen eradication is NETosis, 
which can be induced by a variety of inflammatory stimuli (TNFa, IL-8, immune complexes) 
and PAMPs185. NETosis refers to the formation of neutrophil extracellular traps (NETs) and 
was first described by Brinkmann and colleagues in 2004186. NETs are important for the 
immobilization, neutralization and killing of invading microorganisms, thereby preventing 
their dissemination187. They consist of large, extracellular meshworks of decondensed 
chromatin fibres, decorated with cytosolic and granule-derived proteins such as MPO, 
neutrophil elastase, serine proteases, defensins and cathelicidins186,188. It has been suggested 
that NETs increase the effectiveness of these antimicrobial components by concentrating 
them in a fibrous network186. The lack of “eat me” signals on their cell surface distinguishes 
them from apoptotic neutrophils185.  
 
 
1.3.4.2 Immunomodulatory function of neutrophils 
 
In recent years, it has become clear that neutrophils participate in complex bidirectional 
cross-talk with other immune cells189. Neutrophils receive signals from other leukocytes that 
modulate their own survival and function190. For example, T cell-derived cytokines such as 
IFNg and GM-CSF greatly enhance neutrophil responsiveness to a secondary stimulus during 
activation191. In addition, both aCD3-activated CD4+ and CD8+ T cells were shown to increase 
neutrophil activation and delay their spontaneous apoptosis rate192.  
 
In turn, neutrophils can both amplify and suppress other effector responses via direct and 
indirect mechanisms190. For instance, they have been shown to promote DC maturation into 
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more effective antigen-presenting cells through direct contact-dependent mechanisms193. 
Moreover, neutrophil-macrophage interactions are important for both initiation and 
resolution of inflammation189. More specifically, neutrophils secrete several chemokines 
(CCL2, CCL3) and AMPs (cathelicidin) that recruit macrophages to sites of inflammation194. 
Neutrophils are also major producers of cytokines (BAFF, APRIL, IL-21) required for B cell 
survival, maturation and differentiation189. Conversely, Kamenyeva and colleagues 
demonstrated that neutrophil recruitment to the lymph nodes limits local humoral responses 
to S. aureus: neutrophil depletion increased the production of IgG and IgM in the lymph node 
following infection195.  
 
In addition, apoptotic neutrophils have been shown to possess anti-inflammatory potential 
and therefore play a role in the resolution phase of inflammation and in promoting tissue 
repair196. Neutrophils undergoing programmed cell death change their phenotype to produce 
‘eat me’ signals that are recognised by surrounding phagocytes196. For example, annexin-1 is 
released by apoptotic neutrophils, which serves as a signal to initiate phagocytosis by 
macrophages197. Phosphatidylserine (PS) residues exposed on the surface of apoptotic cells 
interact with receptors on macrophages, which modifies the latter’s transcriptional profile 
to increase production of immunoregulatory cytokines such as IL-10 and TGFb198.  
 
If clearance does not follow apoptosis, secondary necrosis can occur in which cellular 
membrane integrity is lost, resulting in the release of harmful intracellular neutrophil 
mediators and subsequent exacerbation of inflammation196. However, necrotic neutrophils 
also possess anti-inflammatory potential196. For instance, Li and colleagues demonstrated 
that the human cathelicidin peptide, LL-37, induces secondary necrosis of neutrophils 
without promoting macrophage inflammation199. However, the authors of this study suggest 
that necrotic neutrophils may mediate host damage through the release of toxic granule 
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1.4 Neutrophil – T Cell Interactions 
 
Cross talk between the innate and adaptive arms of the immune system is critical for the 
clearance of pathogens and the development of an effective memory response200. 
Historically, the differentiation and activation of T cells was thought to occur later than, and 
separate to, the innate response. However, neutrophils and T cells have been shown to co-
exist in several acute and chronic inflammatory diseases. For example, one of the prominent 
features of EAE is the presence of a large number of neutrophils and early-infiltrating CD3+ T 
lymphocytes in the spinal cord during the pre-clinical phase of disease201. Furthermore, both 
neutrophils and T cells were shown to co-localize for a short time during influenza and RSV 
infection (respiratory syncytial virus)202,203. Neutrophils and T cells can therefore be present 
at the same site and at the same time, although the implications of this are unknown. 
 
 
1.4.1 Stimulatory effects of neutrophils on T cell behaviour 
 
1.4.1.1 Neutrophils can act as antigen presenting cells  
 
Neutrophils are capable of transporting antigen to sites of T cell priming204. For instance, 
Maletto and colleagues found that when FITC-labelled OVA was injected into the footpad of 
OVA/CFA (complete Freund’s adjuvant) immunized mice, the main OVA-FITC+ cells recruited 
to the draining popliteal lymph nodes were neutrophils205. Similarly, neutrophils have been 
shown to rapidly migrate and shuttle live bacilli to the draining lymph nodes following 
Mycobacterium bovis BCG intradermal vaccination206. The migration of both human and 
mouse neutrophils to the lymphoid organs has been linked to the upregulation of CCR7; 
Beavillain et al. demonstrated that this migration was impaired in CCR7-/- knockout mice207.  
 
Besides simply transporting antigen to lymphoid organs, neutrophils are also capable of 
interacting with T lymphocytes and acting as professional APCs208. In a mouse model of acute 
graft-versus-host disease, neutrophils migrated to the mesenteric lymph nodes, where they 
co-localized with T cells to present alloantigen209. Abdallah and colleagues demonstrated that 
mouse neutrophils express MHC II and upregulate the co-stimulatory molecules CD80 and 
CD86 when co-incubated in vitro with CD4+ T lymphocytes, resulting in increased T cell 
proliferation, IFNg and IL-17A production210. Similarly, neutrophils sorted from the draining 
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lymph nodes of vaccinated rhesus macaques were able to present vaccine antigen to 
autologous antigen-specific memory CD4+ T cells ex vivo211. In humans, neutrophils exposed 
to GM-CSF or IFNg were also shown to upregulate MHC II expression in order to present S. 
aureus superantigens to CD4+ T cells212. More recently, Polak et al. found that neutrophils 
isolated from the peripheral blood of birch pollen-allergic donors induced proliferative and 
cytokine responses of Bet v 1-specific effector T cells213.  
 
Neutrophils are also capable of cross-presenting antigens to CD8+ T cells208. For example, one 
study used an in vivo model in which professional APCs do not express functional MHC I, to 
show that the injection of antigen-pulsed neutrophils induced the differentiation of naïve 
CD8+ T cells into mature cytotoxic T cells214. Furthermore, Hufford and colleagues 
demonstrated that influenza-infected neutrophils can act as professional APCs for anti-viral 
CD8+ T cells215. 
 
 
1.4.1.2 Neutrophils promote T cell responses by modulating dendritic cells  
 
Neutrophils promote T cell responses by enhancing dendritic cell (DC) activation and 
migration through contact- and cytokine-dependent mechanisms216. For instance, 
neutrophils produce a number of chemokines that attract DCs216. Toxoplasma gondii 
infection triggers neutrophil synthesis of CCL3, CCL4, CCL5 and CCL20, all of which are 
strongly chemotactic for immature DCs217. Moreover, the early release of CCL3 by 
neutrophils in response to Leishmania major is involved in the first wave of DC recruitment 
to the site of infection218. Mycobacteria have also been reported to induce the release of DC 
chemoattractants: neutrophil depletion during M. tuberculosis infection delayed DC 
migration to the draining lymph nodes and as a result, impaired the protective anti-
mycobacterial response219. Similarly, Weber and colleagues demonstrated that gelatinase is 
critical for the generation of contact hypersensitivity by promoting DC migration to the site 
of sensitization and subsequent allergen-specific T cell priming220. Cathepsin G and 
neutrophil elastase have also been shown to catalyse the removal of the C-terminal peptide 
from the inactive prochemerin, thereby releasing the active form, which is a potent 
chemoattractant for APCs221.  
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Neutrophils strongly cluster with immature DCs and provide local co-factors that are required 
for their maturation into professional APCs193. More specifically, TNFa produced by activated 
neutrophils is essential for inducing DC maturation193. For instance, T gondii-stimulated 
neutrophils that release TNFa are responsible for the upregulation of CD40 and CD86 by 
DCs217. Similarly, the in vitro co-incubation of neutrophils with DCs exposed to Aspergillus 
fumigatus induces the upregulation of DC co-stimulatory molecules in a contact- and DC-
SIGN-dependent manner222. Steinbach and colleagues demonstrated that CNS-infiltrating 
neutrophils secrete pro-inflammatory molecules and induce the maturation of bone-
marrow-derived DCs in vitro, which in turn enhances their ability to re-stimulate myelin-
specific T cells223. This implies that neutrophil-DC crosstalk plays a crucial role in the 
amplification of early CNS inflammation and the development of autoimmune disease223. 
 
DCs are also capable of acquiring antigen directly from phagocytosed neutrophils216. For 
example, they were shown to take up C. albicans-derived antigens from both live and 
apoptotic neutrophils and were thus capable of eliciting an antigen-specific T lymphocyte 
response224. Moreover, Blomgran et al. showed that DCs that acquired M. tuberculosis 
through the ingestion of infected neutrophils, migrated better to the draining lymph nodes 
compared to those that acquired the bacteria directly219. The authors suggested that this was 
a mechanism for the delivery of antigen to DCs, in a form that makes them more effective 
initiators of naïve CD4+ T cell activation219.   
 
 
1.4.1.3 Neutrophils promote T cell activation and differentiation 
 
Neutrophils can stimulate the immune response by directly priming T cells204. For example, 
NETs released by human neutrophils have been shown to reduce the activation threshold of 
T lymphocytes, resulting in increased proliferation and cytokine production in response to 
antigen225. Furthermore, Davey and colleagues demonstrated that ingestion of bacterial 
pathogens by human neutrophils and the subsequent release of microbial metabolites (HMB-
PP) activates antimicrobial γδ T cells during early infection226. Several intracellular neutrophil 
mediators can also influence the cytokine microenvironment, which dictates how T cells 
respond8. For instance, proteinase-3 can process pro-TNFa to a biologically active soluble 
form, as well as directly activate pro-IL-1b227. Both TNFa and IL-1b enhance the expansion, 
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effector function, tissue localization and memory response of antigen-specific CD4+ and CD8+ 
T cells, thereby increasing and perpetuating the immune response228. 
 
In addition, neutrophils are capable of skewing T helper cell polarization229. For instance, 
rhinovirus infection in a mouse model of allergic airway hypersensitivity triggers double-
stranded DNA release associated with NETs, which in turn promotes the development of type 
2 immunopathology230. Conversely, McFarlane et al. found that neutrophils play a significant 
role in the development of a protective Th1 immune response during Legionella 
pneumophilia infection231. Neonatal neutrophils stimulated by group B Streptococcus have 
also been shown to induce a pro-inflammatory T helper cell bias, by promoting Th1 and Th17 
characteristics in Tregs232. More recently, a study published by Krishnamoorthy et al. 
demonstrated that neutrophil cytoplasts present in the mediastinal lymph nodes activated 
lung DCs to specifically promote Th17 differentiation233. Another mechanism through which 
neutrophils promote Th17 responses is through the release of neutrophil elastase, which has 
been shown to process DC-derived CXCL8 into a truncated, potent Th17-inducing form234.  
Neutrophils can also influence the differentiation and effector functions of CD8+ T 
lymphocytes. Neutrophil depletion during influenza infection results in impaired cytokine 
production and cytotoxic effector function of virus-specific CD8+ T cells235. However, the 



































Figure 1.6: Mechanisms of neutrophil-mediated T cell stimulation. Neutrophils can directly 
present antigen to T cells by upregulating MHCII and co-stimulatory molecules such as CD80 and 
CD86. Dendritic cells can acquire antigen from phagocytosed neutrophils. Neutrophils skew T cell 
polarization towards a Th1/Th17 phenotype. Neutrophils can also promote T cell activation and 
differentiation by inducing DC recruitment and maturation.  
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1.4.2 Inhibitory effects of neutrophils on T cell behaviour 
 
Neutrophils possess immunosuppressive mechanisms that inhibit T cell activation and 
proliferation (Figure 1.7)204. For instance, Tak and colleagues showed that immune 
suppression by neutrophils reduces T cell-mediated pathology after influenza infection236. 
Moreover, neutrophil depletion during Brucella abortus infection resulted in the more 
efficient elimination of the microbe due to enhanced B cell and Th1 responses237. Similarly, 
neutropenic mice infected with Cryptococcus neoformans displayed increased proportions of 
IL-17-producing γδ T cells in the lungs, suggesting that neutrophils exert a regulatory effect 
on this T cell subset as well238.  
 
 
1.4.2.1 Neutrophils produce immunosuppressive cytokines 
 
Neutrophils can produce immunoregulatory cytokines that suppress the T cell response204. 
For instance, they have been shown to be significant producers of IL-10 during sepsis in 
mice239. The effects of IL-10 include the downregulation of key signalling receptors on APCs 
(CD40, CD80, CD86 and MHC II), suppression of T cell proliferation, IL-2, IL-6 and IFNg 
production, and the maintenance of FOXP3 expression by Tregs240. Indeed, Doz et al. found 
that during mycobacterial infection, IL-10-producing neutrophils inhibit CD4+ IL-17+ 
lymphocytes, which they suggest is an important mechanism to control an otherwise 
exuberant and damaging Th17 response241. Moreover, both mouse and human neutrophils 
can produce TGFb, which plays an essential role in establishing immune tolerance195,242.  
 
 
1.4.2.2 Neutrophil serine proteases inhibit T cell responses 
 
Neutrophil serine proteases are traditionally known for their roles in the intracellular killing 
of pathogens243. However, they are also key regulators of the inflammatory response and can 
impair host defence by degrading immune receptors229. More specifically, Bank et al. 
demonstrated that neutrophil elastase was responsible for the selective proteolytic cleavage 
of CD25 and IL-6R at foci of inflammation, both of which play important roles in T cell 
activation244.  
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In addition, neutrophil proteases can fine-tune the local inflammatory response through the 
disruption of gradients, or by modulating the biological activity of chemokines, cytokines and 
growth factors245. For example, CXCL12 is an important lymphocyte chemoattractant and its 
proteolytic cleavage by neutrophil elastase inactivates the chemokine and leads to decreased 
secondary recruitment of lymphocytes to the site of inflammation246. Furthermore, whilst 
proteinase-3 can process pro-TNFa to its biologically active soluble form, neutrophil elastase 
and cathepsin G have both been shown to degrade mature TNFa, resulting in a loss of 
activity247. Neutrophil-derived serine proteases have also been implicated in the degradation 
of pro-inflammatory IL-6, the inactivation of which could in turn dampen T cell responses248.  
 
 
1.4.2.3 Neutrophil-derived reactive oxygen species suppress T cells 
 
Another mechanism through which neutrophils suppress T cells is the release of ROS, such 
as hydrogen peroxide (H2O2)204. H2O2 is the product of NADPH oxidase and potently inhibits 
T cell activation and proliferation204. For instance, Pillay et al. showed that in a model of acute 
inflammation induced by systemic challenge with LPS, a population of human neutrophils 
(CD62LdimCD11cbrightCD16bright) potently inhibits T cell proliferation through the highly 
localized release of H2O2 into the immunological synapse249. Furthermore, activated 
neutrophils inhibit DNA synthesis in human T lymphocytes proportionally to superoxide 
levels in the medium, which is associated with alterations in TCR signalling (downregulated 
TCRζ and decreased Nf-κB activation)250.  
 
Gelderman and colleagues found that mice that possess allelic polymorphisms in the Ncf1 
gene (neutrophil cytosolic factor 1, a component of neutrophil NADPH oxidase) have a lower 
capacity to produce ROS and are more susceptible to developing severe arthritis251. They 
suggested that ROS production is important in regulating surface redox levels of T cells and 
suppressing autoreactivity251. Severe systemic T cell suppression in patients with advanced 
cancer has also been attributed to granulocyte-derived H2O2252. For example, Mensurado et 
al. demonstrated that tumour-associated neutrophils suppress the proliferation and IL-17 
production of gd T cells through the induction of oxidative stress253. Interestingly, the 
susceptibility of human T cells to H2O2-induced inhibition strongly depends on the T cell 
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subset: effector T cells are largely protected from ROS-mediated effects whereas memory T 
cells are the most vulnerable254.   
 
 
1.4.2.4 Arginase-1 impairs T cell activation and proliferation 
 
Neutrophil tertiary (gelatinase) granules contain arginase-1, an enzyme that is inactive at 
physiological pH but activated by other factors released during primary granule release159. 
Arginase-1 catalyses the conversion of L-arginine to urea and L-ornithine, thus depleting the 
microenvironment of the former255. L-arginine is required for the expression of the invariant 
z chain of the TCR complex and its subsequent downregulation following depletion impairs 
T cell activation, function and proliferation255. Sippel et al. demonstrated that peripheral 
immunosuppression in post-stroke mice is mediated by neutrophil-derived arginase-1256. 
They observed decreased expression of CD3ζ on splenic T cells, which correlated with 
decreased functional activity256. Mature neutrophils from the cystic fibrosis airway have also 
been shown to suppress T cell activation via arginase-1257.  
 
Another mechanism through which arginase-1 reduces T cell function is cell cycle arrest: 
activated T cells cultured in the absence of L-arginine are arrested in the G0-G1 phase258. 
Rodriguez et al. proposed that L-arginine starvation results in the inhibition of protein 
synthesis and the inability of T cells to upregulate cyclin D3258. In addition, arginase-1 impairs 
the formation and stability of the immunological synapse between T cells and DCs, thereby 
suppressing T cell activation259. This is mediated by the inhibition of cofilin 
dephosphorylation, which leads to altered actin polymerization259.   
 
Neutrophils play an important role in regulating L-arginine levels during normal human 
pregnancy, as they express increased levels of arginase-1 in the blood and placenta260. This 
is associated with T cell hyporesponsiveness and may contribute to tolerance of the semi-
allogenic fetus260. Moreover, neonatal neutrophils have a higher arginase-1 content than 
adult neutrophils and are therefore more suppressive261. This could provide an explanation 
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1.4.2.5 The PD1/PDL1 pathway 
 
PD1 is one of several co-inhibitory T cell receptors that regulate T cell responses262. Binding 
of PD1 to its ligand, PDL1, delivers a negative signal that contributes to the cessation of T cell 
proliferation262. Neutrophils have been shown to upregulate PDL1 under various 
conditions178. For example, Wang et al. found that neutrophils increase PDL1 expression 
during sepsis, which they postulated may be related to sepsis-induced 
immunosuppression263. Furthermore, neutrophils isolated from the peripheral blood of 
patients infected with Burkholderia pseudomallei also displayed increased expression of 
PDL1, which was responsible for inhibiting polyclonal T cell activation264. Similarly, HIV-1 
virions are potent inducers of neutrophil PDL1 expression265. Increased neutrophil PDL1 is 
increased in individuals with HIV and correlates to the dampening of T cell responses265.   
 
The PD1/PDL1 axis has been heavily implicated in cancer262. Neutrophils that accumulate in 
gastric cancer tissues express higher levels of PDL1 and effectively inhibit the proliferation 
and activity of PD1+ T cells in vitro266. This dampens T cell-mediated anti-tumour immune 
responses and has therefore been associated with poor patient survival266. In addition, Cheng 
et al. discovered that cancer-associated fibroblasts induce PDL1+ neutrophils that foster 
immune suppression in hepatocellular carcinoma267.  
 
 
1.4.2.6 Neutrophils suppress dendritic cell maturation and function  
 
Whilst neutrophils can positively regulate DCs, they are also capable of suppressing their 
maturation and function216. For instance, supernatants from sputum isolated from patients 
with chronic obstructive pulmonary disease (COPD) and cystic fibrosis suppress the 
expression of DC costimulatory molecules (including CD40, CD80 and CD86), in a neutrophil 
elastase-dependent manner268. Moreover, Odobasic et al. demonstrated that neutrophil 
MPO regulates T cell−driven tissue inflammation in mice by inhibiting DC function269. More 
specifically, MPO inhibits DC activation and migration to the lymph nodes by reducing their 
expression of CCR7269.  
 
Neutrophils have also been shown to compete with DCs at the level of antigen 
presentation204. Yang and colleagues found that neutrophils modulate antigen presentation 
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following immunization in various adjuvants and that the CD4+ T and B cell responses are 
enhanced in neutropenic mice270. In addition, MPO was found to inhibit antigen uptake and 
processing by DCs in a model of antigen-induced arthritis269. 
 
 
1.4.2.7 Neutrophils promote Treg development and function  
 
Neutrophils modulate the behaviour of regulatory T cells by promoting their development, 
recruitment and immunosuppressive activity229. For example, neutrophil elastase acts 
specifically on immature human DCs to turn off IL-6 production and increase TGFb, a cytokine 
that is critical for Treg development271. Indeed, Tateosian et al. found that neutrophil 
elastase-treated DCs promote the generation of suppressive CD4+ FOXP3+ T cells in vitro271. 
Similarly, lactoferrin acts directly on T lymphocytes to upregulate Treg-specific genes and 
skew differentiation towards a regulatory phenotype272. In vivo, this rescued normal 
intestinal physiology by enhancing gut barrier function in several models of IBD272. Finally, 
Mishalian et al. demonstrated that neutrophil-derived CCL17 recruits regulatory T cells into 
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Figure 1.7: Mechanisms of neutrophil-mediated T cell suppression. Neutrophils secrete inhibitory 
cytokines and serine proteases that inactivate pro-inflammatory cytokines, disrupt chemokine 
gradients and promote the shedding of receptors such as CD25. The production of ROS and 
arginase-1 inhibit T cell activation and proliferation by downregulating TCRζ signaling. Neutrophils 
upregulate the expression of PDL1 and deliver suppressive signals upon binding to its receptor on 
T cells. Neutrophils suppress DC activation and compete with them for antigen presentation. 
Neutrophils also promote the development and immunosuppressive activity of regulatory T cells.  
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1.4.3 Conflicting data of how neutrophils affect T cell behaviour 
 
Extensive research investigating how neutrophils affect T cell behaviour has yielded 
conflicting and confusing data: neutrophils can both suppress and promote T cell activation, 
depending on the context204,229. It remains to be seen whether these differential effects are 
mediated by discrete neutrophil populations that have not yet been stratified, or by pre-
existing neutrophils that acquire immunomodulatory properties under specific 
pathophysiological conditions208. For example, it has been suggested that the maturation 
status of neutrophils dictates their inhibitory or stimulatory phenotype: those released from 
the bone marrow during sepsis are immature and suppressive to T cells, whereas neutrophils 
present during hyperlipidemia are primed and produce high levels of MPO249.  
 
Other possibilities that can explain these wildly different outcomes include 1) the 
inflammatory model or infection used 2) differences between human and mouse neutrophils 
and 3) experimental techniques employed229. For instance, low-density neutrophils have 
been shown to find their way to the PBMC (peripheral blood mononuclear cells) layer 
following density gradient centrifugation, a popular method used for the isolation of 
neutrophils274. Low-density neutrophils may represent granulocytic myeloid-derived 
suppressor cells (G-MDSC), which impair T cell proliferation in vitro274. It is virtually 
impossible to distinguish MDSC from mature neutrophils and contamination of PBMCs with 
this subset can skew experimental readouts155,274. Furthermore, neutrophils have been 
shown to phagocytose aCD3/CD28-coated activation beads, which are commonly used to 
















Antimicrobial host defence peptides (AMP or HDP) are a large group of relatively small, 
cationic molecules that constitute a highly conserved component of the innate immune 
system and are traditionally known for their ability to kill microbes, including bacteria, 
viruses, fungi and protozoa183. Mammalian AMPs can be subdivided in to two major families: 
the defensins and cathelicidins183.  
 
 
1.5.1 The discovery of cathelicidin 
 
The first cathelicidin, cecropin, was isolated in 1980 from the Hyalophora cecropia moth275. 
Magainin was isolated in 1987 by Zasloff and colleagues from the skin of the Xenopus leavis 
frog276. The first mammalian cathelicidins discovered were rabbit CAP18 and the bactenecins, 
which were isolated from bovine neutrophils277,278. However, since then, around 30 
cathelicidin family members have been identified in multiple mammalian species, including 
humans, monkeys, mice, rats, pigs and cattle277. Humans and mice possess only a single 
cathelicidin, whereas pigs and cattle possess multiple genes encoding this HDP277. Human 
cathelicidin, human cationic antimicrobial peptide 18 (hCAP18), was first isolated from 
neutrophils in 1995279. Mouse cathelicidin, or mCRAMP (cathelin-related antimicrobial 
peptide) was identified in 1997 by Gallo et al.280. The cathelicidin family is highly 
heterogenous: peptides can display a variety of different structures and amino acid 




1.5.2 Cathelicidin expression and regulation  
 
1.5.2.1 Cathelicidin expression 
 
Cathelicidins can be found in a wide variety of tissues, typically at mucosal surfaces that are 
in direct contact with the environment281. These include the airways, gastrointestinal mucosa 
and reproductive tract, where they play a role in early host defence281. Cathelicidins are 
produced by a variety of cells, including neutrophils, epithelial cells, keratinocytes, 
macrophages, NK cells and mast cells282. Depending on the cell type, cathelicidin expression 
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is either constitutive, or induced in response to infection, injury and/or inflammation277. For 
instance, cathelicidin is up-regulated in skin in response to cutaneous injury or infection with 
group A Streptococcus265. Furthermore, whilst CAMP is not expressed in normal, healthy skin, 
it is induced in human keratinocytes during inflammatory disorders such as lesional 
psoriasis266.  
 
Cathelicidin can also be detected in numerous secretions, including sweat, wound and airway 
surface fluids, as well as seminal plasma, where it provides a sterile environment during 
fertilization281. For example, the average concentration of human cathelicidin in broncho-
alveolar lavage (BAL) fluid is around 5 µg/mL in healthy individuals285. However, this can rise 
to 30 µg/mL in cystic fibrosis patients285.  
 
The human and mouse cathelicidin genes (CAMP) have been mapped to chromosomes 3 and 
9, respectively277. Cathelicidins are encoded by genes consisting of four exons and are 
produced as inactive pre-pro-peptides277. In neutrophils, cathelicidin is produced at the 
myelocyte and metamyelocyte stages of maturation277,286. The first exon encodes the “pre-” 
signal peptide, whilst exons two and three encode the highly conserved “pro-” N-terminal 
cathelin domain277,285. The cathelin domain is made up of approximately 100 residues and 
shows great interspecies homology277,285. Exon 4 encodes the mature C-terminal peptide, 
consisting of the antimicrobial sequence (Figure 1.8)277,285.  
 
Inactive cathelicidin precursors must be proteolytically processed to release the biologically 
active C-terminal domain277. This was first illustrated by Zanetti and colleagues who found 
that bovine bactenecins are generated from precursor molecules and require proteolytic 
cleavage by neutrophil azurophilic serine proteases, later found to be neutrophil 
elastase287,288.  In humans, the extracellular processing of neutrophil-derived hCAP18 is 
mediated by proteinase-3 and liberates a linear 37 amino acid-long peptide, LL-37289. The 
segregation of hCAP18 and proteinase-3 within different granules prevents unwanted 
intracellular processing of AMPs in resting neutrophils281.  
 
On the other hand, epididymal-derived hCAP18 in seminal plasma is cleaved by the prostate-
derived gastricsin (pepsin C) when exposed to vaginal fluid at low pH281,290. Furthermore, 
Yamasaki et al. identified novel cathelicidin peptide forms at the skin surface that were 
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generated following proteolytic processing by the serine protease, kallikrein 5291. Abnormal 
production of this enzyme within the epidermis and the presence of these cathelicidin 
peptides was subsequently shown to promote skin inflammation in rosacea292. In addition, 
proteases in human sweat can cleave LL-37 to smaller peptides at the skin surface, which 
increases their antimicrobial activity but alters their immunostimulatory capacity to induce 
IL-8 release from keratinocytes293. This demonstrates the importance of proteolytic 








1.5.2.2 Regulation of cathelicidin expression 
 
Vitamin D deficiency has been linked to an impaired immune response and increased 
susceptibility to infection294. One of the major regulators of human cathelicidin expression is 
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Figure 1.8: Cathelicidin expression and maturation. Cathelicidins are encoded by genes made up 
of 4 exons. Cathelicidins are produced as inactive precursors and must be proteolytically cleaved 
to release the biologically active peptide. The cathelin domain is highly conserved, whilst the C-
terminus is highly variable. Both human (LL-37) and mouse (CRAMP) cathelicidin adopt an α-helical 
structure. 
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Element (VDRE) sequence that binds to active 1,25-dihydroxyvitamin D3 and several of its 
analogues295. Gombart and colleagues demonstrated that the in vitro stimulation of human 
epithelial cells and monocytes with vitamin D3 increased LL-37 expression296. However, 
induction of CAMP in mouse cells was not observed and they postulated that this was due to 
the evolutionary loss of their VDRE296. In addition, TLR2 activation following bacterial 
challenge increases the expression of the CYP27B1 hydroxylase enzyme in keratinocytes, 
which is responsible for the catalytic conversion of the inactive vitamin D pro-form and 
subsequent upregulation of cathelicidin expression297. However, there is little evidence that 
suggests vitamin D increases cathelicidin expression in vivo. Furthermore, many of the 
benefits that some have speculated are due to the effects of vitamin D on the expression of 
this peptide could in fact be related to its regulation of other processes, including skewing T 
cell differentiation away from a pro-inflammatory Th17 phenotype and facilitating the 
induction of regulatory T cells298.  
 
Several vitamin D-independent regulatory mechanisms have also been identified282. For 
instance, Park et al. found that the perturbation of the epidermal permeability barrier 
induces ER stress, which in turn stimulates the synthesis of cathelicidin in epithelial cells, 
thereby restoring or enhancing antimicrobial defence barriers299. Cathelicidin expression can 
also be regulated by various endogenous factors such as pro-inflammatory cytokines and 
growth factors282. The CAMP gene contains promoter elements that are potentially regulated 
by IL-6, and a co-localization between IL-6 and hCAP18 has been observed in squamous 
epithelial tissue, suggesting a role for this peptide in epithelial antimicrobial defense300.  
 
Other signals, such as glucocorticoids produced in response to psychological stress, suppress 
cathelicidin expression301. Interestingly, calcipotriol, a synthetic derivative of vitamin D, 
negatively regulates cathelicidin in cells cultured under inflammatory conditions302. 
Moreover, certain pathogens, such as Shigella flexneri, are also capable of downregulating 
cathelicidin in intestinal epithelial cells during early infection as part of a strategy to 
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1.5.3 Cathelicidin structure 
 
Biologically active cathelicidin peptides are highly heterogenous: they vary in amino acid 
sequence and size and display considerable structural diversity277. Like most AMPS, 
cathelicidins display an overall positive charge, ranging from +2 to +9, due to the presence of 
a high number of positively charged amino acids, such as lysine and arginine183. Furthermore, 
up to 50% of the structure is made up of hydrophobic resides183. Most cathelicidins are 
therefore linear peptides that adopt an amphipathic α-helical structure in environments 
mimicking biological membranes (e.g. LL-37, mCRAMP)281,304. Others possess a β-hairpin 
motif (e.g. protegrin-1), whilst some contain a high number of tryptophan residues (e.g. 
indolicidin), or form extended polyproline-type structures if proline/arginine rich (e.g. 
bactenecins)277,281,304. Small changes in the charge, helicity and hydrophobicity of 
cathelicidins can have a significant impact on their activity: a single amino acid change within 
the sequence can dramatically alter the anti-bacterial and/or toxicity profile of a peptide305. 
 
 
1.5.4 The antimicrobial effects of cathelicidin 
 
The C-terminal peptide of cathelicidin exhibits broad antimicrobial activity against both 
Gram-positive and Gram-negative bacteria, enveloped viruses and fungi304. As such, 
cathelicidin knockout mice are prone to developing infections of the skin, lungs, 
gastrointestinal and urinary tract, as well as the eyes306–309. For example, mCRAMP-deficiency 
predisposes animals to skin infection by group A Streptococcus and low levels of hCAP18 have 
been detected in skin lesions from patients with atopic dermatitis, who display increased 
susceptibility to skin infections306,310. Furthermore, neutrophils from individuals with morbus 
Kostmann syndrome (or severe congenital neutropenia) exhibit LL-37 deficiency (and 
reduced concentrations of a defensins)311. No LL-37 could be detected in the plasma or saliva 





The mixed cationic and hydrophobic composition of cathelicidins enables them to interact 
with and permeabilize microbial cytoplasmic membranes, which typically present anionic 
surfaces, rich in lipids312. Gross disruption of the microbial membrane structure and 
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morphology is often noted following treatment with cathelicidin, including membrane 
blebbing and fragmentation312. Several studies have determined that cathelicidin creates 
trans-bilayer toroidal pores to disrupt bacterial cell wall integrity and induce cell death313. 
More specifically, monomers and oligomers cover the surface of the lipid bilayer, with 
positively charged amino acids binding to the head groups of negatively charged 
phospholipids314. The accumulation of peptides causes a positive curvature strain, which 
induces the transient formation of small toroidal pores313. This results in a loss of 
transmembrane potential, ultimately causing leakage of cytoplasmic components and 
rendering intracellular processes vulnerable314. For example, cathelicidin can impair 
RNA/DNA synthesis and enzyme activity, as well as promote protein degradation285. 
 
Cathelicidins exhibit several other anti-bacterial functions285. For example, Kirikae et al. 
demonstrated that human cathelicidin possesses LPS-neutralizing activity and was capable 
of preventing antibiotic-induced endotoxic shock in mice with septicemia315. Furthermore, 
cathelicidins are readily incorporated into NETs in vivo, where they stabilize the structure and 
contribute to their antimicrobial effects285.  
 
Finally, low concentrations of LL-37 prevent the formation of Pseudomonas aeruginosa 
biofilms316. Microarray studies revealed that cathelicidin downregulates the expression of 
quorum-sensing-controlled genes and upregulates type IV pili, thereby increasing twitching 
behaviour and impairing attachment of the bacteria to each other and/or other surfaces316. 
As such, immobilized or gel-trapped cathelicidins are commonly used to coat medical devices 





Cathelicidin exhibits potent anti-viral activity285. Both LL-37 and mCRAMP reduce disease 
severity and viral load in mice infected with influenza A virus (IAV)317. More specifically, 
animals treated with therapeutic cathelicidin had lower concentrations of pathogenic, pro-
inflammatory cytokines in the lung compared to untreated controls317. However, this was not 
a result of direct anti-viral activity. Conversely, Currie and colleagues demonstrated that LL-
37 prevented respiratory syncytial virus (RSV)-induced cell death in epithelial cultures by 
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significantly inhibiting the production of new infectious particles and reducing the spread of 
infection318. Similarly, Bergman et al. discovered that LL-37 is capable of inhibiting the 
replication of HIV in vitro in primary CD4+ T cells and cell lines319. 
 
Electron microscope studies have shown that LL-37 exerts its effects, in part, by disrupting 
the viral membrane, thereby impairing viral survival and propagation within infected cells320. 
For instance, Dean et al. found that human cathelicidin removes the outer membrane of 
vaccinia virus (VV), which results in exposure of normally sequestered antigens and viral 





Cathelicidin possesses anti-fungal activity against multiple fungi, including C. albicans322. 
Human LL-37 and mouse  mCRAMP have both been shown to kill this fungus by 
permeabilizing the membrane and inhibiting fungal growth322. LL-37 induces rapid phase 
separation and disintegration of the C. albicans membrane into discrete vesicles, resulting in 
the formation of large pores and the instantaneous efflux of small molecules such as ATP323. 
However, it has been suggested that this is not the sole cause of death: increased membrane 
permeability may lead to the uptake of the peptide and intracellular effects324. For example, 
Ho Wong and colleagues found that reactive oxygen species could be detected in the yeast 
form of C. albicans after treatment with active human cathelicidin fragments324.  
 
In addition, Luo et al. recently showed that synthetic LL-37 directly binds to the surface of A. 
fumigatus and disrupts the integrity of the cell wall325. LL-37 inhibits mycelial growth in a 
concentration-dependent manner and significantly attenuates mycelial adhesion and the 
invasion/destruction of epithelial cells325. Moreover, cathelicidin-overexpressing mice are 
less susceptible to pulmonary A. fumigatus infection compared to wildtype animals325.  
 
 
1.5.5 The immunomodulatory effects of cathelicidin 
 
As well as exerting powerful antimicrobial effects, cathelicidins play a significant 
immunomodulatory role285. They are capable of directly and indirectly recruiting, activating 
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1.5.5.1 Cathelicidin acts through multiple receptors  
 
Cathelicidins are both immunostimulatory and immunoregulatory282,285. One explanation for 
the plethora of effects exerted by cathelicidin is that they are driven by the activation of 
multiple receptors, dependent on cell type and context326. For example, LL-37 can activate 
Formyl Peptide Receptor 2 (FPR2), a pertussis toxin-sensitive G-protein coupled receptor 
(GPCR), to recruit peripheral blood neutrophils, monocytes and T cells to sites of 
inflammation327. However, several groups have shown that specific FPR2 blockers, such as 
WRW4, could not abrogate the effect of LL-37 under certain conditions326. Several other 
GPCRs have consequently been suggested to mediate the effects of cathelicidin, including 
the IL-8 receptor CXCR2: Zhang et al. demonstrated that binding of LL-37 to CXCR2 on 
neutrophils induced intracellular calcium mobilization and promoted their migration328.  
 
Alternative receptors of cathelicidin include the purinergic P2X7 receptor (P2X7R), which 
binds to extracellular ATP and whose activation leads to inflammasome formation and the 
processing of IL-1β and IL-8329. For example, the ability of LL-37 to stimulate fibroblast growth 
was inhibited by P2X7R inhibitors330. However, the precise mechanism through which LL-37 
activates P2X7R remains unknown326. It has been suggested that unlike GPCRs who generally 
require a structurally unique ligand, the interaction with P2X7R could be a consequence of 
cathelicidin inserting itself into the membrane and interacting with the C’ terminal end of the 
receptor326. In a similar vein, Tjabringa and colleagues demonstrated that LL-37 promotes 
innate immunity at the airway epithelial surface by transactivating the epidermal growth 
factor receptor (EGFR) via metalloproteinase-mediated cleavage of membrane-anchored 
EGFR-ligands331. In addition, transactivation of EGFR by LL-37 was also shown to contribute 
to wound healing by inducing keratinocyte migration332.  
 
In addition, cathelicidin can be taken up by cells in a non-specific manner333,334. For instance, 
LL-37 can bind to extracellular DNA plasmids through electrostatic interactions and target 
them to the nuclear compartment of mammalian cells (human embryonic fibroblasts, 
bladder carcinoma cells), in a process that is dependent on lipid rafts and proteoglycans333. 
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Furthermore, Lande and colleagues demonstrated that LL-37 helps break innate tolerance 
and drives autoimmunity in psoriasis by binding to self-DNA to form aggregated and 
condensed structures that are delivered to and retained within early endocytic 
compartments in plasmacytoid DCs (pDC)334. This triggers TLR9 and interferon production334. 
In both studies, a specific receptor was not required.  
 
 
1.5.5.2 The pro-inflammatory effects of cathelicidin 
 
Cathelicidins promote the expression of pro-inflammatory cytokines and cytokine 
receptors285. For instance, LL-37 increases blood monocyte polarization of macrophages 
towards a more pro-inflammatory M1 phenotype335. van der Does et al. found that even the 
treatment of fully matured M2 macrophages with LL-37 for 6 days resulted in an enhanced 
M1 pro-inflammatory cytokine signature upon LPS stimulation335.  
 
Cathelicidins can also influence the maturation and function of DCs285. LL-37 stimulates the 
differentiation of monocytes into immature DCs, which express higher levels of HLA-DR and 
the co-stimulatory molecule, CD86336. Similarly, LL-37 promotes the very rapid and highly 
efficient sensing of CpG motifs in bacterial DNA by human pDCs337. This results in the 
upregulation of CD40/CD86 and increased IL-6 production, thereby promoting rapid 
responses to invading microbes337. Gwyer Findlay et al. demonstrated that DCs generated in 
the presence of human cathelicidin enhance the proliferation, activation and cytokine 
production of CD8+ T cells, which in turn promote tumour regression in established squamous 
cell carcinomas in mice338.  
 
Cathelicidin can act as a T cell autoantigen285. Two-thirds of patients with moderate to severe 
plaque psoriasis harbour LL-37-specific T cells, which produce significant amounts of IFNg and 
IL-17339. The presence of circulating LL-37-specific T cells correlates with disease activity, 
suggesting a contribution to disease pathogenesis339. It is thought that high levels of LL-37 
bind to self-DNA released by dead cells in psoriatic lesions, forming a complex that activates 
intracellular TLRs within pDCs334. This breaks tolerance to self-antigens and promotes a 
strong IFNa response, resulting in the maturation of conventional DCs and the subsequent 
pathogenic proliferation of Th1 cells334.  
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Cathelicidins can also influence T cell proliferation and differentiation285. Thomi and 
colleagues demonstrated that LL-37 increased the proliferation of healthy, human CD4+ T 
cells in vitro340. Moreover, cathelicidin can act as an immune adjuvant: immunisation with 
OVA and mCRAMP led to increased splenocyte proliferation, as well as enhanced cytokine 
production and OVA-specific humoral responses341. In addition, LL-37-derived DCs display 
enhanced secretion of Th1 inducing cytokines such as IL-12, and are therefore capable of 
promoting Th1 differentiation in vitro336. LL-37 is localized inside the nucleus after it has been 
endocytosed and some have postulated that it can act directly as a transcription factor or 
enhancer to skew T cell polarization thanks to its ability to bind DNA and RNA285,342.  
 
It is important to note that the pro-inflammatory effects of cathelicidin can be beneficial to 
the host. Beaumont and colleagues demonstrated that the delivery of exogenous synthetic 
cathelicidin enhanced a protective pro-inflammatory response to P. aeruginosa lung 
infection, which promoted bacterial clearance from the lung in the absence of direct 
microbicidal activity343. More specifically, cathelicidin enhanced the development of an early 
pulmonary neutrophil response, which was absent in cathelicidin-deficient mice, resulting in 
significantly impaired pathogen clearance343.  
 
 
1.5.5.3 The anti-inflammatory effects of cathelicidin 
 
Cathelicidin stimulates the production of anti-inflammatory cytokines by a variety of cell 
types285. For instance, several studies have shown that LL-37-stimulated monocytes and 
macrophages produce IL-10 and upregulate their expression of TGFbR285. Furthermore, Choi 
et al. demonstrated that human cathelicidin enhances PBMC production of IL-1RA, a well-
known IL-1β antagonist, which inhibits IL-1β and TNFα production by IL-32 induced 
inflammatory monocytes344. Similarly, Luo and colleagues found that treatment of A. 
fumigatus-stimulated macrophages with LL-37 results in the downregulation of pro-
inflammatory cytokines such as IL-6 and TNFa325.  
 
Thanks to its cationic and amphipathic properties, extracellular cathelicidin can directly bind 
and neutralize negatively charged, hydrophobic LPS molecules, preventing its interaction 
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with TLR4 and suppressing endotoxin-mediated upregulation of inflammatory 
cytokines285,345. For example, TNFα release by human monocytes stimulated with LPS in vitro 
is dramatically reduced upon treatment with low, physiological concentrations of LL-37 (≤1 
μg/mL)346. In addition, the inhibition of TLR4 signalling in DCs by cathelicidin suppresses 
priming by LPS (downregulated HLA-DR, CD80, CD86) and the subsequent proliferation and 
differentiation of T lymphocytes (less IL-2 and IFNg)347. mCRAMP was also found to constrain 
allergic contact dermatitis by inhibiting TLR4-induced cytokine release and upregulation of 
co-stimulatory molecules such as CD40, CD80 and CD86, presumably by binding and 
neutralizing LPS348.  
 
Taken together, one could speculate that high concentrations of cathelicidin at the site of 
infection in vivo serve to directly kill the invading pathogen, whilst simultaneously 
neutralizing endotoxins released as a result of this killing285. This could prevent excessive 
immune activation and reduce the chance of septic shock285.  
 
 
1.5.5.4 Chemotaxis  
 
Cathelicidin can act as a direct chemoattractant to recruit both innate and adaptive immune 
cells to sites of inflammation285. For instance, LL-37 signals via FPR2 to attract a variety of 
leukocytes including neutrophils, eosinophils and monocytes349,350. However, it does not 
recruit monocyte-derived immature DCs through this mechanism because they 
downregulate FPR2 during differentiation351. Interestingly, while CD4+ T cells migrate 
towards LL-37, CD8+ T lymphocytes do not352.  
 
Cathelicidins can also indirectly promote chemotaxis by stimulating the expression of 
chemokines and chemokine receptors285. For example, several immune cells upregulate the 
expression of CCL2 in response to cathelicidin, including neutrophils, monocytes and 
macrophages, which in turn recruits T cells and DCs to the site of inflammation285,353. 
Furthermore, both LL-37 and mCRAMP induce CXCL10 expression, which attracts 
macrophages, T cells, NK cells and DCs354. Human cathelicidin also induces the production of 
IL-8 by macrophages, which stimulates neutrophil migration285,353.  
 
 




Cathelicidin suppresses apoptosis of several cell types during inflammation, including 
epithelial cells and neutrophils326. For instance, Nagaoka et al. demonstrated that LL-37 
prolongs the lifespan of neutrophils by suppressing apoptosis via the activation of FPR2 and 
P2X7R355. LL-37 has also been shown to provide anti-apoptotic signals to intestinal epithelial 
cells to maintain barrier integrity356. The inhibition of apoptosis results in a prolonged period 
where these cells are able to produce chemokines and cytokines, as well as clear microbes 
from the site of infection326. However, uncontrolled regulation of apoptosis can cause 
disease326. Systemic sclerosis patients display increased levels of LL-37, which correlate with 
their fibroblasts’ inability to undergo apoptosis357. Similarly, Chamorro and colleagues 
suggested that the overexpression of LL-37 may contribute to reduced keratinocyte 
apoptosis in conditions such as psoriasis358.  
 
Conversely, several reports suggest that cathelicidin promotes apoptosis of certain cell 
types359,360. For example, Mader and colleagues demonstrated that LL-37 induces granzyme-
mediated apoptosis of regulatory T cells and cytotoxic CD8+ T lymphocytes359,360. However, it 
is important to note that the concentration of cathelicidin used in these studies was very high 
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Figure 1.9: The biological effects of cathelicidins. Cathelicidins directly kill bacteria, viruses and 
fungi. Cathelicidins induce the production of both anti-inflammatory and pro-inflammatory 
cytokines and receptors. Cathelicidins influence T cell differentiation and DC maturation/function. 
Cathelicidins can also directly and indirectly promote chemotaxis of other cell types to the site of 
inflammation.  
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1.6 Preliminary Data 
 
Preliminary data generated by the laboratory (Lucy Jackson Jones, Emily Gwyer Findlay) 
suggests that cathelicidin plays a role in the development of Th17 responses.  
 
More specifically, in a pilot study using a model of inflammation induced by heat-killed 
Salmonella typhimurium (HKST), wildtype C57Bl6/JOlaHSd (WT) and cathelicidin knockout 
(Camptm1Rlg, KO) mice were subcutaneously inoculated with 25 µg HKST in to the top of each 
hind paw. Mice were culled on day 7 and the draining popliteal lymph nodes removed. Cells 
were then re-stimulated for three days before assessing cytokine production by ELISA. 
mCRAMP KO mice displayed a complete loss of IL-17 production and a significant increase in 
IFNg compared to WT animals (Figure 1.10 B). However, other cytokines measured following 
re-stimulation, including IL-10, were no different between the two genotypes.  
 
Interestingly, KO mice that were inoculated with Schistosoma mansoni eggs, which promotes 
type-two driven inflammation, did not display a significantly different response: the 
concentrations of Th2 cytokines, such as IL-5, were no different (Figure 1.10 C).  
 
This data shows that mCRAMP-deficient mice have a specific defect in IL-17 production 
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Figure 1.10: mCRAMP KO mice cannot produce IL-17 in response to immunization with heat-
killed S. typhimurium A) WT and CRAMP KO mice were inoculated with 25 µg HKST or 2500 
S.manosni eggs. Draining popliteal lymph nodes were harvested on day 7 and cells re-stimulated 
for 3 days before assessing cytokine production by ELISA B) Concentration of IL-17A, IFNɣ and IL-
10 in cell culture supernatants following re-stimulation with HKST C) Concentration of IL-5 and IL-
10 in cell culture supernatants following re-stimulation with SEA. Data shown is mean +/- standard 
error. Statistical significance (where * represents < 0.05, ** < 0.01) was determined using a 
unpaired t-test. Experiments performed by Lucy Jackson Jones and Emily Gwyer Findlay. WT: 
wildtype; KO: knockout; HKST: heat-killed S. typhimurium; SEA: S. mansoni soluble egg antigen; s.c: 
subcutaneous.  
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1.7 Aims and Objectives 
 
Preliminary data generated by the laboratory suggests that cathelicidin has a profound 
impact on T cell behaviour. I hypothesized that cathelicidin plays a role in the generation and 
amplification of Th17 responses during inflammation. The aims of this project were therefore 
to: 
 
1) Determine the impacts of mouse cathelicidin (mCRAMP) on CD4+ Th17 and CD8+ Tc17 
differentiation in vitro. 
 
2) Analyse genetic changes induced by mCRAMP in CD4+ T cells cultured under Th17-
driving conditions and identify the mechanism through which it acts. 
 
3) Identify the cellular source of mCRAMP responsible for boosting Th17 responses in 




































Wild type C57Bl/6JOlaHsd and mCRAMP knockout (Camptm1Rlg) mice were bred and housed 
in individually ventilated cages, under specific pathogen-free conditions. Knockout mice were 
backcrossed with the wildtype population for 10 generations. Male and female mice 
between 6-12 weeks of age were used.  All animal experiments were performed in 
accordance with Home Office UK project licenses PAF438439 and 70/8884, under the Animal 





mCRAMP, LL-37, scrambled LL-37, PP47, human b defensin 2 (hBD2), bactenecin 2A (Bac2A) 
and indolicidin were custom synthesized by Almac (Penicuik, Scotland) using Fmoc solid 
phase synthesis and reversed phase HPLC purification (Table 2.1). Peptide identity was 
confirmed by electrospray mass spectrometry. Purity (>95% area) was determined by RP-
HPLC and net peptide content determined by amino acid analysis. D-LL-37 was a kind gift 
from Professor P. Barlow (Edinburgh Napier University). Lyophilized peptides were 
reconstituted in endotoxin free water at 5 mg/mL. Reconstituted peptides were tested for 
endotoxin contamination using a Limulus Amebocyte Lysate Chromogenic Endotoxin 




Peptide Amino Acid Sequence Net Charge 
mCRAMP GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ +6 
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES +6 
Scrambled LL-37 RSLEGTDRFPFVRLKNSRKLEFKDIKGIKREQFVKIL +6 
D-LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES* +6 
PP47 EFKRIVQRIKDFLRNLVPRTES +3 
Bac2A RLARIVVIRVAR +4 
Indolicidin ILPWKWPWWPWRR +4 
hBD2 GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP +6 
 
Table 2.1: Antimicrobial Peptides. Peptides used throughout this study, their corresponding amino 
acid sequences and net charge. *D-enantiomer.  
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2.3 Mouse Tissue Isolation and Single Cell Preparations 
 
Mice were culled by rising CO2 and the tissues of interest harvested into complete medium 
(RPMI, 10% fetal calf serum, 10 units/mL penicillin, 10 μg/mL streptomycin and 2 mM L-
glutamine, all supplied by Gibco, ThermoFisher UK).  
 
2.3.1 Spleen, Mesenteric Lymph Nodes and Peyer’s Patches 
 
Tissues were mashed through a 100 µM strainer and the resulting cell suspension centrifuged 
for 5 mins at 900 x g. If necessary, red blood cells were lysed by adding 1 mL of 1X Lysis Buffer 
(BD, #555899) and incubating at room temperature for 3 mins. The reaction was stopped by 




One lobe of the liver was mashed through a 100 µM strainer and the resulting cell suspension 
centrifuged for 5 mins at 900 x g. Hepatic lymphocytes were isolated by Percoll density 
gradient centrifugation. Cells were resuspended in 15 mL 37.5% Percoll in HBSS and 
centrifuged for 10 mins at 900 x g. The supernatant containing hepatocytes was discarded 
and the cell pellet resuspended in complete medium. Red blood cells were lysed, as 




One lung lobe was added to 1X PBS containing 0.2 mg/mL Collagenase VIII (Sigma Aldrich, 
#C2139) and minced with scissors. This was then incubated at 37°C, with shaking, for 20 mins. 
The reaction was stopped by adding an excess of 1X PBS and mashing the digested tissue 
through a 100 µM strainer. The cells were washed twice more in 1X PBS, and the red blood 
cells lysed as previously described.  
 
2.3.4. Bone Marrow 
 
Femurs were taken and the bones cleaned by removing any excess tissue. The bone marrow 
was then flushed out with complete medium and single cell suspensions prepared by passing 
the cells through a 19G needle.  
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2.4 EasySepTM Cell Isolations 
 
2.4.1 Mouse T Cell Isolation 
 
EasySep separation was used to isolate a highly purified population of CD3+ T cells from 
single-cell suspensions of mouse splenocytes, as per the manufacturer’s instructions 
(StemCell Technologies, #19851). Cells were resuspended at 1 x 108 cells/mL in 1 X PBS and 
incubated with 50 µL/mL rat serum and 50 µl/mL Isolation Cocktail for 10 mins at room 
temperature. 75 µL/mL Streptavidin RapidSpheres was then added for 2.5 mins. Samples 
were topped up to 2.5 mL with 1X PBS and placed in a suitable magnet for a further 2.5 mins. 






2.4.2 Mouse Neutrophil Enrichment 
 
Bone marrow-derived neutrophils were isolated using the EasySepTM Mouse Neutrophil 
Enrichment Kit, as per the manufacturer’s guidelines (StemCell Technologies, #19762). Cells 
were resuspended at 1 x 108 cells/mL in 1X PBS, with 50 µL/mL rat serum and 50 µL/mL 
Enrichment Cocktail for 15 mins at 4°C. Samples were then washed in 1X PBS and centrifuged 
for 10 mins, 300 x g. Supernatants were discarded and the cells resuspended in the original 
volume of 1X PBS. Samples were incubated with 50 µL/mL Biotin Selection Cocktail for 
another 15 mins at 4°C, followed by 150 µL/mL Magnetic Particles for 10 mins at 4°C. Finally, 




Figure 2.1: Example purity of splenic T cells (CD4+ and CD8+) isolated by EasySep. 
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2.5 In Vitro Differentiation of Th1, Th2, Th17 and Treg subtypes 
 
200,000 cells were plated in complete medium and cultured at 37°C, 5% CO2, 100% humidity, 
with the correct combination of cytokines and neutralizing antibodies (Table 2.2).  
 
 
2.5.1 Th1 Differentiation  
 
200,000 whole splenic single cell suspensions were plated in an aCD3-coated well in 
complete medium with rIL-12, rIL-18 and rIL-2, with or without 2.5 µM mCRAMP. Cells were 
split (1:2) on day 2 and IFNg production assessed by flow cytometry on day 3.  
 
 
2.5.2 Th2 Differentiation  
 
200,000 whole splenic single cell suspensions were plated in an aCD3-coated well in 
complete medium with rIL-4, rIL-2, aIL-12 and aIFNg, with or without 2.5 µM mCRAMP. Cells 
were split (1:2) on day 2 or 3, depending on growth. IL-4 production was assessed by flow 
cytometry on day 4.  
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2.5.3 Th17 Differentiation  
 
200,000 whole splenic single cell suspensions were plated in an aCD3-coated well in 
complete medium with rIL-6, rIL-23 and rTGFb, with or without 2.5 µM mCRAMP. Cells were 
cultured for 1-3 days before phenotypic analysis by flow cytometry. When using pure 
populations of CD3+, CD4+ or CD8+ T cells, aCD28 was also included to ensure T cell activation.  
 
 
2.5.4 Treg Differentiation  
 
CD4+ T cells were isolated from mouse splenocytes by fluorescence activated cell sorting. 
200,000 sorted CD4+ T cells were plated in an aCD3-coated well in complete medium with 
rTGFb and aCD28, with or without 2.5 µM mCRAMP. FOXP3 expression was assessed by flow 
cytometry on days 2 and 5.  
 
 
2.5.5 Splenocyte – neutrophil co-cultures 
 
To examine the effects of neutrophils on Th17 differentiation, splenocyte – neutrophil co-
cultures were carried out. Bone marrow neutrophils were isolated by EasySep, as previously 
described and re-suspended at a concentration of 10 million cells/mL in 1X PBS. Neutrophils 
were activated and induced to degranulate by stimulating them with 10 µM cytochalasin B 
for 5 mins at 37°C, with shaking, followed by 100 nM fMLF for a further 25 mins. Neutrophils 
were plated with whole singe cell splenic suspensions at a ratio of 1:1 and cultured under 
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2.6 Flow Cytometry 
 
2.6.1 Surface staining for flow cytometry  
 
Cells were harvested and washed twice in 1X PBS before live/dead staining. Samples were 
incubated for 20 mins with 100 µL of Live/Dead Yellow (in 1X PBS, working dilution: 1/1000; 
Invitrogen, #L-34959) at 4°C, protected from light. Cells were then washed with 1X PBS, 
resuspended in 50 µL of FACS buffer (1X PBS + 2% FCS) containing the surface antibody 
cocktail (Table 2.3), and incubated in the dark for 20 mins at 4°C. Samples were washed again 

































Figure 2.3: Gating strategy: surface staining of T cells to assess activation status. Cells were 
first gated for lymphocytes (SSC-A vs FSC-A). Doublets and dead cells were excluded from the 
analysis. Surface expression of PD1, CD44 and CD62L was analysed on CD4+ and CD8+ T cells.  
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2.6.2 Intracellular cytokine staining for flow cytometry 
 
Cells were first stimulated for 4 hrs at 37°C with a Cell Stimulation Cocktail containing PMA, 
ionomycin and protein transport inhibitors (eBioscience, #00-4970-03, working dilution: 
1/500).  
 
After staining for surface markers, cells were fixed and permeabilised for 20 mins at 4°C in 
150 µl BD Cytofix/Cytoperm (BD Biosciences, #554722). Cells were then washed with 1X BD 
Perm/Wash buffer (BD Biosciences, #554723) and stained in 50 µL containing the 
intracellular cytokine antibody cocktail (Table 2.3). Samples were incubated in the dark for 
30 mins at 4°C, before being washed again in 1X BD Perm/Wash and resuspended in FACS 






























Figure 2.4: Gating strategy: intracellular staining of T cells to assess cytokine production. Cells 
were first gated for lymphocytes (SSC-A vs FSC-A). Doublets and dead cells were excluded from 
the analysis. IL-17A and IFNg production by CD4+ and CD8+ T cells was analysed accordingly. 
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2.6.3 Intracellular transcription factor staining for flow cytometry 
 
Cells were stained for transcription factors using the True-Nuclear Transcription Factor Buffer 
Set, as per the manufacturer’s guidelines (Biolegend, #424401). Cells were harvested and 
stained for surface markers as previously described, before fixation in 150 µL 1X Fix solution 
for 1 hour at room temperature. Cells were then washed in 1X Perm Buffer and stained in 50 
µL containing the transcription factor antibody cocktail (Table 2.3), for 30 mins at room 
temperature, protected from light. Samples were washed in 1X Perm buffer, resuspended in 













Figure 2.5: Gating strategy: intracellular staining to assess transcription factor expression. Cells 
were first gated for lymphocytes (SSC-A vs FSC-A). Doublets and dead cells were excluded from 
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2.6.4 Annexin/propidium iodide apoptosis assay  
 
Cell viability was assessed by flow cytometry using the Annexin-V-FLUOS Staining Kit, as per 
the manufacturer’s instructions (Roche, #11 858 777 001). Cells were first stained for surface 
markers before being resuspended in 50 µL Incubation Buffer containing Annexin-V-FLUOS 
labelling reagent (working dilution: 1/50) and Propidium Iodide Solution (working dilution: 
1/50). Cells were incubated for 15 mins at room temperature, protected from light, and then 



























Figure 2.6: Gating strategy: assessment of T cell viability. Cells were first gated for lymphocytes 
(SSC-A vs FSC-A) and doublets excluded from the analysis. Cell viability was assessed by analysing 
the uptake of propidium iodide (PI) and the expression of annexin by CD4+ and CD8+ T cells.  
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2.6.5 CFSE cell proliferation assay 
 
 In order to assess cellular proliferation, samples were resuspended in 1X PBS and stained 
with CFSE (carboxyfluorescein succinimidyl ester, Invitrogen, #C34554, working dilution: 
1/1000) at 37°C for 20 mins and then washed twice with an excess of media. Proliferation 
analysis by dye dilution was performed by flow cytometry on day 2, following culture under 























Figure 2.7: Proliferation analysis by CFSE dye dilution. Each generation’s fluorescence intensity is 
half that of its parents because the CFSE is split evenly between the daughter cells during mitosis. 
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Marker Fluorochrome Clone Catalogue # Company Dilution 
AHR PE-Cy7 4MEJJ 25-5925-80 eBioscience UK 1/200 
CD103 BV421 2E7 121422 Biolegend UK 1/200 
CD11b APC-Cy7 M1/70 101226 Biolegend UK 1/200 
CD11c PE-Cy7 N418 117318 Biolegend UK 1/200 
CD25 BV510 PC61 102041 Biolegend UK 1/200 
CD3 AF700 17A2 100216 Biolegend UK 1/200 
CD4 APC GK1.5 100412 Biolegend UK 1/200 
CD4 BUV395 RM4-5 740208 BD Biosciences 1/200 
CD4 AF647 GK1.5 100424 Biolegend UK 1/200 
CD4 BV785 GK1.5 100453 Biolegend UK 1/200 
CD4 FITC GK1.5 100406 Biolegend UK 1/200 
CD44 ef450 IM7 48-0441-82 eBioscience UK 1/200 
CD62L BV570 MEL-14 104433 Biolegend UK 1/200 
CD64 APC X54-5/7.1 139306 Biolegend UK 1/200 
CD8 BUV395 53-6.7 563786 Biolegend UK 1/200 
CD8 BV650 53-6.7 563234 Biolegend UK 1/200 
CD86 BV650 GL-1 105035 Biolegend UK 1/200 
CLEC9A PE 7H11 143504 Biolegend UK 1/200 
FOXP3 BV421 MF-14 126419 Biolegend UK 1/200 
gd TCR APC/Fire 750 GL3 118136 Biolegend UK 1/200 
GITR PerCP-Cy5.5 DTA-1 126315 Biolegend UK 1/200 
GMCSF PE MP1-22E9 12-7331-82 eBioscience UK 1/100 
IFNɣ PE-Cy7 XMG1.2 505825 Biolegend UK 1/100 
IL-17A PE/Dazzle 594 TC11-18H10.1 506937 Biolegend UK 1/100 
IL-17F AF647 9D3.1C8 517004 Bioegend UK 1/100 
IL-22 PerCP-Cy5.5 POLY5164 516411 Biolegend UK 1/100 
IL-23R PE 12B2B64 150904 Biolegend UK 1/200 
IL-4 PE 11B11 504103 Biolegend UK 1/100 
IL-6Rα APC D7715A7 115811 Biolegend UK 1/200 
IRF8 APC V3GYWCH 17-9852-80 eBioscience UK 1/200 
MHCII PerCP-Cy5.5 M5/114.15.2 107625 Biolegend UK 1/200 
PD1 PE 29F.1A12 135016 Biolegend UK 1/200 
RORɣt PE B2D 12-6981-80 eBioscience UK 1/200 
SIRPα FITC P84 144006 Biolegend UK 1/200 
T-bet PerCP-Cy5.5 4B10 644805 Biolegend UK 1/200 
TNFα BV421 MP6-XT22 506325 Biolegend UK 1/100 
XCR1 PerCP-Cy5.5 ZET 148207 Biolegend UK 1/200 
 
Table 2.3: List of antibodies used for flow cytometry.  
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2.7 Gene Expression 
 
2.7.1 RNA extraction 
 
RNA was extracted using the Qiagen RNeasy Mini Kit (Qiagen, #74104), as per the 
manufacturer’s guidelines. Up to 1 x 106 cells were disrupted in lysis buffer containing β-
mercaptoethanol and homogenised using QIAshredder columns. Genomic DNA 
contamination was eliminated by passing the sample through a gDNA Eliminator spin 
column. 70% Ethanol was then added to promote selective binding of RNA to the RNeasy 
membrane. Finally, the sample was washed multiple times and RNA eluted using RNase-free 
water, pre-warmed to 45°C.  
 
 
2.7.2 Nanostring  
 
Mouse Th17 cultures were set up as previously described (48 wells per condition, 200,000 
cells per well, a total cell count of 9.6 million). On Day 1, wells were pooled and DAPI- γδ- 
CD4+ T cells were sorted on a BD FACSAria III into 1X PBS + 2% FCS. Samples were centrifuged 
for 5 mins at 900 x g and the RNA extracted immediately. Multiplex gene expression analysis 
(Mouse Immunology Panel) was performed by HTPU Microarray Services, University of 
Edinburgh. Analysis of nanostring data was carried out using nSolver 4.0 and nCounter 
Advanced Analysis software. Data was normalized to internal reference controls and 
differentially expressed genes analysed. Genes with a log2 fold change of 1 or more and a p 
value of 0.05 or less were deemed of interest and statistically significant.  
 
 
2.8 Protein Expression 
 
2.8.1 Cytokine ELISAs 
 
Concentrations of mouse IL-17A (Biolegend, #432504), IL-2 (Biolegend, #431004), IL-22 
(Biolegend, #431004), IL-23 (R&D Systems, #DY1887), IL-6 (Biolegend, #431304), IFNγ 
(Biolegend, #430804) and TGFb (R&D Systems, #DY1769) were determined in cell culture 
supernatants by ELISA, as per the manufacturer’s guidelines. 96 well microplates were 
coated with 100 µL capture antibody and incubated overnight at 4°C. Plates were then 
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washed and blocked for at least one hour with 1X Assay Diluent. Samples of interest and 
standards were incubated for 2 hours, prior to the addition of the detection antibody for a 
further hour. After washing, Streptavidin-HRP was added and incubated for 20 mins, 
protected from light. Finally, wells were incubated with TMB substrate solution until a strong 
colour developed, at which point the reaction was stopped (Invitrogen, #11652159). The 
optical density of each well was read at 450 nm (corrected to 570 nm), and cytokine 
concentrations calculated from a standard curve. 
 
 
2.9 In Vivo Mouse Models of Inflammation 
 
2.9.1 Heat-killed Salmonella typhimurium model 
 
Heat-killed Salmonella typhimurium (HKST) was a kind gift from Professor Andrew McDonald 
(Lydia Becker Institute, University of Manchester). 25 µg HKST was injected subcutaneously 
in to the top of each hind paw in 50 µL PBS. Mice were monitored daily and the draining 
popliteal lymph nodes removed 7 days later.  Single cell suspensions were prepared as 
previously described.  
 
Neutrophil depletion: mice were injected intraperitoneally with 200 µg anti-Ly6G (clone 1A8; 
BioXCell, #BE0075-1) in 200 µL PBS on days -1, 1 and 3.  
 
 
2.9.2 Ear inflammation model  
 
Skin inflammation was induced by daily application of a topical dose of 40 mg AldaraTM cream, 
containing 5% imiquimod, with or without 5 µg CRAMP, on each ear for 3 days. Ears and 
draining proximal auricular lymph nodes were collected for flow cytometric analysis. Lymph 
nodes were prepared as previously described. Ears were minced and enzymatically digested 
in a cocktail containing collagenase VIII (Sigma, #C2139) and DNaseI (Zymo Research, #E1010) 
for 45 mins at 37°C, with shaking. Samples were dissociated using a gentleMACSTM 
dissociator, program B (Miltenyi Biotec), passed through a 100 µM filter and washed. 
 
 




All data shown are expressed as individual data points with line at mean. Analysis was 
performed with GraphPad Prism software. Two groups were compared with Student’s t-
tests. Multiple groups were compared by one- or two-way analysis of variance tests with 
either Bonferroni or Dunnett post-tests. “N” refers to individual mice. A minimum of three 
mice was used over at least 2 experiments to mitigate cage/individual mice effects. A power 



























































Th17 cells play an important role in driving many autoimmune and chronic inflammatory 
disorders361. For instance, IL-23 is essential for inducing the pathogenic features of Th17 
lymphocytes and single nucleotide polymorphisms in the IL23R gene have been linked to a 
number of autoimmune conditions, including rheumatoid arthritis (RA), multiple sclerosis 
(MS),  and psoriasis362,363. Furthermore, studies using IL-17-, IL-22-, or IL-23-deficient mice, as 
well as antibody-mediated inhibition, have shown that these Th17-related cytokines are 
required for the development of autoimmunity363.  
 
A role for cathelicidin in the pathogenesis of several autoimmune disorders has also recently 
emerged364. For example, levels of human cathelicidin (LL-37) are elevated in the psoriatic 
epidermis284. LL-37 promotes loss of tolerance by forming complexes with inert self-DNA, 
which stimulates TLR9 in psoriatic dermal plasmacytoid DCs (pDCs) and type I IFN 
production334. Furthermore, increased expression of LL-37 and its activating protease 
(proteinase-3) have been detected in RA patients364,365. LL-37 induces apoptosis of 
osteoclasts, which contributes to reduced bone formation in arthritic joints366.  
 
Several reports have linked cathelicidin to IL-17. For instance, elevated levels of LL-37 in 
hidradenitis suppurativa (HS) lesions positively correlates with the concentration of IL-17 and 
IL-23340. Moreover, the release of type I IFN by pDCs following TLR9 stimulation by LL-37/self-





Preliminary data generated by the laboratory (Lucy Jackson Jones, Emily Gwyer Findlay) 
demonstrated that, following inoculation with heat-killed S. typhimurium (HKST), mice 
deficient for cathelicidin (mCRAMP) displayed a complete loss of IL-17 production compared 
to wildtype animals (Chapter 1: Figure 10).  
 
I hypothesized that mCRAMP is necessary for the development of a Th17 response during 
inflammation. I therefore sought to: 
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1) Determine whether mCRAMP KO mice possess an underlying T cell defect that is 
responsible for their inability to produce IL-17 in response to HKST 
 





3.3.1 CD4+ T cells that develop in the absence of mCRAMP have normal cytokine 
responses 
 
Pilot data demonstrated that mCRAMP KO mice had a near absolute defect in production of 
IL-17 in response to inoculation with HKST. I therefore first sought to determine whether 
CD4+ T cells that developed in the absence of this host defence peptide were normal, or 
whether they possessed an underlying defect that was responsible for their inability to 
mount a Th17 response.  
 
I compared CD4+ T cell cytokine production ex vivo in a variety of different tissues from naïve 
WT and mCRAMP KO mice by intracellular flow cytometry, in order to assess baseline 
cytokine responses (Figure 3.1). Fluorescence minus one (FMO) controls were used to define 
gates in the context of data spread due to the use of multiple fluorochromes.  
 
There were no significant differences in the production of IL-17A, IL-17F, IFNg, IL-22 or GM-
CSF in the liver, lungs, spleen, mesenteric lymph nodes or Peyer’s patches. However, a 
significant increase in the frequency of CD4+ TNFa+ T cells was observed in the liver of 
mCRAMP-deficient mice (Figure 3.1 D: from 46.00% +/- 7.00 to 67.23% +/- 3.00). Despite this, 
these data suggest that CD4+ T cells that develop in the absence of mCRAMP have relatively 
normal cytokine responses at resting state, but that the Th17 response is impaired in vivo 





















































































Figure 3.1: Naïve T cells that develop in the absence of mCRAMP have normal cytokine 
responses. CD4+ T cell cytokine production in the liver, lungs, spleen, Peyer’s patches and 
mesenteric lymph nodes from naïve WT and mCRAMP KO mice was assessed by intracellular flow 
cytometry (A) Representative plots of IL-17A production by CD4+ T cells in WT and mCRAMP KO 
mice (B) Percentages of CD4+ IL-17A+ T cells in WT and KO mice (C) Percentages of CD4+ IL-17F+ T 
cells in WT and KO mice (D) Percentages of CD4+ TNFα+ T cells in WT and KO mice (E) Percentages 
of CD4+ IFNɣ+ T cells in WT and KO mice (F) Percentages of CD4+ IL-22+ T cells in WT and KO mice 
(G) Percentages of CD4+ GM-CSF+ T cells in WT and KO mice. Data shown is mean +/- standard 
error. N = 4. Statistical significance (where * represents < 0.05) was determined using an unpaired 
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3.3.2 CD4+ T cells from mCRAMP-deficient mice can produce IL-17 in response to 
exogenous cytokines 
 
Next, I sought to determine whether CD4+ T cells from mCRAMP KO animals were capable of 
producing IL-17 in vitro in response to exogenous Th17-polarizing cytokines. Whole single 
cell splenic suspensions from WT and mCRAMP KO mice were cultured under Th17-driving 
conditions with IL-6, IL-23 and TGFb for 2 days, using the standard Th17-generating 
protocol368. IL-17A production was assessed by intracellular flow cytometry on day 2 (Figure 
3.2).  
 
There was no significant difference in the percentage of CD4+ IL-17A+ T cells between WT and 
KO mice (WT: 14.03% +/- 1.01; KO: 13.40% +/- 1.30), demonstrating that CD4+ T lymphocytes 
from mCRAMP-deficient mice are capable of producing IL-17A and to the same extent as WT 
T helper cells. This provides further evidence suggesting that CD4+ T cells that develop in the 
















WT KO FMO IL-17A A B 
Figure 3.2: CD4+ T cells from mCRAMP-deficient mice can produce IL-17A in response to 
exogenous cytokines. Whole single cell splenic suspensions from WT and KO mice were cultured 
under Th17-driving conditions (with 20 ng/mL IL-6, 20 ng/mL IL-23 and 3 ng/mL TGFb) for 2 days 
(A) Representative plots of IL-17A production by CD4+ T cells in WT and mCRAMP KO mice on day 
2, assessed by flow cytometry (B) Percentages of WT and mCRAMP KO CD4+ IL-17A+ T cells on day 
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3.3.3 mCRAMP transiently increases the activation status of CD4+ T cells cultured 
under non-lineage-driving conditions  
 
I have shown that CD4+ T lymphocytes that developed in the absence of mCRAMP were 
capable of producing IL-17 and that cytokine production was unaffected in naïve KO mice. 
However, preliminary data demonstrated that mCRAMP-deficient animals could not produce 
IL-17 during inflammation induced by HKST (Chapter 1: Figure 1.10). I therefore hypothesised 
that mCRAMP enhances the development of T cell immunity. To test this, I cultured whole 
single cell splenic suspensions under non-lineage-driving conditions with plate-bound aCD3, 
with or without synthetic mouse cathelicidin (mCRAMP).  
 
Figure 3.3 shows that there were no significant differences in the total number of CD4+ T 








First, I sought to determine whether mCRAMP had any effect on T cell activation by analysing 
the expression of classical activation markers including PD1, CD44 and CD62L by flow 
cytometry every 24 hours for 3 days (Figure 3.4). Activated T cells are defined as being CD62L- 
CD44+. CD62L acts as a homing receptor for naïve lymphocytes to enter secondary lymphoid 
tissues where they encounter antigen and is consequently downregulated upon T cell 
activation, redirecting lymphocytes away from the lymph nodes and towards sites of 
infection/inflammation369. CD44 is another prominent activation marker that also plays a role 















Figure 3.3: mCRAMP has no effect on the total number of CD4+ T cells cultured under non-
lineage-driving conditions. Whole single cell splenic suspensions from WT mice were cultured 
under non-lineage-driving conditions (αCD3 only, 5 µg/mL), with or without 2.5 µM synthetic 
mCRAMP, for 3 days. N = 3.    
mCRAMP
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in early T cell signalling events370. mCRAMP significantly increased the percentage of CD4+ 
CD62L- CD44+ T cells, from 47.22% (+/- 3.46) to 53.27% (+/- 2.69), on day 1 (Figure 3.4 A). 
 
PD1 is an inhibitory receptor that is involved in the regulation of T cell activation262. It is 
induced by TCR-mediated signalling within 24 hours of stimulation and is therefore not 
expressed on resting T cells262. Almost 100% of CD4+ T cells were PD1+ by day 1 (data not 
shown). However, Figure 3.4 B shows that mCRAMP significantly increased the geometric 
mean of PD1, from 8133 (+/- 1040) to 12407 (+/- 948), on day 1. Furthermore, there was a 
trend indicating that this was also the case on days 2 and 3, although this was not statistically 
significant. 
 
Taken together, these data suggest that mCRAMP transiently increases the activation status 









































































Figure 3.4: mCRAMP transiently increases the activation of CD4+ T cells cultured under non-
lineage driving conditions. Whole single cell splenic suspensions from WT mice were cultured 
under non-lineage-driving conditions (αCD3 only, 5 µg/mL), with or without 2.5 µM synthetic 
mCRAMP, for 3 days (A) Representative plots of CD44 and CD62L expression by CD4+ T cells on day 
1, assessed by flow cytometry (B) Representative plots of PD1 expression by CD4+ T cells on day 1, 
assessed by flow cytometry (C) Percentages of CD62L- CD44+ T cells, ex vivo and days 1-3 (D) 
Geometric mean of PD1 expression by CD4+ T cells, ex vivo and days 1-3. Data shown is mean +/- 
standard error. N = 6. Statistical significance (where * represents < 0.05) was determined using a 
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3.3.4 mCRAMP does not affect cytokine production by CD4+ T cells cultured under 
non-lineage-driving conditions 
 
Next, I sought to determine whether mCRAMP had any effect on cytokine production. Whole 
single cell splenic suspensions were cultured with plate-bound aCD3, with or without 
synthetic mCRAMP, and the expression of IL-17A and IFNg determined by intracellular flow 
cytometry (Figure 3.5).  
 
The addition of mCRAMP to cells cultured under non-lineage polarizing conditions did not 
have any effect on CD4+ T cell cytokine production: no differences were observed in the 



























Figure 3.5: mCRAMP does not affect cytokine production by CD4+ T cells cultured under non-
lineage-driving conditions. Whole single cell splenic suspensions from WT mice were cultured 
under non-lineage-driving conditions (αCD3 only, 5 µg/mL), with or without 2.5 µM synthetic 
mCRAMP, for 3 days (A) Representative plots of IL-17A and IFNɣ expression by CD4+ T cells on day 
2, assessed by flow cytometry (B) Percentages of CD4+ IL-17A+ T cells, ex vivo and days 1-3 (C) 
Percentages of CD4+ IFNɣ+ T cells, ex vivo and days 1-3. Data shown is mean +/- standard error. N 
= 6. Statistical significance (where * represents < 0.05, ** < 0.01, *** < 0.001 and *** < 0.0001) 
was determined using a two-way repeated measures ANOVA with a Bonferroni multiple 
comparison post-test. UT: untreated.  
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3.3.5 mCRAMP increases the activation status of CD4+ T cells cultured under Th17-
driving conditions 
 
mCRAMP transiently increased CD4+ T cell activation but had no effect on cytokine 
production when the cells were cultured under non-lineage-driving conditions in the absence 
of polarizing cytokines. However, the pilot data discussed previously suggests that this host 
defence peptide is important for the generation of Th17 responses during inflammation 
induced by HKST (Chapter 1: Figure 1.10). CD4+ T cells from mCRAMP-deficient mice were 
capable of generating normal amounts of IL-17 in response to exogenous IL-17-inducing 
cytokines. I therefore hypothesised that mCRAMP plays a role in enhancing the development 
of Th17 lymphocytes. To address this, I examined the effects of adding synthetic mCRAMP to 
cells cultured under Th17-driving conditions. Whole single cell splenic suspensions were 
cultured in the presence of IL-6, IL-23 and TGFb, with or without synthetic mCRAMP.  
 
Figure 3.6 shows that mCRAMP had no significant effect on the total number of CD4+ T 








I first sought to determine whether mCRAMP had similar effects on T cell activation when 
the cells were cultured under Th17-polarizing conditions compared to non-lineage-driving 
(Figure 3.7). Once again, almost 100% of CD4+ T cells were PD1+ by day 1 (data not shown). 














Figure 3.6: mCRAMP has no effect on the total number of CD4+ T cells cultured under Th17-
driving conditions. Whole single cell splenic suspensions from WT mice were cultured under Th17-
driving conditions (20 ng/mL IL-6, 20 ng/mL IL-23 and 3 ng/mL TGFβ), with or without 2.5 µM 
synthetic mCRAMP, for 3 days. N = 3. 
UT
mCRAMP
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However, the geometric mean of PD1 was significantly increased by mCRAMP on days 1 to 3 
(Figure 3.7 C). For example, this increased by 43% from 15773 +/- 1134 to 22487 on day 2.  
Furthermore, activated T cells, defined as CD62L- CD44+, were significantly increased 
following exposure to mCRAMP (Figure 3.7 D). This was the case as early as day 1 (UT: 46.27% 
+/- 3.8; mCRAMP: 57.32% +/- 2.80) but was also observed on days 2 and 3.  
 
These results indicate that mCRAMP increases the activation status of CD4+ T cells cultured 
under Th17-driving conditions. However, unlike when generated in the absence of 
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Figure 3.7: mCRAMP increases the activation status of CD4+ T cells cultured under Th17-driving 
conditions. Whole single cell splenic suspensions from WT mice were cultured under Th17-driving 
conditions, with or without 2.5 µM synthetic mCRAMP, for 3 days (A) Representative plots of CD44 
and CD62L expression by CD4+ T cells on day 2, assessed by flow cytometry (B) Representative 
plots of PD1 expression by CD4+ T cells on day 2, assessed by flow cytometry (C) Percentages of 
CD62L- CD44+ T cells, ex vivo and days 1-3 (D) Geometric mean of PD1 expression by CD4+ T cells, 
ex vivo and days 1-3. Data shown is mean +/- standard error. N = 6. Statistical significance (where 
*** represent < 0.001 and **** < 0.0001) was determined using a two-way repeated measures 
ANOVA with a Bonferroni multiple comparison post-test. UT: untreated.   
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3.3.6 mCRAMP increases IL-17 production by CD4+ T cells cultured under Th17-
driving conditions 
 
To further examine the effects of mCRAMP on Th17 cells, I analysed the expression of RORgt 
and IL-17 by CD4+ T cells. Whole single cell splenic suspensions from WT mice were cultured 
under Th17-driving conditions, as previously described, with or without synthetic mCRAMP.  
 
RORgt is the master transcription factor that, together with STAT3, promotes the expression 
of signature Th17 genes in response to IL-6 and TGFb43. To examine Th17 induction, RORgt 
expression was examined by intracellular flow cytometry every 24 hours for 3 days. Figure 
3.8 demonstrates that synthetic mCRAMP induced a significant increase in the percentage of 
CD4+ RORgt+ T cells on days 1 and 2 (Figure 3.8 C). For example, this rose from 17.00 % (+/- 
2.62) to 33.93% (+/- 4.97) on day 1.  
 
Reflecting the upregulation of RORgt expression, mCRAMP also significantly increased the 
percentage of CD4+ IL-17A+ T cells on days 2 and 3 (Figure 3.8 D & E). For instance, this rose 
from 12.48% (+/- 1.10) to 22.15% (+/- 1.35) on day 2 (Figure 3.8 E). Interestingly, the 
geometric mean of IL-17A of CD4+ IL-17A+ T cells was not significantly different between 
untreated and mCRAMP-treated samples (Figure 3.8 F). Moreover, there was a trend 
suggesting that this was in fact decreased when the cells were cultured in the presence of 
the peptide (from 3180 +/- 371 to 2882 +/- 270). This could indicate that mCRAMP increased 
the frequency of CD4+ IL-17A+ T cells but that they were potentially producing less of this 
cytokine than their untreated counterparts. Nonetheless, the concentration of IL-17A in cell 
culture supernatants rose significantly, from 1,506 (+/- 338) to 2,073 (+/-476) pg/mL, as 
measured by ELISA (Figure 3.7 G).  
 
These results indicate that synthetic mCRAMP significantly enhances the development of IL-
17-producing CD4+ T cells. Furthermore, this increase in response to mCRAMP was 
concentration-dependent (up until 2.5 µM), as well as time-dependent (Figure 3.8 C & H). 
However, a concentration of 5 µM did not amplify IL-17A production any further, potentially 
due to the toxic side effects of the peptide and subsequent cell death.  
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Figure 3.8: mCRAMP increases RORɣt expression and enhances the development of IL-17-
producing CD4+ T cells cultured under Th17-driving conditions. Whole single cell splenic 
suspensions from WT mice were cultured under Th17-driving conditions, with or without 2.5 µM 
synthetic mCRAMP, for up to 3 days (A) Representative plots RORɣt expression by CD4+ T cells on 
day 1, assessed by flow cytometry (B) Representative plots of IL-17A production by CD4+ T cells on 
day 2, assessed by flow cytometry (C) Percentages of CD4+ RORɣt+ T cells, ex vivo and days 1-3 (n 
= 6) (D) Percentages of CD4+ IL-17A+ T cells, ex vivo and days 1-3 (n = 6) (E) Percentages of CD4+ IL-
17A+ T cells on day 2 (n = 24) (F) Geometric mean of IL-17A expression by CD4+ IL-17A+ T cells on 
day 2 (n = 24) (G) Concentration of IL-17A in cell culture supernatants on day 2, determined by 
ELISA (n = 13) (H) CD4+ IL-17A+ vs. mCRAMP dose response (n = 3). Data shown is mean +/- standard 
error. Statistical significance (where * represents < 0.05, ** < 0.01, *** < 0.001 and **** < 0.0001) 
was determined using a two-way repeated measures ANOVA with a Bonferroni multiple 
comparison post-test (C & D) or a paired t-test (E & G) or or an ordinary one-way ANOVA with a 
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3.3.7 mCRAMP increases IL-17F but not IL-22 production by CD4+ T cells cultured 
under Th17-driving conditions  
 
Th17 cells express three different dimeric forms of IL-17 of varying potency: IL-17A, IL-17F, 
and the heterodimer IL-17A/F98. I therefore also examined the effects of synthetic mCRAMP 
on IL-17F production (Figure 3.9). Whole single cell splenic suspensions were cultured under 
Th17-driving conditions, as previously described, with or without synthetic mCRAMP, for 2 
days.  
 
mCRAMP significantly increased the percentage of IL-17F single positive CD4+ T cells from 
6.67% (+/- 1.37) to 13.26% (+/- 2.20) (Figure 3.9 C). Moreover, mCRAMP increased the 
percentage of CD4+ IL-17A+ IL-17F+ T lymphocytes from 5.37% (+/- 1.19) to 12.68% (+/- 2.41) 
(Figure 3.9 D). The proportion of IL-17A single-positive CD4+ T cells was not significantly 
different between untreated and mCRAMP-treated samples (Figure 3.9 B). However, there 
was a trend suggesting that mCRAMP also increased the frequency of CD4+ IL-17A+ IL-17F- T 
cells; statistical significance was not reached as a result of one particular sample, which was 
not an obvious outlier and therefore not excluded from analysis (Grubb’s test: P > 0.05). As 
a result, these data suggest that the effects of mCRAMP are limited to promoting the 
differentiation of Th17 cells that express IL-17F and IL-17A/IL-17F dual-producers. 
 
Th17 lymphocytes produce significant quantities of IL-21, which drives the self-amplification 
phase of Th17 differentiation26,72. The concentration of IL-21 in cell culture supernatants 
measured by ELISA, rose from 37 (+/- 23) to 130 (+/- 80) pg/mL on day 2 following exposure 
to mCRAMP, although this was not statistically significant due to high variability (Figure 3.9 
E). Whether or not this rise in IL-21 production is a cause or a consequence of increased Th17 
differentiation is unknown.  
 
Th17 lymphocytes can also express IL-22 and CD4+ IL-17+ IL-22+ T cells have been identified 
as a particularly pathogenic population of autoreactive T lymphocytes during EAE108,371. 
However, mCRAMP did not have any effect on the concentration of IL-22 in cell culture 
supernatants (Figure 3.9 F), indicating that the peptide does not promote the production of 
all Th17-related cytokines, but has some specificity in its action.  
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Figure 3.9: mCRAMP increases IL-17F, but not IL-22, production by CD4+ T cells cultured under 
Th17-driving conditions. Whole single cell splenic suspensions from WT mice were cultured under 
Th17-driving conditions, with or without 2.5 µM synthetic mCRAMP, for 2 days (A) Representative 
plots of IL-17A and IL-17F expression by CD4+ T cells on day 2, assessed by flow cytometry (B) 
Percentages of CD4+ IL-17A+ IL-17F- T cells on day 2 (n = 6) (C) Percentages of CD4+ IL-17A+ IL-17F+ 
T cells on day 2 (n = 6) (D) Percentages of CD4+ IL-17A- IL-17F+ T cells on day 2 (n = 6) (E) 
Concentration of IL-21 in cell culture supernatants on day 2, determined by ELISA (n = 4) (F) 
Concentration of IL-22 in cell culture supernatants on day 2, determined by ELISA (n = 5). Data 
shown is mean +/- standard error. N = 6. Statistical significance (where ** represents < 0.01 and 
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I have shown that synthetic mCRAMP enhances the development of IL-17-producing CD4+ T 
lymphocytes in vitro. There are several potential mechanisms through which the peptide 
could act to achieve this (Figure 3.10). For example, mCRAMP could act directly on CD4+ T 
cells, or indirectly, to boost Th17 differentiation. It is also possible that mCRAMP promotes 
the killing of non-Th17 subsets and/or protects CD4+ IL-17+ T lymphocytes from death, as well 







Figure 3.10: Potential mechanisms of action by mCRAMP to enhance Th17 differentiation. 
mCRAMP could act directly on CD4+ T helper cells (e.g. increase the expression of receptors 
required for Th17 polarization). mCRAMP could also act indirectly, by modulating the function of 
another cell type, such as dendritic cells. mCRAMP could increase the frequency of CD4+ IL-17+ T 
cells by increasing their proliferation. mCRAMP could promote the death of non-Th17 subsets 
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3.3.8 mCRAMP acts directly on CD4+ T cells to enhance Th17 differentiation in vitro 
 
The data presented thus far was generated by culturing whole single cell splenic suspensions 
under Th17-driving conditions. The spleen is predominantly composed of CD4+ (approx. 25%) 
and CD8+ (approx. 20%) T lymphocytes, as well as B cells (approx. 20%)372. However, dendritic 
cells (approx. 10%), natural killer cells (approx. 5%), macrophages (approx. 5%), and 
neutrophils (approx. 5%) can also be found372. As such, it was unclear whether mCRAMP 
directly enhances the development of IL-17-producing CD4+ T lymphocytes or acts indirectly 
via another cell type. 
 
To determine whether mCRAMP could act directly on CD4+ T cells to enhance Th17 
differentiation, I sorted CD4+ T lymphocytes by flow cytometry (DAPI- CD4+ CD8-; purity > 
97%) and cultured them under Th17-driving conditions for 2 days, as previously described, 
with or without synthetic mCRAMP. Figure 3.11 shows that mCRAMP significantly increased 
the percentage of CD4+ IL-17A+ T cells from 1.18% (+/- 0.03) to 7.29% (+/- 0.02) (Figure 3.11 
B). This was confirmed by measuring the concentration of IL-17A in cell culture supernatants 
by ELISA, which rose significantly from 1,518 to 2,550 pg/mL (Figure 3.11 C).  
 
The percentage of CD4+ IL-17A+ T cells generated was substantially lower compared to when 
using whole single cell splenic suspensions. One possible explanation for this is that the 
quality of activation signals received from DCs within the splenocyte preparations is superior 
to those provided by aCD3/CD28 antibodies. On the other hand, the fold change observed 
following exposure to mCRAMP was substantially larger than when culturing total 
splenocytes (6.18 compared to 1.99). This could potentially be due to the presence of other 
cell types providing suppressive signals that typically restrain Th17 differentiation. For 
example, IL-12 is produced mainly by APCs and plays a significant role in promoting Th1 
polarization, while simultaneously inhibiting TGFb-dependent T cell developmental 
programs (Th17/Treg)373,374.  
 
Nonetheless, these data suggest that mCRAMP does indeed act directly and specifically on 
CD4+ T lymphocytes to boost Th17 differentiation.  
 
 






However, it is also possible that mCRAMP acts both directly and indirectly to boost Th17 
differentiation, which has an additive effect. For example, human cathelicidin (LL-37) has 
been shown to modulate the differentiation of immature dendritic cells (DCs) and 
subsequently promote DC-induced Th1 cell polarization375. Furthermore, Gwyer Findlay and 
colleagues recently demonstrated that exposure of DC precursors to LL-37 dramatically 
enhances their expansion and differentiation to immature DCs with altered phenotypes, 
which enhances CD8+ T cell proliferation, activation and cytokine production (IFNg and IL-
17A)338.  
 
To address the possibility that mCRAMP also influenced the behaviour of DCs to indirectly 
enhance the development of IL-17-producing CD4+ T cells, I cultured whole single cell splenic 
suspensions under Th17-polarizing conditions for 2 days, as previously described, with or 
without synthetic mCRAMP, and analysed DC phenotype by flow cytometry (Figure 3.12). 
Markers included MHCII and CD86, both DC activation markers that play important roles in T 
cell activation8; XCR1 and CLEC9A, both of which have been shown to play important roles in 
antigen cross-presentation to CD8+ T lymphocytes376; CD103, which defines a population of 
DCs that promote Th17 development377. However, there were no significant differences in 
the proportions of MHCII+, SIRPa+, XCR1+, CD86+, CD103+ or CLEC9A+ DCs between untreated 
and mCRAMP-treated samples. This suggests that mCRAMP does not act indirectly by 
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Figure 3.11: mCRAMP acts directly on CD4+ T cells. Sorted CD4+ T cells were cultured under Th17-
driving conditions, with or without 2.5 µM synthetic mCRAMP, for 2 days (A) Representative plots 
of IL-17A production by CD4+ T cells on day 2, assessed by flow cytometry (B) Percentages of CD4+ 
IL-17A+ T cells on day 2 (n = 3) (C) Concentration of IL-17A in cell culture supernatants on day 2, 
determined by ELISA (n = 5). Data shown is mean +/- standard error. Statistical significance (where 
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Figure 3.12: mCRAMP does not affect the phenotype of differentiated dendritic cells cultured 
under Th17-driving conditions. Whole single cell splenic suspensions were cultured under 
Th17-driving conditions for 2 days, with or without 2.5 µM synthetic mCRAMP (A) 
Representative plots of SIRPα+ DCs (B) Percentages of SIRPα+ DCs (C) Representative plots of 
XCR1+ DCs (D) Percentages of XCR1+ DCs (E) Representative plots of CD86+ DCs (F) Percentages 
of CD86+ DCs (G) Representative plots of CD103+ DCs (H) Percentages of CD103+ DCs (I) 
Representative plots of CLEC9A+ DCs (J) Percentages of CLEC9A+ DCs (K) Representative plots 
of MHCII+ cells (gated on CD11c+) (L) Percentages of MHCII+ cells (gated on CD11c+). Data shown 
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3.3.9 mCRAMP has no significant effect on CD4+ T cell expression of IL-6R or IL-23R 
 
I have shown that mCRAMP can act directly on CD4+ T cells to enhance the development of 
IL-17-producing lymphocytes but how the peptide achieves this is unclear. One possibility is 
that mCRAMP upregulates the expression of receptors required for Th17 differentiation, 
thereby increasing their sensitivity to Th17-polarizing cytokines. I therefore analysed the 
expression of IL-6R and IL-23R by CD4+ T cells when cultured under Th17-driving conditions, 
with or without synthetic mCRAMP (Figure 3.13). The lack of a reliable antibody that can be 
used to detect TGFbR by flow cytometry prevented the analysis of CD4+ TGFbR+ T cells.  
 
Figure 3.13 shows that the results were highly variable but no significant differences were 
observed in the frequencies of CD4+ IL-6R+ or IL-23R+ T cells between untreated and 
mCRAMP-treated samples. This suggests that this is not how the peptide enhances Th17 











































Figure 3.13: mCRAMP has no significant effect on IL-23R or IL-6R expression by CD4+ T cells 
cultured under Th17-driving conditions. Whole single cell splenic suspensions were cultured 
under Th17-driving conditions, with or without 2.5 µM synthetic mCRAMP, for up to 3 days (A) 
Representative plots of IL-23R expression by CD4+ T cells on day 2, assessed by flow cytometry (B) 
Representative plots of IL-6R expression by CD4+ T cells on day 2, assessed by flow cytometry (C) 
Percentages of CD4+ IL-23R+ T cell, ex vivo and days 1-3 (D) Percentages of CD4+ IL-6R+ T cell, ex 
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3.3.10 mCRAMP increases the viability of CD4+ T cells  
 
Another potential mechanism through which mCRAMP could enhance Th17 differentiation 
is by promoting the survival of CD4+ IL-17+ T cells and the death of non-Th17 subsets. Indeed, 
mCRAMP has previously been shown to induce programmed cell death in certain T cell 
subsets. For example, Mader and colleagues demonstrated that human cathelicidin (LL-37) 
induces granzyme-mediated apoptosis in cytotoxic CD8+ and regulatory T cells360,378.  
 
I therefore performed an annexin/propidium iodide (PI) apoptosis assay to examine cell 
death in non-lineage-driving and Th17 cultures, treated with synthetic mCRAMP. Annexin V 
is a Ca2+-dependent phospholipid binding protein that has high affinity for phosphatidylserine 
(PS)379. PS locates to the cytoplasmic surface of the cell membrane in live cells but is 
translocated to the outer leaflet during apoptosis, thereby exposing it379. PI is a dead cell 
marker that binds to nucleic acids but cannot permeate living cells380. Together, annexin and 
PI can be used to distinguish living, apoptotic and necrotic cells (Figure 3.15 A).  
 
Unfortunately, this technique cannot be employed alongside intracellular cytokine staining 
due to the fixation step. Various studies have identified Th17 cells based on their expression 
of several surface markers381,382. For example, Annunziato et al. demonstrated that Th17 
lymphocytes selectively express CCR6381. However, the definition of Th17 cells by surface 
markers might overestimate their frequency in comparison to functional assessment of IL-17 
production by intracellular cytokine staining, although both methods have been suggested 
to yield proportionate results383. In my hands, I found CCR6 to be inadequate for the 
identification of Th17 lymphocytes: I saw no CD4+ CCR6+ IL-17A+ T cells and while the 
percentage of CD4+ IL-17A+ T cells was increased following exposure to mCRAMP, the 
frequency of CD4+ CCR6+ T lymphocytes was decreased (Figure 3.14). As a result, it was only 
possible to analyse the CD4+ T cell population as a whole using this method. 
 






mCRAMP had no effect on the total number of CD4+ T cells following culture under non-
lineage-polarising conditions, (Figure 3.15 B) but significantly increased the percentage of 
CD4+ annexin- PI- (“alive”) T lymphocytes on day 3, from 43.13% (+/- 6.90) to 53.70% (+/- 
3.51) (Figure 3.15 D). Furthermore, there was a trend suggesting mCRAMP decreased the 
proportion of CD4+ annexin+ PI+ (“necrotic”) T cells, although this was not statistically 
significant (Figure 3.15 H). No differences in the percentage of apoptotic (annexin+ PI-) T cells 
were observed between untreated and mCRAMP-treated samples (Figure 3.15 F). 
 
When the cells were cultured under Th17-driving conditions, mCRAMP had no effect on the 
total number of CD4+ T cells (Figure 3.15 C) but significantly increased the percentage of CD4+ 
annexin- PI- (Figure 3.15 E) and decreased the percentage of CD4+ annexin+ PI+ T cells (Figure 
3.15 I) on days 2 to 3 and 1 to 3, respectively. For instance, on day 3, mCRAMP increased the 
proportion of CD4+ annexin- PI- T cells from 57.32% (+/- 6.00) to 70.18% (+/- 1.49), and 
decreased CD4+ annexin+ PI+ from 28.43% (+/- 5.15) to 15.98% (+/- 1.84). No significant 
differences in the frequency of CD4+ annexin+ PI- T cells were observed between untreated 










Figure 3.14: CCR6 is not a suitable surface marker for the identification of CD4+ IL-17+ T cells. 
Whole single cell splenic suspensions from WT mice were cultured under Th17-driving conditions, 
with or without 2.5 µM synthetic mCRAMP. Cells were stained on day 2 for CCR6 and intracellular 
IL-17A. Very few cells were CCR6/IL-17A double-positive. CRAMP appeared to decrease the 
percentage of CD4+ CCR6+ T lymphocytes but increase the percentage of IL-17-single positive cells. 
UT: untreated.  









Figure 3.15: mCRAMP increases CD4+ T cell viability. Whole single cell splenic suspensions were 
cultured under non-lineage-driving or Th17-polarizing conditions, with or without 2.5 µM 
mCRAMP, for up to 3 days (A) Representative plots of annexin/PI staining of CD4+ T cells on day 2, 
assessed by flow cytometry (B) Total numbers of CD4+ T cells in non-lineage driving cultures (C) 
Total numbers of CD4+ T cells in Th17 cultures (D) Percentages of CD4+ annexin- PI- T cells on days 
1-3 following culture under non-lineage-driving conditions (n = 3) (E) Percentages of CD4+ annexin- 
PI- T cells on days 1-3 following culture under Th17-driving conditions (n = 6) (F) Percentages of 
CD4+ annexin+ PI- T cells on days 1-3 following culture under non-lineage-driving conditions (n = 3) 
(G) Percentages of CD4+ annexin+ PI- T cells on days 1-3 following culture under Th17-driving 
conditions (n = 6) (H) Percentages of CD4+ annexin+ PI+ T cells on days 1-3 following culture under 
non-lineage-driving conditions (n = 3) (I) Percentages of CD4+ annexin+ PI+ T cells on days 1-3 
following culture under Th17-driving conditions (n = 6). Data shown is mean +/- standard error. 
Statistical significance (where * represents < 0.05 and ** < 0.01) was determined using a two-way 




Th17-driving conditions Non-lineage-driving conditions 
H 






























































































































































CHAPTER 3: RESULTS 
 98 
To identify the effects of mCRAMP on the viability of CD4+ IL-17+ and CD4+ IL-17- T 
lymphocytes, I analysed the uptake of a fixable live/dead cell stain on day 2 in Th17 cultures 
(Figure 3.16). Using this method, I observed a significant decrease, from 39.08% (+/- 2.68) to 
26.65% (+/- 3.02), in the percentage of dead CD4+ T cells (Figure 3.16 A & B). This supports 
the results obtained from the annexin/PI apoptosis assay and suggests that mCRAMP 
protects the CD4+ T cell population as a whole from death. However, it is important to note 
that this could reflect an increase in the viability of a particular subset (within the whole CD4+ 
population).  
 
mCRAMP significantly decreased the percentage of dead CD4+ IL-17+ T lymphocytes from 
19.71% (+/- 2.32) to 12.13% (+/- 1.83) (Figure 3.16 C & D). Furthermore, the percentage of 
dead CD4+ IL-17- T cells was also significantly reduced (41.10% +/- 2.86 to 29.57% +/- 3.44) 
(Figure 3.16 E & F).  
 
These results imply that mCRAMP acts as a survival factor to increase the viability of all CD4+ 
T cells cultured under Th17-driving conditions. This does not therefore explain the increase 





































Figure 3.16: mCRAMP promotes the survival of CD4+ IL-17+ and IL-17- T cells. Whole single cell 
splenic suspensions were cultured under Th17-driving conditions, with or without 2.5 µM 
mCRAMP, for 2 days (A) Representative plots of dead CD4+ T cells on day 2 (gated on single, CD4+ 
lymphocytes), assessed by flow cytometry (B) Percentages of dead CD4+ T cells on day 2 (C) 
Representative plots of dead CD4+ IL-17A+ T cells on day 2 (gated on CD4+ IL-17A+), assessed by 
flow cytometry (D) Percentages of dead CD4+ IL-17A+ T cells on day 2 (E) Representative plots of 
dead CD4+ IL-17A- T cells on day 2 (gated on CD4+ IL-17A-), assessed by flow cytometry (F) 
Percentages of dead CD4+ IL-17A- T cells on day 2. Data shown is mean +/- standard error. N = 22. 
Statistical significance (where **** represents < 0.0001) was determined using a paired t-test. UT: 
untreated.  
A UT mCRAMP 
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3.3.11 mCRAMP does not increase the proliferation of CD4+ T cells cultured under 
Th17-driving conditions 
 
To determine whether mCRAMP enhanced Th17 differentiation by specifically increasing the 
proliferation of CD4+ IL-17+ T lymphocytes, I monitored the proliferation of these cells by CFSE 
dye dilution (Figure 3.17). CFSE is a non-fluorescent dye that passively diffuses across cell 
membranes384. Cleavage by intracellular esterases within viable cells renders it highly 
fluorescent and capable of covalently binding to protein amine groups via its succinimidyl 
ester group384. As cells divide, the dye is distributed uniformly between daughter cells, 
allowing for the analysis of proliferation by serial halving of fluorescence intensity384.  
 
mCRAMP had no effect on the proliferation of total CD4+ T cells when cultured under Th17-
driving conditions (Figure 3.17 A & B).  
 
Due to high levels of cell death observed in stimulated, intracellular cytokine- and CFSE-
stained cultures, I analysed the division of RORgt+ and RORgt- lymphocytes in order to 
monitor Th17 proliferation. The proliferation of CD4+ RORgt+ T cells was no different between 
untreated and mCRAMP-treated samples (Figure 3.17 C & D), which suggests that the 
peptide does not boost Th17 differentiation by increasing the proliferation of this T helper 
cell subset. Furthermore, there were no significant differences in the proliferation of CD4+ 
RORgt- T cells (Figure 3.17 E & F), indicating that mCRAMP does not suppress the proliferation 










































Figure 3.17: mCRAMP has no effect on CD4+ T cell proliferation. CFSE-stained whole single cell 
splenic suspensions were cultured under Th17-driving conditions, with or without 2.5 µM 
synthetic mCRAMP, for 2 days (A) Representative CFSE plot of CD4+ T cells, assessed by flow 
cytometry (B) Geometric mean of CFSE by CD4+ T cells (C) Representative CFSE plot of CD4+ RORɣt+ 
T cells, assessed by flow cytometry (D) Geometric mean of CFSE by CD4+ RORɣt+ T cells (E) 
Representative CFSE plot of CD4+ RORɣt- T cells, assessed by flow cytometry (F) Geometric mean 
of CFSE by CD4+ RORɣt- T cells. Data shown is mean +/- standard error. N = 4. UT: untreated.  
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3.3.12 mCRAMP acts specifically on the Th17 pathway 
 
I have shown that mCRAMP enhanced the development of IL-17-producing CD4+ T cells when 
cultured under Th17-driving conditions in vitro. To determine whether this host defence 
peptide acts specifically on the Th17 pathway, or non-specifically boosts all cytokine 
production, I next assessed the effects of mCRAMP on the differentiation of other T helper 
subsets.  
 
Whole single cell splenic suspensions were cultured under Th1- (IL-12, IL-18, IL-2) or Th2-
polarizing (IL-4, IL-2, aIL-12, aIFNg) conditions, with or without synthetic mCRAMP. Due to 
poor polarization using splenocytes, CD4+ T cells isolated by EasySep were cultured under 
Treg-driving conditions (TGFb), with or without synthetic mCRAMP. The fold change in the 
percentage of CD4+ IFNg+ (Th1), CD4+ IL-4+ (Th2) or CD4+ FOXP3+ (Treg) T cells was determined 
by intracellular flow cytometry (Figure 3.18).  
 
Whilst mCRAMP induced a 1.99-fold increase in the percentage of CD4+ IL-17A+ T cells, it did 
not have any effect on Th1 or Th2 differentiation: no significant changes in the proportions 
of CD4+ IFNg+ or IL-4+ lymphocytes were detected. This is in accordance with the preliminary 
data demonstrating that cytokine production following inoculation with Schistosoma 
mansoni eggs, which induces a type 2 immune response, was not significantly different in 
mCRAMP-deficient mice (Chapter 1: Figure 1.10).  
 
However, a small (1.30 fold) increase in the percentage of CD4+ FOXP3+ cells was observed 
on day 2 when CD4+ T lymphocytes were cultured under Treg-driving conditions in the 
presence of mCRAMP. The development of Th17 cells and regulatory T lymphocytes both 
require TGFb49,385. These results therefore suggest that mCRAMP may interact with, or boost, 















3.3.13 mCRAMP requires TGFb to increase RORgt expression and enhance Th17 
differentiation in vitro 
 
mCRAMP had no effect on the frequency of CD4+ IL-17A+ T lymphocytes when cultured under 
non-lineage-driving conditions in the absence of IL-6, IL-23 and TGFb (Figure 3.5). This 
suggests that the peptide requires at least one, or all, of the Th17-polarizing cytokines to 
exert its effects. Furthermore, a small increase in Treg differentiation was observed when 
CD4+ T cells were cultured with a high concentration of TGFb and synthetic mCRAMP. I 
therefore hypothesised that mCRAMP interacts with, or boosts, signals from TGFb. 
 
To explore this possibility, I cultured whole single cell splenic suspensions with each cytokine 
alone, or by systematically omitting each one at a time. By doing so, I sought to highlight not 
only the importance of TGFb in mCRAMP-induced changes, but also determine whether the 
addition of synthetic mCRAMP could restore a Th17-inducing environment in the absence of 
IL-6, IL-23 or TGFb. 
 
Figure 3.19 A shows that mCRAMP failed to increase the geometric mean of RORgt expression 
when the cells were cultured in the absence of TGFb. This supports the hypothesis that 
mCRAMP requires TGFb to enhance Th17 differentiation.  















P = 0.32 **
Figure 3.18: The effects of mCRAMP on the differentiation of other T helper subsets. Whole 
single cell splenic suspensions were cultured under Th17- (n = 27), Th1- (n = 6) or Th2-driving (n = 
6) conditions, with or without 2.5 µM synthetic mCRAMP. CD4+ T cells were cultured under Treg-
driving conditions, with or without 2.5 µM synthetic CRAMP (n = 4). Fold change in the percentage 
of CD4+ IL-17A+ (Th17), CD4+ IFNɣ+ (Th1), CD4+ IL-4+ (Th2) or CD4+ FOXP3+ (Treg) expression was 
determined. Data shown is mean +/- standard error. Statistical significance (where ** represents 
< 0.001 and **** < 0.0001) was determined using a paired t-test (UT vs. CRAMP).  
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However, while mCRAMP failed to increase the percentage of CD4+ RORgt+ T cells on day 1 
when the cells were cultured with IL-6 and IL-23 (but in the absence of TGFb), mCRAMP 
significantly increased the percentage of CD4+ RORgt+ T cells under all other conditions, 
including when the cells were generated in the presence of IL-6 or IL-23 alone (Figure 3.19 
B). One possible explanation for this is that the increase in the proportion of CD4+ RORgt+ T 
cells when cultured with only IL-6 or IL-23 (and mCRAMP) reflects an increasing number of 
CD4+ T lymphocytes transiently expressing very low levels of RORgt, which is likely insufficient 
to have any downstream effects on IL-17 production. 
 
It should be noted that an increase in the percentage of CD4+ RORgt+ T cells did not 
necessarily translate into an increase in the number of IL-17-producing CD4+ T lymphocytes 
(Figure 3.19 C). RORgt and STAT3 act cooperatively with several other transcription factors 
(e.g. IRF4, BATF) on the Il17 locus to promote its transcription386. It is therefore likely that all 
three Th17-polarizing cytokines are required to provide an optimal environment in which 
mCRAMP can promote the expression of this cytokine. 
 
Nonetheless, taken together, these results support the hypothesis that mCRAMP requires 

























Figure 3.19: mCRAMP fails to increase RORɣt expression in the absence of TGFβ. Whole single 
cell splenic suspensions were cultured with different combinations of IL-6 (20 ng/mL), IL-23 (20 
ng/mL) and TGFβ (3 ng/mL), with or without 2.5 µM synthetic mCRAMP, for up to 2 days (A) 
Geometric mean of RORɣt expression by CD4+ T cells on day 1 (B) Percentages of CD4+ RORɣt+ T 
cells on day 1 (C) Percentages of CD4+ IL-17A+ T cells on day 2. Data shown is mean +/- standard 
error. N = 6. Statistical significance (where * represents < 0.05, ** < 0.01 and **** < 0.0001) was 
determined using a two-way repeated measures ANOVA with a Bonferroni multiple comparison 
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3.3.14 The effects of mCRAMP on CD4+ T cells are not receptor-mediated 
 
Cathelicidin has been shown to activate a multitude of receptors to exert its 
immunomodulatory effects, including P2X7R, FPR2 and EGFR387. To determine whether 
mCRAMP acted via a receptor to enhance Th17 differentiation, I cultured whole single cell 
splenic suspensions under Th17-driving conditions, with or without synthetic mCRAMP, LL-
37, the D-enantiomer of LL-37 (D-LL-37) or scrambled LL-37 (Figure 3.20).  
 
mCRAMP and LL-37 show significant homology in structure and sequence identity and as a 
result, often display similar effects388.  Scrambled LL-37 has the same peptide sequence as 
LL-37 but in an incorrect order, which can result in a loss of its helix-forming properties. D-
LL-37 maintains its a-helical configuration but each amino acid is in the D-configuration 
(cannot be superimposed on its mirror image). I hypothesized that if the effects of mCRAMP 
were receptor-dependent, D-LL-37 and the scrambled peptide would not increase the 
frequency of CD4+ IL-17A+ T cells due to a loss of chirality, structure and/or sequence 
specificity, which would prevent binding.  
 
As predicted, LL-37 increased the percentage of CD4+ IL-17A+ T cells from 9.71% (+/- 1.44) to 
19.82% (+/- 0.80), similarly to mCRAMP (19.67% +/- 2.22). Surprisingly, both scrambled LL-
37 and D-LL-37 also increased the generation of IL-17-producing CD4+ T lymphocytes to 
17.13% (+/- 1.48) and 17.65% (+/- 0.99), respectively.  
 
These data suggest that it is highly unlikely that mCRAMP acts directly on CD4+ T cells via a 













Pilot data from the laboratory determined that mCRAMP-deficient mice were incapable of 
generating a type-17 response during inflammation induced by heat-killed S. typhimurium 
(HKST). Emily Gwyer Findlay demonstrated that T cell numbers in both primary (thymus) and 
secondary (spleen, inguinal lymph nodes) lymphoid organs were not significantly different 
between naïve WT and mCRAMP KO animals (unpublished data, Emily Gwyer Findlay). I have 
shown that CD4+ T cells from naïve mCRAMP-deficient mice displayed relatively normal 
cytokine responses (IL-17A, IL-17F, IFNg, IL-22 and GM-CSF) at resting state. Furthermore, 
CD4+ T lymphocytes from mCRAMP KO mice were capable of producing IL-17 in vitro in 
response to exogenous cytokines and to the same extent as WT T cells. Taken together, this 
indicates that CD4+ T lymphocytes that develop in the absence of mCRAMP do not possess 
an obvious underlying defect that is responsible for their inability to produce IL-17 in vivo. 
Nevertheless, the development of the Th17 response is impaired upon stimulation, such as 




Figure 3.20: D-LL-37 and scrambled LL-37 increase Th17 differentiation. Whole single cell splenic 
suspensions were cultured under Th17-driving conditions, with or without 2.5 µM synthetic 
CRAMP, LL-37, D-LL-37 or scrambled LL-37, for 2 days. Percentages of CD4+ IL-17A+ T cells on day 
2. Data shown is mean +/- standard error. N = 6. Statistical significance (where ** represents < 
0.01 and *** < 0.001) was determined using an ordinary one-way ANOVA with a Dunnett’s 
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3.4.1 mCRAMP enhances Th17 differentiation  
 
I sought to examine the effects of synthetic mouse cathelicidin (mCRAMP) on the 
differentiation of Th17 cells in vitro. A standard, previously published, Th17 differentiation 
protocol (TGFb/IL-6) was chosen to determine the effects of synthetic mCRAMP on the 
development of IL-17-producing CD4+ T cells385,389,390. IL-23 was added to cultures due to its 
known roles in maintaining and stabilising the Th17 phenotype76. Whole single cell splenic 
suspensions were used, as opposed to purified naïve CD4+ T cells, as it was unknown whether 
mCRAMP acted directly or indirectly on this cell type. Phenotypic analysis was carried out ex 
vivo and on days 1 to 3 and it was determined that Th17 polarization was achieved by day 2 
(measured by the percentage of CD4+ IL-17+ T cells). As such, further experiments were 
typically terminated on day 2, which allowed for the examination of the early effects of the 
peptide. However, additional studies should be carried out in the future to determine the 
consequences of mCRAMP exposure at later time points, particularly with regards to Th17 
plasticity.  
 
The concentration of mCRAMP used throughout this study (2.5 µM, approximately 10 µg/mL) 
is physiologically relevant during inflammation. For example, human cathelicidin (LL-37) is 
present in airway secretions from healthy newborns at around 5 µg/mL and can rise to 
between 10 to 30 µg/mL in infants with systemic or pulmonary infections391. LL-37 has also 
been detected in BAL fluid at 5 µg/mL in healthy individuals but this can rise to 30 µg/mL in 
cystic fibrosis patients285. However, levels of cathelicidin can increase even further in certain 
inflammatory conditions: Ong et al. measured a concentration of around 300 µM (approx. 
1.2 mg/mL) LL-37 in psoriatic plaques310. In comparison, the amount of human b-defensin 2 
present was only around 20 µM310. Nonetheless, it is important to note that a gradient of 
cathelicidin will surround leukocytes at a site of infection/inflammation and that the local 
concentration could be much higher285.  
 
 
3.4.1.1 mCRAMP increases CD4+ T cell activation  
 
mCRAMP increased the activation status of CD4+ T lymphocytes cultured under Th17-driving 
conditions. For example, mCRAMP increased the percentage of CD4+ CD62L- CD44+ T 
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lymphocytes in Th17 cultures. Schumann et al. have demonstrated a role for CD44 in the 
development of Th17 cells. More specifically, they identified three distinguishable 
populations of CD4+ T lymphocytes following stimulation with allogeneic DCs: CD44+, CD44++ 
and CD44+++370. IL-17-producing T helper cells were mainly CD44+++, whereas IFNg+ T 
lymphocytes were CD44++370. Furthermore, blocking CD44 resulted in decreased IL-17 
secretion but had no discernible effect on IFNg370. Increased CD44 expression in response to 
mCRAMP could therefore contribute to the amplification of Th17 development. 
 
mCRAMP also significantly increased the geometric mean of PD1. PD1 is expressed by T cells 
following TCR engagement and eventually declines following acutely resolved antigen 
encounter392. However, its expression is maintained in chronic disease settings, which has 
been associated with a progressive loss of function392. For example, high PD1 expression by 
human CD4+ T lymphocytes identifies a population of exhausted effector cells that are 
enriched in malignant cancer393. Nevertheless, PD1 expression status alone cannot 
discriminate between exhausted and activated T cells392. mCRAMP increased CD44 and 
decreased CD62L expression, both hallmarks of an activated T cell. Moreover, two days in 
culture is unlikely to result in an exhausted phenotype, which is supported by the fact that 
CD4+ T cells were still producing cytokines and proliferating normally. This data therefore 
indicates that upregulated PD1 expression by CD4+ T lymphocytes in response to mCRAMP 
represents increased T cell activation and not dysfunction. However, longer term cultures 
(up to 14 days) could be performed to formally determine whether mCRAMP has a significant 
effect on T cell exhaustion. 
 
On the other hand, it could be argued that my in vitro Th17 cultures simply might not contain 
cells expressing the PD1 ligand (PDL1). PDL1 expression is upregulated following exposure to 
cytokines such as IFNg and elevated levels are displayed on the surface of tumour cells394. 
Activation of the PD1-PDL1 pathway leads to an arrest in T cell proliferation and apoptosis395. 
In the absence of PDL1+ cells, PD1+ T lymphocytes might not receive the required signalling 
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3.4.1.2 mCRAMP increases the frequency of CD4+ IL-17+ T cells in Th17 cultures 
 
mCRAMP significantly and concentration-dependently increased the percentages of CD4+ 
RORgt+ and CD4+ IL-17A+ T cells. RORgt expression is necessary for driving Th17 polarization 
and the transcription of Il17 in response to IL-6 and TGFb43. The upregulation of RORgt in 
Th17 cultures therefore accurately reflects changes in the frequency of IL-17 producing 
lymphocytes induced by mCRAMP. However, an increase in the percentage of CD4+ RORgt+ T 
cells did not necessarily translate into IL-17 production if one or two of the three Th17-
stimualting cytokines were absent. RORgt and STAT3 act cooperatively with several other 
transcription factors (e.g. IRF4, BATF) on the Il17 locus to promote its transcription386. It is 
therefore likely that all three Th17-polarizing cytokines are required to provide an optimal 
environment in which mCRAMP can promote the expression of this cytokine.  
 
Furthermore, TGFb alone was sufficient to induce percentages of CD4+ RORgt+ T lymphocytes, 
akin to those observed when culturing the cells with all three cytokines. However, this did 
not result in the development of IL-17-producing CD4+ T lymphocytes. Manel et al. 
demonstrated that TGFβ upregulates RORgt expression in human CD4+ T cells but suppresses 
its ability to induce IL-17 expression unless another inflammatory cytokine is present to 
relieve this inhibition71. This is in accordance with my results.  
 
Elevated levels of IL-17F were observed in samples treated with mCRAMP. There is a 
significant degree of sequence homology and functional similarity between IL-17A and IL-
17F, particularly in terms of their regulation and ability to induce chemokines that are 
important in neutrophil recruitment and activation396. Both genes are localised in the same 
chromosome region and require STAT3 and RORgt for their expression397. The polarization of 
polyclonally activated naïve CD4+ T cells with TGFb and IL-6 induces a large proportion of IL-
17A and IL-17F co-expressing lymphocytes, whereas Th17 cells differentiated in the presence 
of IL-1b and IL-6 mainly express IL-17A398. In the present study, the vast majority of CD4+ IL-
17A+ T cells were also IL-17F+, which is in line with these observations made using a TGFb/IL-
6 differentiation protocol.  
 
Interestingly, mCRAMP had no significant effect on the percentage of IL-17A single-positive 
lymphocytes but significantly increased the frequency of CD4+ IL-17A- IL-17F+ cells and IL-
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17A/IL-17F dual-producers. There is only a limited amount of published data looking at the 
differential effects of Th17 modulators on the production of IL-17A compared to IL-17F. For 
example, Piccinni and colleagues demonstrated that medroxyprogesterone acetate (MPA) 
has no effect on IL-17F, but suppresses immune function by decreasing the production of IL-
17A in an AHR-dependent manner399. Conversely, polycyclic aromatic hydrocarbons have 
been shown to increase AHR expression, which promotes IL-17A but not IL-17F production 
in allergic asthmatic patients400.  
 
According to the manufacturer’s technical specifications, the antibodies I used for the 
intracellular detection of IL-17A and IL-17F by flow cytometry recognise both homodimers, 
as well as the IL-17A/F heterodimer. However, based on my staining, it was not possible to 
distinguish T cells that express the heterodimer from IL-17A/IL-17F co-expressing cells. 
Future investigations should therefore take advantage of antibodies that specifically 
recognise the heterodimeric form so as to evaluate the effects of mCRAMP on its production.  
 
 
3.4.1.3 Are Th17 cells generated in the presence of mCRAMP more or less pathogenic? 
 
Differentiation of Th17 cells in the presence of IL-1b (instead of TGFb) is known to 
preferentially lead to the generation of pathogenic T cells that favour production of IL-17A 
over IL-17F398,401. This has led some to speculate that IL-17A+ Th17 lymphocytes are more 
pathogenic than those that are IL-17F single- or double-positive398,401. Indeed, the majority 
of encephalitogenic CD4+ T cells in the CNS during EAE express only IL-17A398. Moreover, IL-
23 promotes the pathogenicity of Th17 cells by increasing IL-17A production398,402. I found 
that mCRAMP had no significant effect on the percentage of IL-17A single-positive 
lymphocytes but significantly increased the frequency of IL-17F+ and IL-17A/IL-17F double-
producing cells. Esplugues et al. demonstrated that the systemic application of anti-CD3 
antibodies triggers the generation of “regulatory Th17” cells (rTh17) in the lamina propria, 
which are thought to represent the IL-17A/F double-positive cells found in the TGFb/IL-6 
differentiation protocol398,403. One might therefore speculate that mCRAMP promotes the 
development of a less pathogenic population of Th17 cells. Indeed, there was a trend 
suggesting that the amount of IL-17 produced by CD4+ IL-17+ T cells in mCRAMP-treated Th17 
cultures was decreased compared to their untreated counterparts. In the future, it will be 
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interesting to see whether the peptide has any effect on IL-17A and IL-17F production when 
the cells are cultured with IL-1b and IL-6. This would help determine whether or not our 
observations are based purely on the protocol used for Th17 polarization.  
 
In addition, mCRAMP had no effect on IL-22 production by CD4+ T cells cultured under Th17-
polarizing conditions. IL-22-secreting Th17 cells induced in response to IL-23 have been 
shown to specifically identify a highly pathogenic population of auto-aggressive T cells in 
EAE371,402,404. The Il22 locus is located in proximity to Ifng and displays differential regulatory 
requirements405. More specifically, IL-22 expression is more dependent on AHR than RORgt 
and is induced by IL-6 but inhibited by high concentrations of TGFb79,116. The lack of an 
increase in IL-22 production in response to mCRAMP demonstrates specificity of the peptide 
in enhancing cytokine production by Th17 cells. Furthermore, this could be explained by the 
fact that my results suggest that mCRAMP boosts TGFb signals in order to enhance Th17 
differentiation. It may also imply that mCRAMP does not increase the pathogenicity of 
developing Th17 lymphocytes, or at least not by inducing IL-22 production.  
 
To test whether the pathogenicity of Th17 cells is altered by exposure to mCRAMP, one could 
perform a T cell transfer model of colitis, in which CD4+ T cells cultured under Th17-driving 
conditions, with or without synthetic mCRAMP, are injected intraperitoneally into 
immunodeficient RAG-/- mice406. If Th17 lymphocytes generated in the presence of this host 
defence peptide are indeed less pathogenic, I would hypothesise that animals receiving 
mCRAMP-treated cells would display delayed onset of colitis and/or potentially lower disease 
scores than controls. 
 
 
3.4.2 Mechanism of action 
 
3.4.2.1 mCRAMP acts directly on CD4+ T cells to enhance Th17 differentiation 
 
Original experiments examining the effects of mCRAMP on Th17 differentiation were 
performed using whole single cell splenic suspensions. It was therefore unclear whether 
mCRAMP acted directly on the CD4+ T lymphocytes, or indirectly via a different cell type such 
as dendritic cells (DCs). I have shown that mCRAMP had no effect on the phenotype of 
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differentiated DCs, as determined by the surface expression of various markers involved in T 
cell activation (CD86) and cross-presentation (XCR1, CLEC9A).  
 
Nonetheless, the possibility that mCRAMP influences the differentiation and phenotype of 
immature DCs to further enhance Th17 differentiation cannot be excluded. A novel role for 
cathelicidin in directing the expansion and differentiation of DCs in culture towards an 
enhanced CD141+/CD103+-like phenotype was recently identified338. Several studies have 
shown that CD103+ DCs drive Th17-mediated immunopathology377,407. For example, Zelante 
et al. found that CD103+ DCs in the lung produce IL-2, which promotes the development of 
an optimally protective Th17 response during invasive pulmonary aspergillosis407. Moreover, 
CD103+ DCs induce pathogenic Th17 differentiation that drives spontaneous colitis in 
mucin2-deficient mice377. However, Gwyer Findlay and colleagues demonstrated that human 
cathelicidin (LL-37) only enhanced CD103+ DC generation when the cells were exposed within 
the first 24 hours of culture, indicating that the peptide modulates DC differentiation and 
does not simply upregulate CD103 expression on fully differentiated cells338. This is similar to 
prostaglandin E2, which alters the IL-12/IL-23 balance in DC precursors during differentiation 
to promote Th17 differentiation at the expense of IFNg-secreting Th1 effector cell 
development408.  
 
Another important cell type resident in the spleen and which has been shown to direct and 
regulate the inflammatory response through Th17 induction is B cells. Wang and Rothstein 
found that activated splenic B-2 cells upregulated the expression of CD44, CD80 and CD86, 
which played a crucial role in promoting Th17 polarization409. Furthermore, IFNb-driven 
inflammatory B cells produce increased levels of IL-6, which drives the differentiation of 
myelin-specific, pro-inflammatory Th17 cells410. I have shown that mCRAMP increases the 
activation state of T cells (CD44) and others have demonstrated how this peptide upregulates 
the expression of co-stimulatory molecules on other cell types such as DCs336. One could 
therefore speculate that mCRAMP may exert similar effects on B cells, which could in turn 
contribute to enhancing the development of IL-17-producing CD4+ T lymphocytes. This could 
be examined in the future by examining the effects of mCRAMP on Th17 differentiation in B 
- T cell co-cultures.  
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However, mCRAMP significantly increased Th17 differentiation of sorted CD4+ T cells, 
indicating that this host defence peptide promotes the development of IL-17-producing T 
lymphocytes, at least in part, by acting directly on this cell type. Nonetheless, it is possible 
that mCRAMP exerts additional indirect effects that I have not identified in the present study, 
which also contribute to this.  
 
 
3.4.2.2 mCRAMP has no effect on IL-23R and IL-6R expression 
 
Naïve CD4+ T cells do not express IL-23R, which is induced by IL-6 and IL-2175. Conversely, IL-
6R is downregulated during T cell activation411. However, differentiating T lymphocytes retain 
their responsiveness to this cytokine via IL-6 trans signalling, which has been implicated in 
the local maintenance of Th17 cells411. Increased expression of these receptors has been 
shown to promote IL-17 secretion by this T helper cell subset. For instance, Zhang et al. found 
that elevated IL-6R expression on CD4+ T cells contributes to Th17 responses in patients with 
chronic hepatitis B infection412. Furthermore, oestrogen receptor a signalling upregulates IL-
23R in Th17 cells to increase IL-17 production413.  
 
I found that IL-23R and IL-6R expression were not significantly different between untreated 
and mCRAMP-treated samples. This suggests that mCRAMP does not enhance Th17 
differentiation by increasing the sensitivity of CD4+ T lymphocytes to IL-6 and IL-23 by 
upregulating their receptors. However, the quality of staining was highly variable and the 
expression of TGFbR was not investigated due to the lack of a suitable flow cytometry 
antibody. To confirm these results, the expression of IL-23R, IL-6R and TGFbR in response to 
mCRAMP should therefore be examined by PCR.  
 
 
3.4.2.3 mCRAMP is a CD4+ T cell survival factor 
 
Cathelicidin has been shown to suppress apoptosis of several cell types, including 
cardiomyocytes, endothelial cells and keratinocytes358,414,415. Conversely, there is only a 
limited amount of published data suggesting that this host defence peptide acts as a survival 
factor to protect cells of the immune system from death. For example, Nagaoka et al. found 
that human cathelicidin (LL-37), human b-defensin 3 (hBD3) and HNP-1 suppress neutrophil 
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apoptosis via the activation of FPR2 and P2X7R416. However, findings published by Li and 
colleagues suggested that this was probably an artefact due to rapid secondary necrosis 
induced by LL-37, which selectively permeabilizes apoptotic leukocytes199,417.  
 
Mader and colleagues demonstrated that LL-37 induces granzyme-mediated apoptosis of 
regulatory and cytotoxic CD8+ T cells but had no effect on CD4+ T lymphocytes360,378. This is 
contrary to my findings: mCRAMP significantly increased the percentage of viable CD4+ T 
lymphocytes and decreased the percentage of necrotic cells, as determined by annexin/PI 
staining. One possible explanation for this divergence could be that the concentration of LL-
37 used by Mader et al. was very high (40 µg/mL) and therefore potentially cytotoxic360,378. 
Nevertheless, to my knowledge, my data is the first demonstration of a neutrophil peptide 
increasing the survival of T cells. 
 
Interestingly, mCRAMP protected both CD4+ IL-17+ and IL-17- cells from death. Furthermore, 
this was not a result of increased T cell proliferation, indicating that mCRAMP does not 
enhance Th17 differentiation by increasing the proliferative capacity of CD4+ IL-17+ T 
lymphocytes and/or by promoting the death of non-Th17 cell types.  
 
Increasing the longevity of CD4+ IL-17+ T cells could result in a prolonged period where these 
cells are able to produce inflammatory cytokines in vivo, such as IL-17 and IL-21. IL-21 is 
particularly important in creating a positive feedback loop to expand Th17 cells during the 
self-amplification stage of differentiation418. I found that the increase in IL-17-producing CD4+ 
T lymphocytes in response to mCRAMP was associated with an increase in IL-21 production. 
By protecting IL-21-producing CD4+ IL-17+ T cells from death, mCRAMP may further amplify 




3.4.2.4 mCRAMP requires TGFb to enhance Th17 differentiation 
 
Under non-lineage driving conditions and in the absence of Th17-polarizing cytokines, 
mCRAMP did not increase the percentage of CD4+ IL-17A+ T cells. One possible explanation 
for this is that the peptide exerts its effects by interacting with or boosting signals from IL-6, 
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IL-23 and/or TGFb. However, mCRAMP did transiently increase the geometric mean of PD1 
and the percentage of CD4+ CD62L- CD44+ T cells on day 1. This indicates that there are at 
least two, separate T cell signalling pathways induced by mCRAMP, one of which is switched 
on in all conditions and one which is Th17-specific.  
 
mCRAMP did not have a significant effect on the differentiation of other T helper subsets, 
namely Th1 and Th2. Conversely, a small increase in the percentage of CD4+ FOXP3+ T cells 
was observed following culture under Treg-driving conditions. Th17 cells and regulatory T 
lymphocytes are closely related: the differentiation of both subsets requires TGFb49. More 
specifically, TGFβ alone and at high concentrations induces FOXP3 expression, whereas low 
concentrations of TGFβ, together with IL-6, enhance STAT3 activation and upregulate RORgt 
during the initial stages of Th17 polarization66. I consequently hypothesised that mCRAMP 
enhances the downstream effects of TGFb signalling. For example, TGFβ promotes Th17 
development by suppressing SOCS3, a negative regulator of STAT3 activation, as well as T-
bet and GATA3, thereby inhibiting CD4+ T cells from adopting alternate Th1 and Th2 fates65,66. 
Indeed, when whole single cell splenic suspensions were cultured in the absence of TGFβ, 
mCRAMP had no significant effect on RORgt expression.  
 
Several studies have shown that Th17 cells display late developmental plasticity, which 
allows for functional adaptation to different physiological situations during an immune 
response419. For example, using lineage-tracing mice, Gagliani and colleagues demonstrated 
that Th17 cells acquire the transcriptional profile and potent suppressive functions of Tr1 
cells (produce IL-10 but are FOXP3-) during the resolution phase of Th17-mediated colitis420. 
Sustained TGFb signalling is essential for maintaining the expression of IL-17A and IL-17F: re-
stimulation of committed Th17 precursors with IL-12 and in the absence of TGFb promotes 
the emergence of IFNg-producing cells that lack IL-17 expression421. Another potential 
mechanism through which mCRAMP could promote Th17 differentiation is therefore by 
preventing the transdifferentiation of this T helper cell subset by maintaining TGFb-derived 
signals.  
 
Wanke et al. demonstrated that TGFb drives the development of IL-17F+ and IL-17A+ IL-17F+ 
T cells398. Furthermore, they suggested that IL-17A and IL-17F double-producers represent a 
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regulatory subset of Th17 cells known to be induced in response to TGFb398,403. As discussed 
previously, I have shown that mCRAMP displayed a more pronounced effect on IL-17F 
expression than IL-17A. Taken together, this provides further evidence to support the 
hypothesis that mCRAMP enhances TGFb signals to promote the generation of a less 
pathogenic population of Th17 lymphocytes.  
 
There is a limited amount of previously published data linking host defence peptides to TGFb. 
For example, the TGFb homologue Dpp, found in Drosophila melanogaster, is increased in 
the gut following bacterial entry and contributes to the developing immune response and 
control of bacterial homeostasis by enhancing antimicrobial peptide production422. On the 
other hand, Scott et al. found that human cathelicidin (LL-37) increases the expression of 
TGFbR1 by macrophages353. Furthermore, mCRAMP has been shown to decrease TGFb-




3.4.2.5 The effects of mCRAMP on Th17 differentiation are not receptor-mediated 
 
Cathelicidin activates a variety of different receptors depending on cell type and context, 
including P2X7R, FPR2 and EGFR387.  However, I have shown that both the D-enantiomer and 
scrambled cathelicidin peptide increased the percentage of CD4+ IL-17A+ T cells to the same 
extent as mCRAMP, suggesting that a structurally unique ligand binding site is not involved.  
 
One possible explanation for this is that mCRAMP inserts itself into the membrane and 
interacts with the cytoplasmic C’ terminal end of a receptor, similarly to its activation of 
P2X7R387. D-LL-37, in which each amino acid is in the D-configuration, LL-37 and mCRAMP 
possess the same a-helical configuration; the hydrophobic environment of the membrane 
allows for specific interactions to be formed between polypeptides, irrespective of their 
chirality424. Interestingly, modifications of the physical properties of the lipid membrane 
bilayer resulting in decreased membrane fluidity have been proposed as a potential 
mechanism for the activation of the calcium-permeable channel TRPV2 in breast cancer cells 
by LL-37425. Furthermore, both the D- and L-enantiomer of LL-37 displayed identical effects 
in this study425. However, scrambled LL-37, in which the same amino acids are ordered 
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randomly, maintains its net positive charge but loses its propensity to fold into the correct 
amphipathic structure. This would theoretically prevent the peptide from behaving in the 
same way as mCRAMP, LL-37 and D-LL-37.  
 
Several studies (including unpublished observations from other group members) have 
reported limited activity of the scrambled peptide with regards to its antimicrobial 
function426. For instance, Gordon et al. found that scrambled LL-37 demonstrated limited 
inhibition of herpes simplex virus type 1 (HSV-1) relative to a PBS control, but significantly 
less than that of LL-37426. They proposed that this is due to the fact that the action of 
cathelicidin is dependent not only on size and sequence, but also charge, degree of helicity, 
overall hydrophobicity, amphipathicity and the angles subtended by hydrophobic and 
hydrophilic surfaces426. It is therefore possible that the effects of mCRAMP on Th17 
differentiation are not dependent on its helical structure but are instead mediated by 
something like charge. This would be in contrast to previously published reports, in which it 
was shown that the cationicity of a peptide is not sufficient to induce bacterial membrane 
permeabilization and killing417. Nevertheless, this could be tested in the future by examining 
the effects of other short positive peptides of random sequence and structure.  
 
Cathelicidin can also be taken up by cells in a non-specific manner in which a receptor is not 
required333,334. For instance, LL-37 can bind to extracellular DNA plasmids through 
electrostatic interactions and target them to the nuclear compartment of mammalian cells 
(human embryonic fibroblasts, bladder carcinoma cells)333. A similar phenomenon involving 
lipid rafts and proteoglycan-dependent endocytosis could therefore be required for the 
uptake of mCRAMP by CD4+ T lymphocytes.  
 
Finally, unpublished data from the laboratory has shown that human CD4+ T cells incubated 
with TAMRA-labelled LL-37 rapidly take up the peptide, which locates to the nucleus typically 
within 10 minutes (unpublished observation by Emily Gwyer Findlay & Brian McHugh). 
Several other groups have shown that cathelicidin can localize to the nucleus in other cell 
types. For example, Lau and colleagues demonstrated that LL-37 is actively taken up by A549 
epithelial cells and eventually localises to the perinuclear region342. Like most AMPs, 
cathelicidins are highly cationic and as a result, are capable of binding to negatively-charged 
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DNA285. For example, LL-37 binds to inert self-DNA in psoriatic lesions to form aggregated 
and condensed structures that are delivered to early endocytic compartments in pDCs334. 
Muñoz et al. demonstrated that following migration to the nucleus, LL-37 can bind to gene 
promoter regions and directly modulate the transcriptional program of A375 melanoma 
cells427. mCRAMP may therefore enhance Th17 differentiation by acting as a transcription 
factor to promote the development of this T helper cell subset. However, it is highly unlikely 
that scrambled LL-37 would be able to do this, which suggests that this is not how these 





To summarize, I have shown that T cells that develop in the absence of mouse cathelicidin 
(mCRAMP) do not possess an obvious underlying defect that is responsible for their inability 
to produce IL-17 in vivo in response to inflammation induced by heat-killed S. typhimurium.  
 
Furthermore, mCRAMP is a Th17 differentiation enhancing factor, which acts directly on T 
cells in vitro to increase their activation status, viability and production of IL-17. Whilst I 
suggest that there are at least two, separate T cell signalling pathways induced by the peptide 
(one of which is non-specific and one which is Th17-specific), I have provided evidence that 
indicates mCRAMP requires TGFb to promote the development of a less pathogenic 
population of Th17 lymphocytes. Finally, I predict that these effects are not receptor-
mediated due to the fact that both the D-enantiomer and scrambled peptide display similar 
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I have shown that mCRAMP enhances mouse Th17 differentiation in vitro by acting directly 
on CD4+ T cells to increase RORgt expression and promote the development of IL-17-
producing lymphocytes. However, the exact mechanism through which this occurs remains 
unclear. For instance, Lau and colleagues demonstrated that human cathelicidin (LL-37) is 
actively taken up by A549 lung epithelial cells and eventually localises to the perinuclear 
region342. Furthermore, LL-37 is rapidly endocytosed and localizes to the nucleus of CD4+ T 
lymphocytes (unpublished observation by Emily Gwyer Findlay & Brian McHugh). Based on 
these observations, it has been suggested that cathelicidin can directly modulate gene 
expression by acting as a transcription factor427. 
 
On the other hand, it is also possible that mCRAMP may amplify type-17 responses by 
inducing metabolic reprogramming. For example, glycolysis is especially important for the 
development of Th17 lymphocytes: defective glycolysis can drastically impair the 
proliferation and cytokine production of this T helper cell subset428,429. The transcription 
factor, HIF1a (hypoxia-inducible factor 1α), plays a crucial role in mediating glycolytic activity 
and is selectively expressed in Th17 lymphocytes, in which it regulates the expression of Th17 
signature genes through direct transcriptional activation of RORgt429,430. HIF1a induction 
requires signalling through mTOR (mammalian target of rapamycin), another central 
regulator of cellular metabolism429. Impaired mTOR signalling in naïve CD4+ T cells results in 
their failure to differentiate into Th17 lymphocytes431. Interestingly, cathelicidin has been 
shown to enhance the LPS-induced phosphorylation of mTOR in a keratinocyte cell line432. 
Furthermore, GAPDH is another enzyme that plays a crucial role in glycolysis and has also 
been identified as a novel intracellular receptor for LL-37 in macrophages428,433.   
 
I have shown that mCRAMP requires TGFb to amplify Th17 differentiation in vitro. TGFb 
induces multiple pathways that promote the development of Th17 cells, many of which could 
be enhanced by mCRAMP434. For instance, TGFb receptor signalling phosphorylates SMAD2 
and SMAD3, which form a heterotrimeric complex with SMAD4 that translocates to the 
nucleus434. SMAD4 interacts with the SKI repressor to suppress Th17 differentiation through 
direct binding to Rorc434,435. This is offset by TGFb, which triggers degradation of SKI435. Other, 
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SMAD-independent pathways activated by TGFb that promote Th17 differentiation include 
the suppression of SOCS3, the activation of RhoA/ROCK2 and the inhibition of Eomes434. 
SOCS3 is a negative regulator of STAT3: small interfering RNA knockdown of SOCS3 promotes 
Rorc expression and in vitro Th17 differentiation66. ROCK2 is required for the phosphorylation 
of IRF4, which promotes the expression Th17-related genes including Rorc and Il17434,436. 
TGFb also suppresses Eomes through the Jun N-terminal kinase-c-Jun pathway437. Eomes 
directly inhibits RORgt and IL-17A: ablation of Eomes expression by short hairpin RNA induces 






mCRAMP has the potential to act through a wide variety of mechanisms to promote Th17 
differentiation. I hypothesised that exposure to mCRAMP alters the transcriptional program 
of CD4+ T cells to enhance the development of IL-17-producing T lymphocytes. I therefore 
analysed the gene expression profile of CD4+ T cells cultured under Th17-driving conditions 
for 24 hours, with or without synthetic mCRAMP, to help dissect the mechanism through 





4.3.1 mCRAMP induces genetic changes in CD4+ T cells cultured under Th17-
polarizing conditions 
 
I have shown that mCRAMP is a Th17 differentiation enhancing factor that amplifies the 
development of IL-17-producing CD4+ T lymphocytes. I therefore sought to examine the 
genetic changes induced by mCRAMP that could contribute to this. To do so, I cultured whole 
single cell splenic suspensions under Th17-driving conditions, as previously described, with 
or without synthetic mCRAMP. After 24 hours of culture, I sorted CD4+ T cells (DAPI- CD4+ 
CD8-; purity > 97%) and compared their gene expression profiles by Nanostring.  
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The results revealed that 17 genes were significantly differentially expressed and had a log2 
fold change of 1 or more (i.e. 2-fold or more different). More specifically, mCRAMP 
significantly downregulated the expression of 15 genes and upregulated 2 genes (Figure 4.1; 






4.3.1.1 mCRAMP modulates the expression of genes associated with T cell activation 
A B 
Figure 4.1: mCRAMP induces genetic changes in CD4+ T cells cultured under Th17 driving 
conditions. Nanostring analysis was performed in CD4+ T cells that had been cultured for 24 
hours under Th17 driving conditions, with or without 2.5 µM synthetic mCRAMP (A) Heat map 
of significantly changed genes in untreated and CRAMP-treated samples (B) Table presenting 
statistically significantly differentially expressed genes in response to mCRAMP. N = 3. UT: 
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The Nanostring analysis revealed that Sell, which encodes CD62L, was significantly 
downregulated by mCRAMP (log2 FC = -1.76). The downregulation of CD62L in vivo redirects 
lymphocytes away from the lymph nodes following antigen encounter and towards sites of 
infection/inflammation369. It is therefore commonly used to identify activated T cells, 
together with CD44. I found that mCRAMP increased the activation status of CD4+ T cells 
cultured under Th17-driving conditions, which was marked by a significant increase in the 
percentage of CD4+ CD62L- CD44+ T lymphocytes (Chapter 3: Figure 3.7).  
 
To validate the Nanostring data, I analysed the percentages of CD4+ CD62L single-positive 
cells in Th17 cultures, following exposure to mCRAMP, by flow cytometry. Figure 4.2 shows 
that mCRAMP significantly decreased the frequency of CD4+ CD62L+ T lymphocytes on days 
1 to 3. For example, this dropped from 36.43% (+/- 1.80) to 27.12% (+/- 1.68) on day 2. 
However, the geometric mean of CD62L of CD4+ CD62L+ T lymphocytes was no different 




Figure 4.2: mCRAMP decreases the frequency of CD4+ CD62L+ T cells cultured under Th17-driving 
conditions. Whole single cell splenic suspensions were cultured under Th17-driving conditions, 
with or without 2.5 µM synthetic mCRAMP (A) Representative plots of CD62L expression by CD4+ 
T cells on day 2, assessed by flow cytometry (B) Percentages of CD4+ CD62L+ T cells, ex vivo and 
days 1-3 (C) Geometric mean of CD4+ CD62L+ T cells, ex vivo and days 1-3. Data shown is mean +/- 
standard error. N = 6. Statistical significance (where * represents < 0.05 and ** < 0.01) was 
determined using a two-way repeated measures ANOVA with a Bonferroni multiple comparison 
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4.3.1.2 mCRAMP downregulates genes involved in the negative regulation of Th17 
differentiation 
 
The expression of Socs3 (suppressor of cytokine signalling 3) and Tcf7 (encodes TCF1), which 
have both previously been implicated in the negative regulation of Th17 differentiation, were 
also significantly reduced in response to mCRAMP (log2 FC = -1.04 and -1.12 respectively). 
SOCS3 inhibits STAT3 activation and TCF1 negatively regulates the expression of the IL-17 
family of cytokines438,439. Their downregulation suggests that mCRAMP enhances Th17 
differentiation by relieving the inhibition of these molecules on the expression of genes that 
drive the development of IL-17-producing CD4+ T cells. 
 
 
4.3.1.3 mCRAMP downregulates Th1-related genes 
 
Several classical Th1-related genes were downregulated following exposure to mCRAMP, 
including Bcl3 (B-cell lymphoma 3-encoded protein; log2 FC = -1.46), Irf8 (Interferon 
regulatory factor 8; log2 FC = -1.44), Ikzf4 (IKAROS family zinc finger 4, otherwise known as 
EOS; log2 FC = -1.49), Il2 (interleukin-2; log2 FC = -1.7) and Xcl1 (X-C motif chemokine ligand 
1, otherwise known as lymphotactin; log2 FC = -1.95). This suggests that mCRAMP potentially 
skews T helper cell differentiation away from the Th1 lineage.  
 
Many of these Th1-related genes have been shown to exert a suppressive function on the 
differentiation of Th17 cells. For example, IRF8 is highly expressed in Th1 lymphocytes but 
also directs a silencing program for Th17 differentiation440. More specifically, IRF8 acts as a 
transcriptional inhibitor that suppresses Th17 polarization, in part, by physically interacting 
with RORgt440. I therefore sought to validate the Nanostring data by examining the expression 
of IRF8 in CD4+ T cells by intracellular flow cytometry (Figure 4.3). Whole single cell splenic 
suspensions were cultured under Th17-driving conditions, as previously described, with or 
without synthetic mCRAMP.  
 
The percentage of CD4+ IRF8+ T cells was significantly decreased in response to mCRAMP on 
days 2 and 3 (Figure 4.3 B). For example, this dropped from 73.17% (+/- 5.63) to 58.50% (+/- 
5.18) on day 2. Furthermore, the geometric mean of IRF8 of CD4+ IRF8+ T lymphocytes was 
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also significantly reduced from 4129 (+/- 54) to 3141 (+/- 84) on day 2, as well as on day 3 








Another classical Th1-associated gene identified in the Nanostring analysis that has also been 
shown to restrain Th17 differentiation is Il2. IL-2 is predominantly produced by naïve T helper 
cells and is required for the proliferation and differentiation of precursors into effector 
lymphocytes441. This cytokine primes and maintains Th1 differentiation whilst simultaneously 
antagonizing Th17 development via STAT5442.  
 
To validate this Nanostring result, I measured the concentration of IL-2 in cell culture 
supernatants by ELISA (Figure 4.4). I observed an almost complete suppression of production 
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Figure 4.3: mCRAMP decreases IRF8 expression by CD4+ T cells. Whole single cell splenic 
suspensions were cultured under Th17-driving conditions, with or without 2.5 µM synthetic 
mCRAMP, for up to 3 days (A) Representative plots of IRF8 expression by CD4+ T cells on day 2, 
assessed by flow cytometry (B) Percentages of CD4+ IRF8+ T cells, ex vivo and days 1-3 (C) 
Geometric mean of CD4+ IRF8+ T cells, ex vivo and days 1-3. Data shown is mean +/- standard error. 
N = 3. Statistical significance (where * represents < 0.05, ** < 0.01 and *** < 0.001) was 
determined using a two-way repeated measures ANOVA with a Bonferroni multiple comparison 
post-test. UT: untreated.  
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the concentration of IL-2 fell from 44.36 to 18.12 ng/mL on day 2 and from 64.46 to 5.61 








The downregulation of genes such as IRF8 and IL-2 suggests that mCRAMP skews T helper 
cell differentiation away from the Th1 lineage and in doing so, also suppresses the negative 
regulatory networks that normally limit Th17 responses. 
 
 
4.3.2 mCRAMP decreases T-bet expression and IFNg production by CD4+ T cells 
cultured under Th17-driving conditions 
 
The Nanostring analysis revealed that several Th1-related genes were significantly 
downregulated by mCRAMP, suggesting that the peptide skews T helper cell differentiation 
away from the Th1 lineage. Th1 lymphocytes are the primary producers of IFNg and their 
differentiation is driven, in part, by the master transcriptional regulator T-bet26. I therefore 
investigated the expression of T-bet and IFNg by CD4+ T cells in Th17 cultures, treated with 
or without synthetic mCRAMP (Figure 4.5).  
 
Figure 4.5 shows that mCRAMP significantly decreased the frequency of T-bet-expressing 
CD4+ lymphocytes on days 2 and 3 (Figure 4.5 C). For example, the percentage of CD4+ RORgt- 
T-bet+ T cells dropped from 27.04% (+/- 8.27) to 13.62% (+/- 5.03) on day 2.  
Figure 4.4: mCRAMP suppresses IL-2 production by CD4+ T cells cultured under Th17-driving 
conditions. CD4+ T cells were cultured under Th17-driving conditions, with or without 2.5 µM 
synthetic mCRAMP, for up to 3 days. The concentration of IL-2 in cell culture supernatants was 
determined by ELISA every 24 hours. Data shown is mean +/- standard error. N = 4. Statistical 
significance (where * represents < 0.05 and *** < 0.001) was determined using a two-way 
repeated measures ANOVA with a Bonferroni multiple comparison post-test. UT: untreated.  
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Th17 cells can co-express T-bet and RORgt381. It has been suggested that secondary 
expression of T-bet is required to stabilize pathogenic IL-17 and IFNg double-producing Th17 
lymphocytes443,444. I also observed a significant decrease in the frequency of CD4+ RORgt+ T-
bet+ T cells on day 3 following exposure to mCRAMP, from 28.06% (+/- 6.50) to 18.84% (+/- 
4.03) (Figure 4.5 D).  
 
The reduction in T-bet expression by CD4+ T lymphocytes cultured in the presence of 
mCRAMP was associated with a significant decrease in IFNg-producing cells: the percentage 
of CD4+ IFNg+ T cells fell from 3.77% (+/- 0.47) to 2.06% (+/- 0.33) on day 2 (Figure 4.5 E), 
although no changes in the geometric mean of IFNɣ were detected (Figure 4.5 F). 
Furthermore, no IL-17/IFNg double-producing lymphocytes were identified.  
 
Interestingly, mCRAMP did not decrease the percentage of dead CD4+ IFNg+ T lymphocytes, 
as determined by uptake of a fixable viability dye (Figure 4.5 G). This was in contrast to total 
CD4+ and CD4+ IL-17+ T cells (Chapter 3: Figure 3.16) and suggests that mCRAMP does not 
protect this T helper subset from death. Furthermore, no significant differences were 
observed in the proliferation of CD4+ T-bet+ T lymphocytes between untreated and CRAMP-
treated samples, as determined by CFSE dye dilution (Figure 4.5 H).  
 
Taken together, these results support the hypothesis that mCRAMP skews T helper cell 
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Figure 4.5: mCRAMP decreases T-bet expression and IFNɣ production by CD4+ T cells under Th17-
driving conditions. Whole single cell splenic suspensions were cultured under Th17-driving 
conditions, with or without 2.5 µM synthetic mCRAMP (A) Representative plots of RORgt and T-
bet expression by CD4+ T cells on day 2, assessed by flow cytometry (B) Representative plots of 
IFNɣ production by CD4+ T cells on day 2, assessed by flow cytometry (C) Percentages of CD4+ 
RORgt- T-bet+ T cells, ex vivo and days 1-3 (n = 6) (D) Percentages of CD4+ RORgt+ T-bet+ T cells, ex 
vivo and days 1-3 (n = 6) (E) Percentages of CD4+ IFNɣ+ T cells on day 2 (n = 21) (F) Geometric mean 
of IFNɣ of CD4+ IFNɣ+ T cells on day 2 (n = 15) (G) Percentages of dead CD4+ IFNɣ+ T cells on day 2 
(n = 22) (H) Geometric mean of CD4+ T-bet+ CFSE+ T cells on day 2. Data shown is mean +/- standard 
error. Statistical significance (where * represents < 0.05, ** < 0.01 and **** < 0.0001) was 
determined using a two-way repeated measures ANOVA with a Bonferroni multiple comparison 
post-test (C & D) or a paired t-test (E). UT: untreated.  
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4.3.3 mCRAMP upregulates the expression of the aryl hydrocarbon receptor 
 
Ahr was one of only two genes identified in the Nanostring data that was significantly 
upregulated by mCRAMP (log2 FC = 1.72). The aryl hydrocarbon receptor (AHR) is a ligand-
activated transcription factor that integrates environmental, dietary, microbial and 
metabolic cues to control transcriptional programmes in a ligand-specific, cell-type-specific 
and context-specific manner445.  Moreover, AHR has been shown to play an important role 
in the differentiation of Th17 lymphocytes446.  
 
I therefore confirmed the Nanostring results by intracellular flow cytometry (Figure 4.6). 
Whole single cell splenic suspensions were cultured under Th17-driving conditions, as 
previously described, with or without synthetic mCRAMP. Figure 4.6 shows that mCRAMP 
significantly increased the percentage of CD4+ AHR+ T cells, from 6.04% (+/- 1.05) to 10.29% 
(+/- 1.16) on day 1 (Figure 4.6 B) but had no effect on the geometric mean of AHR (gated 
CD4+ AHR+ T lymphocytes) (Figure 4.6 C). This was cumulative and even more pronounced on 
day 2 (Figure 4.6 D: 75.50% +/- 1.43 compared to 54.83% +/- 1.53). However, statistical 
analysis revealed that the increase in CD4+ AHR+ T lymphocytes in response to the peptide 
was not concentration-dependent (Figure 4.6 E).  
 
I have suggested that mCRAMP requires TGFb to promote Th17 differentiation (Chapter 3: 
Figure 3.19). To investigate the importance of AHR within this pathway, I analysed AHR 
expression by CD4+ T cells following culture in the absence of IL-6, IL-23 or TGFb or with a 
single Th17-polarizing cytokine, with or without synthetic mCRAMP (Figure 4.6 F). Unlike the 
observations made previously, where in the absence of TGFb, mCRAMP failed to increase 
RORgt expression, mCRAMP did not increase the percentage of CD4+ AHR+ T cells in any 
condition, except when all three cytokines were included. This indicates that IL-6, IL-23 and 
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Figure 4.6: mCRAMP increases the frequency of AHR-expressing CD4+ T cells cultured under 
Th17-driving conditions. Whole single cell splenic suspensions were cultured under Th17-driving 
conditions, with or without 2.5 µM synthetic mCRAMP (A) Representative plots of AHR expression 
production by CD4+ T cells on day 1, assessed by flow cytometry (B) Percentages of CD4+ AHR+ T 
cells on day 1 (n = 9) (C) Geometric Mean of CD4+ AHR+ T cells on day 1 (D) Percentages of CD4+ 
AHR+ T cells, ex vivo and days 1-2 (n = 3) (E) CD4+ AHR+ vs. mCRAMP dose response (n = 3) (F) 
Whole splenocytes were cultured with different combinations of IL-6 (20 ng/mL), IL-23 (20 ng/mL) 
and TGFβ (3 ng/mL), with or without 2.5 µM synthetic mCRAMP. Percentages of CD4+ AHR+ T cells 
on day 1 (n = 6). Data shown is mean +/- standard error. Statistical significance (where * represents 
< 0.05, ** < 0.01 and *** < 0.001) was determined using a paired t-test (B) or a two-way repeated 
measures ANOVA with a Bonferroni multiple comparison post-test (D & F) or an ordinary one-way 
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4.3.4 mCRAMP acts via AHR to increase the percentage of CD4+ IL-17A+ IL-17F+ T 
cells 
 
AHR is highly expressed by Th17 lymphocytes and plays an important role in the in vivo and 
in vitro generation of this T helper cell subset79. For example, the AHR agonist FICZ (6-
formylindolo[3,2-b]carbazole) increases IL-17 production by CD4+ T cells cultured under 
Th17-driving conditions79. I therefore sought to determine whether the effects of mCRAMP 
on the differentiation of Th17 cells are dependent on the upregulation of AHR. To do this, I 
cultured whole single cell splenic suspensions under Th17-driving conditions for 2 days, with 
or without synthetic mCRAMP and/or an AHR antagonist, CH223191447.  
 
Figure 4.7 shows that the addition of the AHR antagonist had no effect on the percentage of 
IL-17A or IL-17F single-positive cells. For example, mCRAMP increased the percentage of IL-
17A- IL-17F+ T lymphocytes from 9.10% (+/- 0.83) to 15.76% (+/- 1.00), despite the presence 
of CH223191 (Figure 4.7 B). However, the AHR antagonist did abolish the increase in the 
percentage of IL-17A and IL-17F double-producing T cells normally seen in response to 
mCRAMP (Figure 4.7 C).  
 
These results suggest that mCRAMP upregulates AHR and acts via this transcription factor to 



































Figure 4.7: An AHR antagonist abolishes the increase in the percentage of CD4+ IL-17A+ IL-17F+ T 
cells induced by mCRAMP. Whole single cell splenic suspensions were cultured under Th17-driving 
conditions, with or without 2.5 µM synthetic mCRAMP and/or an AHR antagonist (CH223191, 
10µM) for 2 days (A) Percentages of CD4+ IL-17A+ IL-17F- T cells on day 2 (B) Percentages of CD4+ 
IL-17A- IL-17F+ T cells on day 2 (C) Percentages of CD4+ IL-17A+ IL-17F+ T cells on day 2. Data shown 
is mean +/- standard error. N = 5. Statistical significance (where * represents < 0.05, ** < 0.01, *** 
< 0.001 and **** < 0.0001) was determined using an ordinary one-way ANOVA with a Bonferroni 
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4.3.5 mCRAMP is probably not an AHR ligand  
 
I have shown that mCRAMP upregulated the expression of AHR by CD4+ T lymphocytes, which 
specifically enhanced the differentiation of IL-17A and IL-17F co-expressing cells. AHR is a 
transcription factor that is activated by numerous environmental and endogenous ligands, 
which result in differential downstream effects depending on the cell type445. For instance, 
FICZ is a natural agonist which boosts Th17 differentiation, whereas TCDD, a synthetic 
compound found in combustion products and cigarette smoke, promotes the development 
of regulatory T cells in vitro448.  
 
AHR drives its own expression as part of a positive feedback loop445. Based on the results 
discussed above showing that the addition of an AHR antagonist abolished the increase in 
the frequency of CD4+ IL-17A+ IL-17F+ T cells induced in response to mCRAMP, one might 
speculate that this peptide is a novel endogenous AHR ligand. To explore the possibility that 
mCRAMP can bind to the unique AHR ligand-binding domain based on its structure, I cultured 
whole single cell splenic suspensions under Th17-driving conditions with a variety of other 
host defence peptides that fold into distinctive configurations and display a net charge 
ranging from +3 to +6 (Figure 4.8 A & B). For example, “partial peptide 47” (PP47) consists of 
a fragment of LL-37 (the last 22 amino acids). Human b-defensin 2 (hBD2) forms a three-
stranded anti-parallel β-sheet with one helix flanking the sheet449. Bac2A is a linear variant of 
the loop-shaped bactenecin that is typically found in bovine neutrophils450. Indolicidin is 
another cationic bovine antimicrobial peptide that is rich in tryptophan and proline 
residues277. I hypothesised that if mCRAMP is a novel AHR ligand, other peptides of different 
sequence and structure would not have the same effect on Th17 differentiation.  
 
Figure 4.8 shows that PP47 significantly increased the percentage of CD4+ IL-17A+ T cells from 
10.05% (+/- 3.05) to 17.77% (+/- 2.13). This was comparable to mCRAMP (21.60% +/- 2.00) 
and LL-37 (19.63% +/- 1.63). There was also a trend indicating that hBD2 increased the 
frequency of IL-17-producing CD4+ T lymphocytes, although this was not statistically 
significant (16.90% +/- 1.33; P = 0.156). Conversely, addition of the bovine AMPs, Bac2A and 
indolicidin, led to only a very small and insignificant increase in the percentage of CD4+ IL-
17A+ T cells: 12.92% (+/- 2.4) and 12.18% (+/- 5.01), respectively.  
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PP47 had similar effects on the differentiation of CD4+ T cells compared to mCRAMP and LL-
37. It is possible that this partial peptide has a conserved structural epitope that activates 
the same intracellular receptor. However, hBD2 has a very different amino acid sequence 
and structure compared to mCRAMP but enhanced Th17 development nonetheless. Taken 
together, these results suggest that it is unlikely that mCRAMP is an endogenous AHR ligand. 


































Figure 4.8: Several other peptides also increase Th17 differentiation in vitro. Whole single cell 
splenic suspensions were cultured under Th17-driving conditions with 2.5 µM synthetic mCRAMP, 
LL-37, Scrambled LL-37, PP47, hBD2, Bac2A or indolicidin, for 2 days (A) α-helical structure of 
cathelicidin (mCRAMP/LL-37) (B) Structure of human β-defensin 2 (hBD2) (C) Extended structure 
of indolicidin (D) Amino acid sequences and net charge of the different peptides tested (E) 
Percentages of CD4+ IL-17A+ T cells on day 2. Data shown is mean +/- standard error. N = 3. 
Statistical significance (where * represents < 0.05) was determined using an ordinary one-way 
ANOVA with a Dunnett’s multiple comparison post-test. UT: untreated; PP47: partial peptide 47; 
hBD2: human β-defensin 2.  






















































To dissect the mechanism through which mCRAMP acts to enhance Th17 differentiation, I 
analysed the gene expression profile of CD4+ T cells that had been cultured under Th17-
driving conditions for 24 hours, with or without synthetic peptide. The results revealed that 
17 genes were significantly differentially expressed (2-fold or more different).   
 
 
4.4.1 mCRAMP induces genetic changes that promote T cell activation 
 
I previously demonstrated that mCRAMP increased the activation status of CD4+ T cells 
cultured under Th17-driving conditions (Chapter 3: Figure 3.7). Gene expression analysis 
revealed that Sell (CD62L) was significantly downregulated by mCRAMP, which is a hallmark 
of T cell activation369. The reduction in CD62L expression following exposure to mCRAMP is 
therefore in agreement with observations made previously, in which the percentage of CD4+ 
CD44+ CD62L- T cells was increased.  
 
In addition, CD4+ T lymphocytes treated with mCRAMP displayed a log2 fold change of -1.02 
in Ikbke expression compared to untreated. IκB kinase ε promotes the phosphorylation of 
NFATc1 (nuclear factor of activated T cells, cytoplasmic 1), which in turn inhibits T cell 
responses and is therefore considered a crucial negative regulator of T cell activation451. 
Reduced expression of this gene could therefore also contribute to increasing the activation 
status of CD4+ T cells when treated with synthetic mCRAMP.  
 
 
4.4.2 mCRAMP modulates the expression of genes involved in T cell apoptosis 
 
Several changes in the gene expression profile identified in the Nanostring data support the 
hypothesis that mCRAMP acts as a survival factor to increase the viability of CD4+ T cells 
(Chapter 3: section 3.3.10). For example, CD9 is expressed by T cells and can deliver a potent 
CD28-independent co-stimulatory signal452. Tai and colleagues demonstrated that co-
stimulation of CD9 on naïve T cells during TCR stimulation results in transient activation 
followed by apoptosis453. In the present study, CD9 was significantly downregulated in 
response to mCRAMP (log2 FC = -1.13). Furthermore, IL-2, whose expression displayed a log2 
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fold change of -1.7, participates in a regulatory feedback mechanism by predisposing mature, 
activated T lymphocytes to undergo activation-induced cell death454. The aryl hydrocarbon 
receptor (AHR), which was significantly upregulated by mCRAMP (log2 FC = 1.72), has also 
been shown to regulate gut immunity by promoting the survival of RORgt+ innate lymphoid 
cells (ILC): absence of AHR signalling resulted in decreased levels of anti-apoptotic genes such 
as BCL2/BCL2L1 and increased apoptosis455. The changes in the expression of these genes 
induced by mCRAMP could therefore contribute to increasing CD4+ T cell viability.   
 
Conversely, Fadd was one of two genes that were significantly upregulated (2-fold or more) 
by mCRAMP. FADD (Fas-associated protein with death domain) is an adaptor protein that 
plays a crucial role in apoptosis by helping form the death-inducing signalling complex 
(DISC)456. Moreover, the anti-apoptotic gene Bcl2 also had a log2 fold change of -0.63 in 
response to mCRAMP (P = 0.037; Appendix: Table A1). The upregulation of FADD and the 
concomitant downregulation of BCL2 suggest that mCRAMP promotes apoptosis. One 
possible explanation for these contradictory observations is that the changes in expression 
of Fadd and Bcl2 reflect mCRAMP promoting the death of other non-Th17 subsets that I have 
not specifically investigated, such as Th2 and regulatory T lymphocytes. Indeed, Mader and 




4.4.3 mCRAMP downregulates the expression of Th1-related genes that suppress 
Th17 differentiation 
 
Several of the genes downregulated in response to mCRAMP encode classical Th1-related 
proteins. For instance, the expression of XCL1 was significantly decreased following exposure 
to mCRAMP, with a log2 fold change of -1.95. Th1 cells secrete XCL1 (lymphotactin), although 
unlike IFNg, the expression of this chemokine does not require STAT4 activation457. The 
downregulation of XCL1 may therefore reflect a decrease in Th1 polarization.  
 
Many of these Th1-related genes exert a suppressive function on the differentiation of Th17 
cells. For example, BCL3 is a member of the IκB transcription factor family and has been 
shown to be a physiologically relevant regulator of Th1 cell plasticity458. More specifically, 
CHAPTER 4: RESULTS 
 139 
Tang and colleagues demonstrated that the loss of BCL3 in CD4+ T lymphocytes allowed for 
the conversion of Th1 cells into Th17 cells458. The authors also suggested that BCL3 stabilizes 
the Th1 cell phenotype, in part, by controlling the expression of the Th17 master regulator, 
RORgt458. mCRAMP may therefore increase the percentage of CD4+ IL-17+ T cells by 
downregulating BCL3 expression (log2 FC = -1.46), thereby lifting the inhibition on RORgt and 
promoting the conversion of Th1 lymphocytes to the Th17 lineage.  
 
IRF8 is another transcription factor that has been heavily implicated in Th1 differentiation459. 
For instance, IRF8 has been shown to regulate the expression of IL-12, an important cytokine 
required for driving the development of IFNg-producing Th1 lymphocytes459. IRF8-deficient 
mice fail to mount a protective Th1 response and as a result, develop fulminant, 
disseminated leishmaniasis upon infection with L. major459. In addition, Ouyang et al. 
demonstrated that IRF8 directs a silencing program for Th17 differentiation440. IRF8 KO mice 
exhibit enhanced Th17 polarization and the transfer of naïve T cells from these animals 
induces more severe colitis in RAG-/- mice440. Moreover, IRF8 suppresses the expression of IL-
17 by physically interacting with RORgt440. mCRAMP induced a log2 fold change of -1.44 in 
IRF8 expression. Downregulation of IRF8 by this peptide may therefore contribute to 
increasing Th17 differentiation by preventing the silencing program normally induced by this 
transcription factor from taking effect.   
 
Another Th1-related protein downregulated by mCRAMP was IKZF4/EOS, a member of the 
Ikaros family of transcription factors (log2 FC = -1.49). EOS is highly expressed in Th1 cells460. 
Furthermore, Rieder and colleagues found that EOS-/- mice developed more severe EAE, 
characterized by increased effector T cells in the periphery and CNS, as well as amplified IL-
17 production461. The exact mechanism through which EOS suppresses Th17 differentiation 
remains unknown. However, this transcription factor is required for IL-2 production by CD4+ 
T lymphocytes in vitro461. IL-2 is an important growth factor that promotes the development 
of Th1, Th2 and cytotoxic CD8+ T cells441. For example, IL-2 is essential for the acquisition of 
effector functions mediated by IFNg441. It has also been shown to strongly antagonize Th17 
differentiation: Laurence et al. demonstrated that the addition of IL-2 to Th17 cultures led to 
a dose-dependent decrease in RORgt expression and proportion of cells producing IL-17442. 
This was mediated by STAT5, which can directly bind to the Il17 promoter to suppress its 
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transcription442. Nanostring analysis revealed that mCRAMP significantly downregulated the 
expression of Il2 (log2 FC = -1.7). Furthermore, one of the most important effects of TGFb on 
T cells is the suppression of IL-2 production462. I have previously hypothesised that mCRAMP 
enhances TGFb signals to enhance Th17 differentiation. mCRAMP may therefore promote 
the development of IL-17-producing CD4+ T lymphocytes in vitro by relieving the inhibition of 
IL-2 on Th17 differentiation.  
 
Taken together, the Nanostring data suggests that mCRAMP skews T helper cell 
differentiation away from the Th1 lineage and enhances Th17 polarization by downregulating 




4.4.4 mCRAMP downregulates the expression of genes involved in the negative 
regulation of Th17 differentiation 
 
SOCS3 expression was significantly downregulated by CD4+ T cells in response to mCRAMP 
(log2 FC = -1.04). This “suppressor of cytokine signalling” is a negative modulator of STAT3 
phosphorylation and Th17 differentiation60. For instance, SOCS3 deficiency has no effect on 
the differentiation of Th1 or Th2 T helper subsets but IL-23-induced STAT3 phosphorylation 
is enhanced in its absence60. STAT3 directly binds to the promoter regions of IL-17A and IL-
17F, thereby promoting their transcription60. Signalling through STAT3 therefore plays an 
important role in Th17 development and persistent STAT3 phosphorylation has been 
associated with autoimmune inflammation463. Over-expression of SOCS3 in T cells results in 
reduced STAT3 phosphorylation, decreased Th17 differentiation and significantly delayed 
EAE onset464. TGFb inhibits IL-6 and IL-21-induced SOCS3, thereby enhancing, as well as 
prolonging, STAT3 activation in naïve CD4+ T cells66. My results suggest that mCRAMP 
requires TGFb to amplify Th17 responses. It is therefore possible that mCRAMP achieves this 
by synergizing with TGFb to further downregulate SOCS3 and relieve its inhibitory effects.  
 
Similarly, Tcf7 had a log2 fold change of -1.12 in response to treatment with mCRAMP. Tcf7 
encodes TCF1, which negatively regulates the expression of the IL-17 family of cytokines, in 
part, by binding to the regulatory regions of the Il17 gene439. Moreover, Yu et al. found that 
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Th17 cells from TCF1-deficient mice express high levels of IL-7Ra, which promotes their 
survival and expansion in vivo439. TCF1 is therefore considered a critical negative regulator of 
the inflammatory potential of TCR-activated T cells and autoimmunity439. Downregulation of 
Tcf7 expression is consequently another way in which mCRAMP can enhance Th17 
differentiation, by removing a layer of negative regulation and promoting the survival of CD4+ 








4.4.5 mCRAMP skews T helper cell differentiation away from the Th1 lineage 
 
mCRAMP downregulated the expression of genes classically associated with the Th1 lineage 
when the cells were cultured under Th17-driving conditions. Furthermore, I found that the 
percentage of CD4+ T lymphocytes expressing the Th1 master transcription factor, T-bet, was 
significantly reduced by mCRAMP.  
BCL3 
IRF8 








Figure 4.9: The regulatory networks downregulated by mCRAMP. Nanostring analysis revealed 
that the expression of genes in red was significantly downregulated in CD4+ T cells cultured under 
Th17-driving conditions following exposure to synthetic mCRAMP. IRF8 and BCL3 are classical Th1-
related genes, both of which also target the RORɣt transcription factor to silence the Th17 
differentiation program. EOS is required for the production of IL-2, a potent Th17 antagonist, 
which acts via STAT5 to inhibit the expression of IL-17. TCF1 and SOCS3 are negative regulators of 
the Th17 response. SOCS3 controls the phosphorylation of STAT3, which drives Th17 polarization.  
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Master regulators, such as T-bet, shape immune responses by activating one genetic program 
whilst simultaneously silencing the activity of factors that drive the differentiation of other 
subsets465,466. For example, T-bet suppresses the generation of Th2 cells by blocking the 
expression of IL-4 and interfering with GATA330,467. Lazarevic and colleagues demonstrated 
that T-bet also inhibits the development of the Th17 lineage by interacting with RUNX1 to 
block the transactivation of the Rorc promoter466. Ectopic T-bet expression in both naïve CD4+ 
T cells and committed Th17 cells is sufficient to repress the expression of RORgt and IL-17 
production466. The decrease in T-bet expression induced by mCRAMP therefore supports the 
hypothesis that this host defence peptide skews T helper cell differentiation away from the 
Th1 lineage and in doing so, promotes Th17 development. 
 
Th1 lymphocytes are the primary producers of IFNg26. mCRAMP significantly decreased the 
percentage of CD4+ IFNg+ T cells in Th17 cultures, reflecting the downregulation of T-bet and 
the skewing of T helper cell differentiation. Interestingly, these IFNg-producing CD4+ T 
lymphocytes were not protected from cell death, unlike CD4+ IL-17A+ T cells. This could 
therefore account for the reduced frequency of this T helper subset.    
 
Similarly to T-bet, IFNg also exerts suppressive effects on Th17 development468. More 
specifically, Yeh et al. reported that IFNg signals through STAT1 to inhibit the production of 
IL-17A and IL-17F in a T-bet-independent manner468. The suppression of Th1 polarization and 
subsequent decrease in IFNg production therefore highlights another potential mechanism 
through which mCRAMP increases Th17 potential.   
 
TGFb is a known suppressor of T-bet expression and I have previously shown that mCRAMP 
requires TGFb to amplify Th17 responses (Chapter 3: Figure 3.19)469. mCRAMP did not have 
any effect on IFNg production when the cells were cultured under non-lineage- (Chapter 3: 
Figure 3.5) or Th1-driving conditions (Chapter 3: Figure 3.18), which could be explained by 
the absence of TGFb in these cultures. Taken together, this supports the hypothesis that 
mCRAMP skews T helper cell differentiation away from the Th1 lineage and promotes Th17 
development in a TGFb-dependent manner.  
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T-bet is not only essential for driving Th1 development465. It is also required for the 
differentiation and function of specialized effector populations that arise from other 
lymphocyte lineages443. For instance, Th17 cells can co-express T-bet and RORgt to promote 
their functional diversification443. The chromatin conformation of the Tbx21 locus remains in 
a transcriptionally poised state in differentiated Th17 cells, which partially accounts for the 
plasticity of this T helper subset470. RORgt/T-bet double-positive cells have been found in 
lesional tissue in EAE, as well as in patients with multiple sclerosis444,471. Interestingly, they 
represent a higher proportion of infiltrating Th17 cells in the CNS compared to RORgt single-
positive lymphocytes444. Moreover, T-bet-mediated acquisition of IFNg expression promotes 
the accumulation of encephalitogenic Th17 cells in the CNS and tissue inflammation during 
EAE443,472. It has therefore been suggested that secondary expression of T-bet is required to 
stabilize pathogenic IL-17 and IFNg double-producing Th17 lymphocytes, which correlate 
with disease severity443,444. In the present study, I did not detect any CD4+ IL-17A+ IFNg+ T cells 
in vitro but a substantial proportion of CD4+ T lymphocytes expressed both RORgt and T-bet. 
Furthermore, the addition of mCRAMP appeared to decrease their frequency following 3 
days of culture. The physiological relevance of this is unclear but could provide further 
evidence to support the hypothesis that mCRAMP reduces the pathogenic potential of this T 
helper cell subset. 
 
 
4.4.6 mCRAMP upregulates the aryl hydrocarbon receptor 
 
Gene expression analysis revealed that mCRAMP significantly upregulated the expression of 
the aryl hydrocarbon receptor (AHR) in CD4+ T cells cultured under Th17-driving conditions. 
AHR is ligand-activated transcription factor that responds to a variety of environmental 
stimuli derived from the diet, commensal flora and host metabolism445. AHR expression is 
driven by the direct transactivation of the AHR promoter by phosphorylated STAT3, which is 
induced by IL-6 and IL-21 during Th17 differentiation445,473.  
 
AHR is kept in an inactive state as part of a protein complex, which stabilizes it in the 
cytoplasm and helps it maintain a conformation that has high affinity for its ligands445. Upon 
activation, AHR undergoes a conformational change that exposes the AHR amino-terminal 
nuclear localization and export signal, resulting in its translocation to the nucleus445. AHR 
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controls target gene expression by dimerizing with ARNT, which is recruited to xenobiotic 
response elements (XREs)445.  
 
AHR plays an important role in Th17 development446. For example, several Th17-related 
genes harbour XREs, including IL-17A, IL-17F, IL-22 and RORgt79. CD4+ T lymphocytes from 
AHR-deficient mice can differentiate into Th17 cells but display impaired production of IL-17 
and undetectable IL-2279. In line with attenuated Th17 differentiation in vitro, AHR knockouts 
develop a much milder form of EAE with delayed kinetics79.  
 
Exposure of CD4+ T cells to the AHR agonist, FICZ, under Th17-polarizing conditions strongly 
enhances IL-17A, IL-17F and IL-22 production79. However, the downstream effects of AHR are 
ligand-specific448. Quintana et al. found that binding of TCDD (2,3,7,8-tetrachlorodibenzo-p-
dioxin) to AHR suppressed Th17-mediated autoimmunity and EAE by promoting the 
development of FOXP3+ regulatory T cells, whereas FICZ enhanced the disease by stimulating 
the generation of Th17 lymphocytes79,448. Similarly, administration of ITE (2-(1ʹH-indole-3ʹ-
carbonyl)-thiazole-4-carboxylic acid methyl ester), another tryptophan-derived AHR 
endogenous ligand, also resulted in reduced EAE severity448.  
 
Conversely, Duarte et al. demonstrated that both FICZ and TCDD upregulate Th17 
development in vitro474. The authors suggested that the discrepancy between their work and 
previously published studies is due to the fact that the effects of AHR ligands depend on 
timing and that their mode of action in vivo is likely shaped by their differential susceptibility 
to metabolic feedback control474. For example, FICZ is an ultraviolet photoproduct of 
tryptophan synthesized in vivo that is rapidly metabolized, thus inducing only transient AHR 
signalling, whereas TCDD is the most stable of all xenobiotic AHR ligands474. They concluded 
that the high toxicity of TCDD could cause a proportional shift in the numbers of Tregs due 
to the death of other cell types, rather than an actual expansion of this subset474.  
 
I have shown that mCRAMP increased the percentage of CD4+ IL-17F+ and IL-17A/IL-17F 
double-producing cells in Th17 cultures. Furthermore, mCRAMP significantly increased the 
expression of AHR. Consistent with its established role in promoting the development of 
Th17 lymphocytes, addition of an AHR antagonist (CH223191) abolished the increase in the 
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percentage of CD4+ IL-17A+ Il-17F+ T cells normally induced by mCRAMP. However, it had no 
effect on the proportions of IL-17A and IL-17F single-positive lymphocytes. Once again, this 
implies that there are at least two pathways induced by mCRAMP, one of which is AHR-
dependent. Wanke et al. suggested that the IL-17A and IL-17F double-producers represent a 
regulatory subset of Th17 cells known to be induced in response to TGFb398,403. Furthermore, 
Alves de Lima and colleagues demonstrated that TGFb signalling sustains the expression of 
AHR in CD4+ T cells475. I have shown that mCRAMP requires TGFb in order to boost Th17 
differentiation (Chapter 3: Figure 3.19). It is therefore possible that mCRAMP specifically 
upregulates AHR expression, in concert with TGFb, in this particular Th17 subset to increase 
both IL-17A and IL-17F production.  
 
AHR can control the expression of genes that do not harbour XREs to promote Th17 
differentiation (Figure 4.10)445. For instance, AHR interacts with STAT1 and STAT5 (but not 
STAT3 or STAT6) and subsequently modulates their activity81. IFNg-induced STAT1 activation 
inhibits Th17 differentiation by binding to the Il17 promoter and suppressing its 
expression476. Whilst STAT3 remains active under Th17-culture conditions, STAT1 activation 
is relatively transient and returns to basal levels within 24 hours81. The maintenance of its 
activation can therefore prevent the interaction between RORgt and Il17 by masking their 
binding sites81. Kimura et al. demonstrated that STAT1 activation remains activated at 24 
hours after stimulation in naïve CD4+ T cells from AHR-deficient mice81. AHR has dual 
functions in controlling intracellular protein levels: it serves both as a transcription factor to 
promote the transcription of target genes, as well as a ligand-dependent E3 ubiquitin ligase 
that regulates selective protein degradation477. The authors therefore suggested that AHR 
targets activated STAT1 for degradation, thereby relieving its inhibition on Th17 
differentiation81. Indeed, the Nanostring data generated in this study revealed that STAT1 
was significantly downregulated (log2 FC = -0.69, P = 0.005). The upregulation of AHR induced 
by mCRAMP could consequently represent a mechanism through which it suppresses STAT1 
activation to promote the development of IL-17-producing CD4+ T lymphocytes.    
 
In addition to modulating STAT1 activation, AHR indirectly promotes Th17 differentiation by 
regulating the inhibitory effects of IL-2, which interferes with the development of this T 
helper cell subset through the activation of STAT5442. More specifically, AHR cooperates with 
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STAT3 to induce the expression of AIOLOS (IKZF3), another member of the Ikaros 
transcription factor family478. AIOLOS binds to the IL-2 promoter, inducing chromatin 
modifications that result in IL-2 silencing both in vitro and in vivo478. No significant differences 
in Ikzf3 expression were detected between untreated and mCRAMP-treated samples in the 
Nanostring data generated for this study. However, IL-2 was significantly downregulated 
(log2 FC = -1.7) and an almost complete suppression of production was observed by ELISA. It 
is therefore possible that mCRAMP increases the percentage of CD4+ IL-17A+ IL-17F+ T cells 
in an AHR-dependent manner by reducing the expression of IL-2, thereby preventing it from 







AHR has been heavily implicated in the production of IL-22 by Th17 lymphocytes79. Naïve 
CD4+ T cells from AHR-deficient mice cultured under Th17-driving conditions cannot produce 
IL-2279. RORgt and STAT3 facilitate the recruitment of AHR to the Il22 promoter and activation 
of this transcription factor by FICZ promotes the expression of the cytokine79,111. Although 
mCRAMP significantly upregulated AHR, the peptide had no effect on IL-22 production by 
CD4+ T cells in Th17 cultures (Chapter 3: Figure 3.9). Several groups have suggested that AHR 










Figure 4.10 AHR and its role in Th17 development. AHR was significantly upregulated by CRAMP 
(green). AHR targets STAT1 for degradation, thereby relieving its inhibition on Th17 differentiation. 
AHR cooperates with STAT3 to induce the expression of Aiolos. Aiolos binds to the IL-2 promoter, 
inducing chromatin modifications that result in IL-2 silencing. IL-2 is a Th17 antagonist, which acts 
via STAT5 to inhibit the expression of IL-17. 
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Based on my results, mCRAMP appears to only influence the pathway that is responsible for 
driving IL-17 expression.   
 
 
4.4.7 TGFb is not sufficient for mCRAMP to increase AHR expression 
 
I have provided evidence that suggests mCRAMP requires TGFb to boost Th17 differentiation 
(Chapter 3: Figure 3.19). However, the upregulation of AHR does not: mCRAMP increased 
the percentage of CD4+ AHR+ T cells only when all three Th17-polarizing cytokines were 
present. TGFb is a relatively poor inducer of AHR alone and IL-6 downstream signalling plays 
an important synergistic role that drives its expression475. It is also possible that mCRAMP 
increases AHR expression indirectly. For example, mCRAMP could induce cellular changes 
that modulate tryptophan metabolism and the production of endogenous AHR ligands, 
which in turn promote AHR expression as part of a positive feedback loop445. 
 
 
4.4.8 mCRAMP reduces the pathogenic potential of Th17 cells  
 
AHR has been described as a marker of non-pathogenic Th17 cells475. As discussed previously, 
the cytokine milieu present during the differentiation process determines whether naïve T 
cells become pathogenic or not479. For example, treatment of naïve CD4+ T cells with TGFb 
and IL-6 is generally thought to generate a non-pathogenic population of Th17 lymphocytes: 
adoptive transfer of these cells does not typically induce EAE479,480. However, the addition of 
IL-23 abrogates this and drives their conversion to a more pathogenic phenotype402,479. 
Ghoreschi and colleagues demonstrated that AHR expression was observed only in non-
pathogenic “conventional” Th17 cells (generated with TGFb) and not in those cultured with 
IL-23444,446. The upregulation of this transcription factor in response to mCRAMP may 
therefore suggest that the peptide drives the development of a non-pathogenic population 
of Th17 lymphocytes.  
 
Several studies have tried to identify the transcriptional signature of pathogenic and non-
pathogenic Th17 cells by comparing gene expression profiles of in vitro-generated Th17 
lymphocytes, as well as those induced in vivo (such as during EAE)402,479,481. Pathogenic Th17 
cells express more effector molecules, including pro-inflammatory cytokines/chemokines 
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such as CXCR3, CCL4, IL-2 and IL-22. mCRAMP had no effect on IL-22 production (Chapter 3: 
Figure 3.9) but the Nanostring data revealed a significant downregulation of IL-2, which was 
confirmed by ELISA. Moreover, the expression of CXCR3, which is important for trafficking of 
T cells to sites of inflammation, was reduced in CD4+ T cells cultured under Th17-driving 
conditions and in the presence of mCRAMP (log2 FC = -0.672, P = 0.032; Appendix: Table A1). 
Similarly, CCL4 was also downregulated, although this was not statistically significant (log2 
FC = -1.86, P = 0.399; Appendix Table A1).  
 
Pathogenic Th17 lymphocytes also upregulate the expression of T-bet and HLX1, another 
Th1-related transcription factor that induces IFNg production482. Yang et al. demonstrated 
that T-bet was essential for the encephalitogenicity of both Th1 and Th17 cells during EAE483. 
I have shown that mCRAMP decreases the percentage of CD4+ T-bet+ T lymphocytes, as well 
as those co-expressing RORgt and T-bet.  
 
On the other hand, non-pathogenic Th17 cells upregulate the expression of molecules 
typically associated with immune suppression, including IL-10, AHR and c-MAF402,479. AHR 
physically interacts with c-MAF to promote the transactivation of the Il10 promoter, which is 
essential for the development of IL-10-producing regulatory T cells484. Furthermore, AHR has 
been shown to mediate the conversion of Th17 cells into IL-10+ anti-inflammatory Tregs if 
lacking pathogenicity signals420. In the present study, Maf was significantly upregulated by 
mCRAMP (log2 FC = 0.847, P = 0.004; Appendix: Table A1). IL-10 was also increased across 
all three samples but was excluded from the analysis due to low counts.  
 
Taken together, these results suggest that mCRAMP downregulates the expression of various 
pro-inflammatory molecules, whilst simultaneously upregulating those involved in immune 
regulation, to reduce the pathogenic potential of developing Th17 cells.  
 
 
4.4.9 mCRAMP is probably not an AHR ligand 
 
Based on the results generated throughout this study, one might speculate as to whether 
mCRAMP constitutes an as of yet unidentified endogenous AHR ligand. However, I have 
shown that the D-enantiomer and scrambled peptide increased Th17 differentiation to the 
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same extent as mCRAMP. Moreover, both PP47 (a partial LL-37 peptide) and hBD2 also 
enhanced the development of IL-17-producing CD4+ T lymphocytes in Th17 cultures. It is 
highly unlikely that all six peptides are AHR ligands based on their structural differences and 
amino acid sequences.  
 
Amphipathicity is important for antimicrobial activity485. An amphipathic helix is defined as 
an a helix with opposing polar (hydrophilic) and non-polar (hydrophobic) faces486. mCRAMP, 
LL-37 and D-LL-37 all fold into a characteristic amphipathic a-helical structure277. hBD2 and 
PP47 also both display amphipathic properties: hBD2 possesses an a-helical segment and 
despite being a much shorter peptide (22 amino acids), PP47 retains a hydrophobic face487. 
On the other hand, Bac2A is a linear peptide that cannot spontaneously fold into this helical 
conformation in solution450. Furthermore, indolicidin displays an extended structure due to 
the predominance of tryptophan and proline residues488. It is therefore possible that the 
amphipathicity of mCRAMP, LL-37, D-LL-37, PP47 and hBD2 is responsible for their 
immunomodulatory effects on Th17 differentiation. For instance, amphipathic topology is 
essential for the insertion of antimicrobial peptides into biological membranes485. As 
discussed previously, cathelicidin has been shown to indirectly activate P2X7R by interacting 
with the cytoplasmic C’ terminal end of the receptor following membrane insertion326. 
mCRAMP and similar amphipathic peptides might amplify Th17 differentiation by non-
specifically transactivating a yet unknown intracellular or transmembrane receptor. In 
addition, this could also provide a route that allows for the non-specific uptake of the peptide 
into the cell, similar to how it transfers extracellular DNA plasmids to the nuclear 
compartment via lipid rafts and proteoglycan-dependent endocytosis333.  
 
However, scrambled LL-37, which is made up of the same amino acids but in a random order, 
maintains its net positive charge but loses its propensity to fold into an amphipathic helical 
structure, according to its helical wheel. Despite this, scrambled LL-37 was still capable of 
enhancing Th17 differentiation and to the same extent as LL-37 and mCRAMP. One possible 
explanation for this is that our stocks of this particular peptide contain a contaminant from 
the manufacturing process or low levels of LPS (although it was tested for endotoxin 
contamination at the beginning of the project). On the other hand, it could simply suggest 
that the effects of mCRAMP on Th17 polarization may in fact not be due to its amphipathic 
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nature. I previously postulated that perhaps mCRAMP was non-specifically activating an 
unknown receptor by charge (Chapter 3: section 3.4.4). mCRAMP, LL-37, D-LL-37, scrambled 
LL-37 and hBD2 all display a net charge of +6. PP47 is only +3, although it could be argued 
that this is still quite positive. As a result, this potential mechanism of action should not be 
disregarded and could be tested in the future by examining the effects of other short positive 





To summarize, I have shown that mCRAMP significantly downregulates the expression of 
Th1-related genes in CD4+ T lymphocytes cultured under Th17-driving conditions, as well as 
those that are involved in the negative regulation of Th17 responses. In accordance with this, 
mCRAMP significantly decreases the frequency of T-bet-expressing CD4+ T cells and IFNg 
production, suggesting that the peptide skews T helper cell differentiation away from the 
Th1 lineage to promote the development of IL-17-producing lymphocytes.  
 
Expression of the aryl hydrocarbon receptor was significantly increased by mCRAMP. AHR 
has been heavily implicated in Th17 differentiation and I have shown that the increase in the 
percentage of CD4+ IL-17A+ IL-17F+ T cells induced by mCRAMP is AHR-dependent. However, 
an AHR antagonist had no effect on the frequency of IL-17F single-positive cells, indicating 
that there are at least two pathways induced by the peptide, one of which is AHR-dependent 


















Lymph node neutrophils may be the cellular 
source of mCRAMP that amplifies Th17 
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5.1 Introduction  
 
Cathelicidin is produced by a variety of cell types, including circulating neutrophils, epithelial 
cells, myeloid bone marrow cells, keratinocytes, monocytes and macrophages277,281. 
Transcripts of the CAMP gene, as well as hCAP-18 protein, have also been detected in B and 
T lymphocytes, as well as in natural killer (NK) cells, but in significantly lower 
quantities277,352,489. For instance, Kin et al. demonstrated that all mouse B cell subsets, as well 
as CD4+ and CD8+ T lymphocytes, produce Camp mRNA489. However, these findings were in 
contrast to those published by Agerberth and colleagues, who used RT-PCR and 
immunohistochemical staining to show that CD3+ T cells do not express cathelicidin352. 
Furthermore, whether or not the protein is processed to its biologically active form remains 
to be verified. For example, neutrophil-derived cathelicidin is proteolytically processed by 
proteinase-3, which is released together with cathelicidin during degranulation289. Indeed, 
Kin and colleagues only detected immature cathelicidin in B and T lymphocytes489. The 
physiological significance of cathelicidin expression by these cells is therefore unknown. 
 
There is an abundance of evidence that suggests there is bidirectional cross-talk between 
neutrophils and Th17 cells. For instance, Th17 cells produce neutrophil chemoattractants 
such as CXCL8490. Furthermore, IL-17A and IL-17F increase the release of G-CSF and CXCL8 by 
epithelial cells, which promotes neutrophil migration and activation491. On the other hand, 
neutrophils recruit Th17 lymphocytes to sites of inflammation through the production of 
CCL20/CCL2490. Thewissen et al. found that neutrophils dose-dependently  increased IFNg 
and IL-17 production by CD4+ T cells in an in vitro co-culture model492. In addition, neutrophils 
have been shown to assist in the induction of Th17-specific responses during vaccination 
against Mycobacterium tuberculosis: neutrophil depletion abrogated Th17 induction in the 
lungs and spleen following mc2-CMX vaccination493. Neutrophil cytoplasts, the remnants of 
neutrophil extracellular traps (NETs) following expulsion of their nuclear DNA, also induce 
Th17 differentiation in severe asthma233. 
 
Neutrophils play an important role in several chronic inflammatory and autoimmune 
disorders in which the pathogenesis is driven by Th17 lymphocytes. For example, NETs induce 
the generation of human CD3+ CD4+ IL-17+ T cells and have subsequently been implicated in 
the development of psoriasis494. Moreover, neutrophils migrate to the articular cavity during 
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the early stages of rheumatoid arthritis (RA), where they become activated and are prone to 
NETosis495.  Cathelicidin is displayed extracellularly on the surface of NETs and elevated levels 
of cathelicidin have been detected in the inflamed synovium and psoriatic epidermis284,365,496. 
Based on my previous results, I hypothesised that neutrophils are the cellular source of 
cathelicidin (mCRAMP) that amplifies Th17 responses in vivo following inoculation with heat-





Historical data generated by the laboratory demonstrated that mCRAMP-deficient mice 
could not produce IL-17 following inoculation with HKST (Chapter 1: Figure 1.10). I have 
shown that mCRAMP promotes Th17 differentiation in vitro, in part by enhancing TGFb 
signals and by upregulating the aryl hydrocarbon receptor. I therefore sought to identify the 
cellular source of mCRAMP that is responsible for enhancing the development of IL-17-
producing CD4+ T cells and the location where T lymphocytes sense this host defence peptide 
in vivo during inflammation induced by HKST. 
 
 
5.3 Results  
 
5.3.1 mCRAMP does not boost Th17 differentiation of previously activated CD4+ T 
cells 
 
Antigen-presenting cells (APCs) collect antigen in the peripheral tissues and migrate to the 
draining lymph nodes where they present antigen peptides in complex with MHC molecules 
to naïve T cells497. Naïve T cells recognise antigen-MHC complexes via their TCR and become 
activated upon co-stimulation by mature DCs497. Primed T cells then migrate back to the 
tissue via the lymphatic system or bloodstream, where they receive additional signals and 
become fully differentiated (Figure 5.1 A)497.  
 
Naïve T cells spend up to 24 hours surveying an individual lymph node for their cognate 
antigen and receiving activation signals from DCs498,499. Miller and colleagues demonstrated 
that 80% of antigen-specific T cells within the lymph node were activated (expressed CD69) 
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by 24 hours following immunisation with OVA499. I have shown that the addition of synthetic 
mCRAMP to Th17 cultures on day 0 increased the frequency of CD4+ IL-17+ T cells (Chapter 
3: Figure 3.8). This is a model of naïve T lymphocytes sensing mCRAMP in the lymph node, at 
the same time as they are being activated by APCs.  
 
To determine whether mCRAMP also enhanced Th17 differentiation of previously activated 
or primed T cells, I cultured whole single cell splenic suspensions under Th17-driving 
conditions and compared the effects of the peptide when added on day 0 and day 1 (Figure 
5.1). Figure 5.1 B shows that in my Th17 cultures, there was a significant increase in the 
percentage of activated CD4+ CD62L- CD44+ T cells on day 1 (46.27% +/- 3.80) compared to 
day 0 (14.63% +/- 2.06). Based on this increase in T cell activation, the addition of mCRAMP 
on day 1 is therefore a model of them sensing the peptide after having received primary and 
co-stimulatory signals in the lymph node and having potentially arrived at the site of 
inflammation.  
 
The addition of mCRAMP on day 0 or day 1 had no effect on the percentage of IL-17A single-
positive T cells. On the other hand, mCRAMP also failed to increase the proportions of CD4+ 
IL-17F+ or IL-17A and IL-17F double-producing lymphocytes when added on day 1. For 
example, the addition of mCRAMP on day 0 increased the percentage of CD4+ IL-17A+ IL-17F+ 
T cells from 6.78% (+/- 1.30) to 17.13% (+/- 0.60) (Figure 5.1 E). However, when added on 
day 1, this rose non-significantly to only 9.46% (+/- 1.43).  
 
These results indicate that mCRAMP acts specifically on naïve T lymphocytes and not on 


















Figure 5.1: mCRAMP boosts IL-17 production of naïve but not activated T cells. (A) T cell 
activation and differentiation: antigen-presenting cells collect antigen in the peripheral tissues and 
migrate to the draining lymph nodes where they present antigen peptides to naïve T cells. 
Following activation, primed T cells migrate back to the tissue, where they receive additional 
signals and become fully differentiated (B) Whole single cell splenic suspensions were cultured 
under Th17-driving conditions for 2 days. 2.5 µM synthetic mCRAMP was added on day 0 or day 
1. Percentages of activated CD4+ CD62L- CD44+ T cells on day 0 and day 1 confirm T cell activation 
(C) Percentages of CD4+ IL-17A+ IL-17F- T cells on day 2 (D) Percentages of CD4+ IL-17A- IL-17F+ T 
cells on day 2 (E) Percentages of CD4+ IL-17A+ IL-17F+ T cells on day 2. Data shown is mean +/- 
standard error. N = 3. Statistical significance (where ** represents < 0.01) was determined using 
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5.3.2 mCRAMP at the site of inflammation does not enhance Th17 differentiation 
 
The data discussed above suggests that naïve CD4+ T cells must sense mCRAMP within the 
first 24 hours of activation in order to boost Th17 differentiation, implying that the effects 
seen in vivo are mediated in the lymph nodes. To test this hypothesis, I carried out an in vivo 
model in which the peptide was applied directly to the site of inflammation. T cells would 
therefore only come in to contact with the synthetic peptide after having been activated and 
recruited to the tissue. I therefore hypothesised that the frequency of CD4+ IL-17+ T 
lymphocytes would not be increased in this setting. 
 
The topical application of Aldara cream (containing 5% imiquimod (IMQ)) to mouse skin 
causes cutaneous inflammation500. IMQ activates TLR7/8, which is expressed by monocytes, 
macrophages and plasmacytoid DCs (pDCs)500,501. This leads to the enhanced migration of 
Langerhans cells from the treated skin to the draining lymph nodes, where they activate T 
lymphocytes502,503. The ensuing immune response promotes epidermal hyperplasia, 
leukocyte infiltration and the development of skin lesions resembling those found in human 
psoriasis500. The exact mechanisms that drive IMQ-induced skin inflammation are yet to be 
fully defined504. However, IL-17-producing Th17 cells have been shown to play a crucial 
role500.  
 
Aldara was applied daily to the ears of WT mice, with or without synthetic mCRAMP (10 
µg/mouse). The ears were collected and digested on day 3 for phenotypic analysis by flow 
cytometry (Figure 5.2). Day 3 was chosen because the first signs of inflammation are typically 
observed 2 or 3 days after the start of IMQ treatment (e.g. erythema, scaling, thickening) and 
Horvath and colleagues identified T cell infiltration in the dermis at this time point500,505. 
 
Figure 5.2 shows that mCRAMP did not affect the proportions of CD4+ RORgt+ or IL-17A+ T 
cells recruited to the ears following treatment with 5% IMQ. Assuming that the peptide is not 
transported to the draining auricular lymph nodes, this suggests that mCRAMP present in the 
inflamed tissue is not sufficient to enhance Th17 polarization of previously activated CD4+ T 
lymphocytes. These results therefore support the hypothesis that mCRAMP is required 
during the first 24 hours of T cell activation in order to promote Th17 differentiation.  
 














Figure 5.2: mCRAMP at the site of inflammation does not boost IL-17 production. (A) 5% 
imiquimod (IMQ) was applied daily to WT ears for 3 days, with or without synthetic mCRAMP (10 
µg/mouse). Ears were digested on day 3 for analysis (B) Representative plots of CD4+ RORɣt+ T cells 
in the ears on day 3 (C) Percentages of CD4+ RORɣt+ T cells in the ears on day 3 (D) Representative 
plots of CD4+ IL-17A+ T cells in the ears on day 3 (E) Percentages of CD4+ IL-17A+ T cells in the ears 
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5.3.3 mCRAMP can be found in the lymph nodes of mice inoculated with HKST 
 
The data presented above suggests that T cells sense mCRAMP in the lymph nodes during 
inflammation in vivo. To confirm the presence of this host defence peptide in lymph nodes 
during inflammation, WT mice were inoculated with HKST in the top of each hind paw (25 
µg/paw, subcutaneous) and the draining popliteal lymph nodes harvested and stained for 
mCRAMP (Figure 5.3 A; experiment performed by Virginia Alessandrini). As predicted, no 
mCRAMP was observed in sections from naïve mice. However, mCRAMP was detected in the 
lymph nodes following HKST inoculation, as early as day 1 and as late as day 7. mCRAMP-
expressing cells located to the sub-capsular sinus (SCS) on day 1, where leukocytes have been 
shown to enter the lymph node via the afferent lymphatics506. These became more dispersed 
with time and were scattered throughout the organ by day 7.  
 
 
5.3.4 mCRAMP is released from neutrophils in the lymph nodes of mice following 
inoculation with HKST 
 
I hypothesised that neutrophils are the cellular source of mCRAMP that is responsible for 
amplifying Th17 differentiation following inoculation with HKST. There are several steps 
throughout the T cell differentiation process that can potentially be influenced by neutrophils 
and therefore mCRAMP. For instance, neutrophils can be found in the circulation, as well as 
in the lymph nodes and inflamed tissues155. 
 
Neutrophils are the primary producers of mCRAMP but other cell types, such as activated 
monocytes and macrophages, have been shown to express the peptide277. To confirm that 
mCRAMP+ cells were indeed neutrophils and that positive staining was not simply a result of 
other cells producing or internalising it, additional sections of popliteal lymph nodes 
harvested from mice following inoculation with HKST were stained with DAPI, mCRAMP and 
the neutrophil-specific marker Ly6G (Figure 5.3 B; experiment performed by Katie Smith)507. 
Co-localisation of all three stains confirmed that mCRAMP-expressing neutrophils can be 
found in the lymph nodes of mice during inflammation induced by HKST: 85% of mCRAMP+ 
cells were Ly6G+ on day 7 (analysis by Katie Smith). Interestingly, extracellular mCRAMP was 
also observed, which could be a result of neutrophil degranulation or NETosis. 
 























DAPI Ly6G mCRAMP MERGE 
20 µm 
Haematoxylin mCRAMP Day 0 Day 1 Day 7 
B 
A 
Figure 5.3: Neutrophil-derived mCRAMP can be detected in the lymph nodes following 
inoculation with HKST. WT mice were inoculated with 25 µg HKST in the top of each hind paw (A) 
Draining popliteal lymph nodes were removed on days 0, 1 and 7 and stained for mCRAMP. 
mCRAMP-expressing cells were detected as DAB+ (staining performed by Virginia Alessandrini) (B) 
Draining popliteal lymph nodes were removed on day 1 and stained for DAPI, Ly6G and mCRAMP 
(staining performed by Katie Smith).  
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5.3.5 mCRAMP-deficient neutrophils downregulate RORgt and AHR expression in 
CD4+ T cells cultured under Th17-driving conditions 
 
I have provided evidence, in collaboration with others, that suggests neutrophils are the 
cellular source of mCRAMP within the lymph nodes and that this early mCRAMP - T cell 
interaction enhances Th17 differentiation during inflammation induced by HKST. I therefore 
next investigated whether or not neutrophils are capable of increasing the development of 
IL-17-producing CD4+ T lymphocytes in vitro, and if so, whether this is mCRAMP-dependent 
(Figure 5.4).  
 
Neutrophils were isolated from the bone marrow of WT and mCRAMP KO mice by EasySep 
and activated with cytochalasin B and fMLF for 30 minutes to induce degranulation, as shown 
by Sato and colleagues508. Whole single cell splenic suspensions were then cultured with 
these bone marrow-isolated neutrophils (at a ratio of 1:1) under Th17-driving conditions for 
2 days, as previously described.  
 
Figure 5.4 A shows that WT neutrophils increased the percentage of CD4+ IL-17A+ T cells from 
15.57% (+/- 1.75) to 20.40% (+/- 2.02), although this was not statistically significant (P = 0.08). 
In comparison, this rose to 25.13% (+/- 1.75) in response to synthetic mCRAMP and only 
18.73% (+/- 2.54) following culture with mCRAMP-deficient neutrophils. The moderate 
increase in the frequency of IL-17-producing CD4+ T cells induced by WT neutrophils could be 
a result of a lower concentration of biologically active mCRAMP in neutrophil preparations. 
Indeed, I have previously shown that the increase in CD4+ IL-17A+ T cells induced by mCRAMP 
is concentration-dependent (Chapter 3: Figure 3.8 H). Nonetheless, these results hint that 
neutrophils might increase Th17 polarization in vitro, although it is not possible to conclude 
whether this is mCRAMP-dependent.  
 
While mCRAMP decreased the proportion of CD4+ IFNg+ T cells as expected (from 4.65% +/- 
1.02 to 2.22% +/- 0.41), WT neutrophils did not. Conversely, mCRAMP KO neutrophils 
significantly increased the frequency of IFNg-producing CD4+ T lymphocytes (12.35% +/- 4.17) 
(Figure 5.4 B). However, the results were highly variable between experiments and should 
therefore be analysed with caution. Nonetheless, I have shown that mCRAMP skews T helper 
cell differentiation away from the Th1 lineage. An increase in the percentage of CD4+ IFNg+ T 
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lymphocytes in Th17 cultures containing mCRAMP KO neutrophils could therefore reflect 
increased Th1 polarisation, which arises a result of mCRAMP-deficiency and therefore a lack 
of suppression of IL-2 and T-bet. 
 
Despite increasing the frequency of CD4+ IL-17A+ T cells, WT neutrophils had no effect on the 
expression of RORgt (Figure 5.4 C) or AHR (Figure 5.4 D). On the other hand, mCRAMP-
deficient neutrophils significantly decreased the percentage of CD4+ RORgt+ T cells from 
71.25% (+/- 1.79) to 61.73% (+/- 3.05), as well as the proportion of CD4+ AHR+ T lymphocytes 
from 49.14% (+/- 4.15) to 22.65% (+/- 4.38).  
 
Taken together, these results imply that neutrophils from WT mice might be capable of 
enhancing Th17 differentiation in vitro. Conversely, those from mCRAMP KO mice appeared 
to suppress both RORgt and AHR expression, which could be indicative of increased Th1 



































Figure 5.4: WT neutrophils have no significant effect on Th17 differentiation, whereas mCRAMP-
deficient neutrophils decrease RORgt and AHR expression. Whole single cell splenic suspensions 
were cultured under Th17-driving conditions with 2.5 µM synthetic mCRAMP, WT neutrophils (1:1) 
or mCRAMP-deficient neutrophils (KO; 1:1) (A) Percentages of CD4+ IL-17A+ T cells on day 2 (B) 
Percentages of CD4+ IFNɣ+ T cells on day 2 (C) Percentages of CD4+ RORɣt+ T cells on day 2 (D) 
Percentages of CD4+ AHR+ T cells on day 2. Data shown is mean +/- standard error. Graphs 
represent multiple experiments. Statistical significance (where * represents < 0.05 and ** < 0.01) 
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5.3.6 Neutrophil depletion enhances Th17 responses in vivo following inoculation 
with heat-killed S. typhimurium 
 
The results discussed above suggest that neutrophils are potentially capable of boosting Th17 
differentiation in vitro. To investigate the importance of neutrophils in amplifying Th17 
responses in vivo, I repeated the HKST model in WT and neutrophil-depleted mice (Figure 
5.5).  
 
WT C57BL6/J mice were injected intraperitoneally with an anti-Ly6G antibody (aRIMP1) to 
deplete neutrophils on days -1, 1 and 3. All mice were inoculated with 25 µg HKST in the top 
of each paw on day 0 and the draining popliteal lymph nodes harvested on day 7 for 
phenotyping. Based on previous data, I hypothesized that neutrophil depletion would impair 
the development of IL-17-producing CD4+ T lymphocytes and result in a similar phenotype to 
that observed in mCRAMP KO mice. 
 
Neutrophil depletion was assessed by confirming the absence of SSC-Ahi CD11b+ cells within 
the spleen (Figure 5.5 D). Neutrophil-depleted mice displayed an enlarged spleen (Figure 5.5 
C) and flow cytometric analysis revealed an influx of SSC-Alo CD11b+ cells on day 7 (Figure 5.5 
B). Bruhn et al. determined that neutrophil depletion is mediated predominantly by 
macrophages509. These SSC-Alo CD11b+ cells therefore likely represented this innate 
leukocyte.  
 
Surprisingly, whilst the percentage of CD4+ CD44+ T cells was not significantly different 
between neutrophil-depleted mice and controls, the geometric mean of PD1 expression rose 
significantly from 296 +/- 11 to 396 +/- 21 (Figure 5.5 F & G). This suggests that CD4+ T cells 
are more activated in neutrophil-depleted mice inoculated with HKST.  
 
Furthermore, neutrophil depletion led to a significant rise, from 2.16% (+/- 0.07) to 3.41% 
(+/- 0.23), in the percentage of CD4+ IL-17A+ T cells within the lymph nodes (Figure 5.5 H). 
The concentration of IL-17A in cell culture supernatants following re-stimulation of single cell 
lymph node suspensions was assessed by ELISA (Figure 5.5 I). Cells from neutrophil-depleted 
mice re-stimulated for 3 days with aCD3 (2.5 µg/mL) produced more IL-17A than those from 
control animals (20.16 compared to 5.96 ng/mL). In addition, re-stimulation with HKST (1 
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µg/mL) also led to an increase in IL-17A production by cells from neutrophil-depleted mice 
(from 2.05 to 6.82 ng/mL).  
 
These results were contrary to what was expected. One possible explanation is that 
neutrophil depletion resulted in some antibody-mediated cytotoxicity, which could have led 
to the unprogrammed cell death of neutrophils and a subsequent release/burst of mCRAMP. 
In addition, Patel et al. recently demonstrated that systemic depletion of neutrophils results 
in a dysregulated negative feedback IL-23 – IL-17 – G-CSF regulatory axis in the periphery510. 
Increased levels of IL-23 could therefore provide an explanation as to why neutrophil 
depletion led to an apparent increase in the percentage of CD4+ IL-17A+ T cells following 
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Figure 5.5: Neutrophil depletion enhances Th17 responses following inoculation with heat-killed 
S. typhimurium. (A) WT and neutrophil-depleted mice were inoculated with 25 µg HKST in to the 
top of each hind paw and the draining popliteal lymph nodes removed 7 days later for analysis (B) 
Representative plots of CD11b+ cells in the spleen on day 7 (C) Total number of cells isolated from 
the spleen on day 7 (D) Percentages of SSC-Ahi CD11b+ cells in the spleen on day 7 (E) Total number 
of cells isolated from the popliteal lymph nodes (F) Percentages of CD4+ CD44+ T cells in the lymph 
node on day 7 (G) Geometric Mean of PD1 expression by CD4+ T cells in the lymph node day 7 (H) 
Percentages of CD4+ IL-17A+ T cells in the lymph node on day 7 (I) Concentration of IL-17A in cell 
culture supernatants following 3 days of re-stimulation with αCD3 (5 µg/mL) or HKST (1 µg/mL). 
Data shown is mean +/- standard error. N = 3. Statistical significance (where * represents < 0.05 
and ** < 0.01) was determined using an unpaired t-test. HKST: heat-killed Salmonella 
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mCRAMP-deficient mice cannot produce IL-17 following inoculation with HKST and I have 
shown in previous chapters that mCRAMP enhances Th17 differentiation in vitro. I therefore 
sought to identify where T cells sense this host defence peptide in vivo during inflammation, 
as well as its cellular source. 
 
 
5.4.1 T cells sense mCRAMP in the lymph nodes during inflammation 
 
CD4+ T lymphocytes cultured under Th17-driving conditions required mCRAMP during the 
first 24 hours in order to boost Th17 differentiation in vitro: the addition of mCRAMP on day 
1 had no effect on the percentage of CD4+ IL-17A+ IL-17F-, IL-17A- IL-17F+ or IL-17A+ IL-17F+ T 
cells.  
 
Miller and colleagues used two-photon microscopy to image single cell dynamics of naïve 
CD4+ T cells and in vivo-labelled DCs in lymph nodes following immunization with OVA499. 
They demonstrated that T cell interactions with antigen-presenting DCs could be categorized 
into several stages that overlap499,511. Within the first 6 hours, transient, serial encounters led 
to the upregulation of T cell activation markers: by 2 hours, around 40% of antigen-specific T 
cells had up-regulated CD69499. T cells then entered an extended period lasting 12-14 hours 
in which T cell clusters around DCs could be observed499. These were characterized by more 
stable binding events that lasted for hours499. By 24 hours, 80% of antigen-specific T 
lymphocytes were CD69+ and highly motile499. Based on these observations, exposure to 
mCRAMP from day 0, when the T cells are naïve and un-activated, models them sensing the 
peptide in the lymph node. Conversely, adding the peptide a day later, when the cells have 
already received activation and differentiation signals, models them coming into contact with 
mCRAMP in the inflamed tissue. My results therefore suggest that mCRAMP acts specifically 
on naïve CD4+ T cells, as opposed to fully differentiated or committed lymphocytes. 
Furthermore, the data implies that during inflammation induced by HKST, T lymphocytes 
sense mCRAMP in the lymph nodes, which boosts Th17 differentiation.  
 
This was supported by an experiment in which I applied cream containing 5% imiquimod 
(IMQ), spiked with synthetic mCRAMP, daily to the ears of WT mice. This particular model of 
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acute skin inflammation is the most widely used mouse model for preclinical studies of 
psoriasis501. Imiquimod is an immune response modifier that activates the NF-kB pathway512. 
This single, synthetic innate antigen receptor ligand induces localized skin and systemic 
inflammation, primarily through the activation of TLR7/8, which is expressed by monocytes, 
macrophages and pDCs500,501. This leads to the migration of Langerhans cells from the treated 
skin into the draining lymph nodes where they activate T lymphocytes and the adaptive 
immune response502,503. Other features of IMQ-induced skin inflammation include the 
development of psoriasis-like histological features (epidermal hyperplasia), activation of pro-
inflammatory signalling pathways and the subsequent recruitment of cellular infiltrates 
(CD4+ T cells, neutrophils, CD11c+ DCs and pDCs)500–502. CD4+ T cells and the IL-23/IL-17 axis 
play a pivotal role in mediating the response to imiquimod, demonstrated by the fact that 
IMQ-induced dermatitis is partially dependent on the presence of T cells and is completely 
blocked in mice deficient for IL-23 or IL-17R500.  Indeed, Ueyama et al. demonstrated that 
IMQ induces the production of cytokines required for Th17 differentiation by mouse pDCs 
via TLR7504.  
 
In order to evaluate the early inflammatory process, mice were culled and the ears harvested 
on day 3, before significant increases in ear thickness were observed (this typically occurs 
from days 5-6 onwards). In this model, I hypothesised that T cells encounter the synthetic 
mCRAMP following activation, differentiation and recruitment to the inflamed tissue. 
Quantification of IL-17-expressing cells in the ears on day 3 revealed that the synthetic 
peptide had no effect on the frequencies of CD4+ RORgt+ or IL-17A+ T cells. This supports the 
hypothesis that T lymphocytes must sense mCRAMP in the lymph nodes during the first 24 
hours of activation in order to enhance Th17 differentiation.  
 
In a separate experiment performed by Emily Gwyer Findlay, the HKST inoculum was spiked 
with 10 µg synthetic mCRAMP, which led to an increase in the frequency of IL-17-producing 
CD4+ T lymphocytes within the draining popliteal lymph nodes (Figure 5.6; Emily Gwyer 
Findlay). How the synthetic peptide is transported to this lymphoid organ where it can act on 
naïve CD4+ T lymphocytes is unknown. Xhindoli et al. suggested that cathelicidin is ‘sticky’ 
due to the fact that it favours interactions with any molecular surface offering appropriate 
hydrophobic, electrostatic and H-bonding properties314. In addition, several other immune 
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cells, such as macrophages, have been shown to internalise cathelicidin in a P2X7R-
dependent manner, which could then carry the peptide elsewhere513. However, it is 
important to note that the effects of mCRAMP on Th17 differentiation and IL-17 production 
are potentially mediated indirectly. For example, as discussed previously, the possibility that 
mCRAMP influences the differentiation of DCs that subsequently enhance the development 








 5.4.2 Neutrophils are the cellular source of mCRAMP in the lymph nodes during 
inflammation induced by HKST 
 
My results suggest that T cells sense mCRAMP in the lymph nodes following inoculation with 
HKST, which amplifies Th17 responses. Neutrophils are one of the prominent producers of 
mCRAMP and have the capacity to migrate to the lymph nodes in response to different 
stimuli285,514. For example, neutrophils can shuttle live mycobacterium bacilli to lymphoid 
tissues following intradermal BCG vaccination206. Co-localised staining for Ly6G and mCRAMP 
in the lymph nodes of HKST-inoculated mice indicated that neutrophils may be the cellular 






















Figure 5.6: Synthetic mCRAMP boosts IL-17 production by lymph node CD4+ T cells following 
inoculation with HKST. WT mice were inoculated with 12.5 µg HKST in the top of each hind paw, 
with or without 10 µg synthetic mCRAMP. The draining popliteal lymph nodes were removed on 7 
for phenotyping by flow cytometry. Graph shows percentages of CD4+ IL-17A+ T cells (experiment 
performed by Emily Gwyer Findlay) 
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Neutrophils can enter the lymph node by exiting the circulation through high endothelial 
venules (HEVs)515. For instance, HEVs are the major route of entry of blood-borne neutrophils 
into tumour-draining lymph nodes167. This is dependent on interactions between neutrophil 
L-selectin and CXCR2 with addressin and CXCL2, expressed by HEVs167. Beauvillain et al. also 
found that the recruitment of neutrophils to lymph nodes via this pathway requires CCR7: 
injection of complete Freund’s adjuvant (CFA) failed to induce the rapid recruitment of 
neutrophils to the lymph nodes in CCR7-deficient mice169. On the other hand, neutrophils can 
also be recruited to lymph nodes via the afferent lymphatics, in a process mediated by CD11b 
and CXCR4168. Following inoculation with HKST, mCRAMP localised to the outer rim of the 
lymph node on day 1. This area, known as the sub-capsular sinus (SCS), represents where 
neutrophils enter the lymph node via the afferent lymphatics, suggesting that this is the route 
of entry in this model of inflammation168.   
 
Antigen-bearing DCs and T lymphocytes have also been shown to traffic via the afferent 
lymphatics and enter the lymph nodes through the SCS11,516. For instance, Rantakari et al. 
demonstrated that T cells could be detected within the lymph node parenchyma in close 
proximity to the SCS as early as four hours after adoptive transfer11,517. One might therefore 
speculate that this is where naïve T lymphocytes encounter mCRAMP+ cells for the first time. 
Moreover, our staining showed that with time, mCRAMP+ neutrophils became more 
scattered and dispersed throughout the lymph node following inoculation with HKST: by day 
7, they appeared to localize to the deeper paracortex, which is populated predominantly by 
T lymphocytes518. It is within this T cell zone where naïve T lymphocytes receive signals that 
trigger their activation and differentiation518. mCRAMP+ neutrophils were consequently in 
close proximity to T cells as early as day 1 following inoculation, as well as up to 7 days later, 
and therefore had the potential to induce changes that enhance Th17 differentiation.  
 
Initially, there was some debate as to whether lymph node neutrophils were simply in transit 
or involved in lasting interactions with other immune cells that could subsequently modulate 
the development of the adaptive immune response. Maletto et al. demonstrated that 
immune complexes generated by injecting OVA into the footpad of OVA/CFA-immunized 
mice induced the migration of OVA+ neutrophils to the draining lymph nodes205. 
Subsequently, it was found that this influx of OVA+ neutrophils led to an increase in the 
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proliferation, activation and cytokine production of CD4+ T cells519. In addition, Hampton and 
colleagues found that during skin inflammation, neutrophils migrated within lymphatic 
vessels and re-localised to the SCS of draining lymph nodes in response to microbial 
infection168. This resulted in increased lymphocyte proliferation and the enhancement of 
adaptive immunity168.  
 
The studies discussed above indicate that lymph node neutrophils can have profound effects 
on the development of adaptive immune responses. Neutrophils possess a huge repertoire 
of intracellular mediators that are released upon degranulation and during NETosis or 
necrosis, including mCRAMP229. However, whether or not neutrophils undergo any of these 
processes within the lymph node remains unclear. Odobasic et al. demonstrated that 
neutrophils deposited myeloperoxidase (MPO) in the lymph nodes 4 hours after OVA/LPS 
injection, and that this enzyme inhibited antigen uptake and processing by DCs269. 
Furthermore, Krishnamoorthy and colleagues were able to identify neutrophil cytoplasts in 
the mediastinal lymph nodes of mice that had been exposed to an aeroallergen and 
endotoxin during sensitization in a model of allergic asthma233. Neutrophil cytoplasts are 
defined as the remnants of NETs following the expulsion of their DNA233. These enucleated 
cell bodies were capable of activating lung DCs in vitro to trigger antigen-specific IL-17 
production from naïve CD4+ T cells233. In addition, Ahn et al. explored the involvement of 
NETs in adult-onset Still disease by performing immunohistochemical analysis of skin and 
lymph node biopsies520. They identified neutrophil elastase- and MPO-positive inflammatory 
cells in the lymph nodes of patients, which were expressed in fibre form520. The presence of 
extracellular mCRAMP in the lymph nodes of mice inoculated with HKST suggests that 
neutrophils can undergo these processes that lead to the release of inflammatory mediators.  
 
Activated neutrophils have been shown to produce TGFb195,242. For instance, Kamenyeva and 
colleagues demonstrated that the mobilization of bone marrow neutrophils to the draining 
lymph nodes following challenge with S. aureus led to the suppression of the early humoral 
response and that this was TGFb-dependent195. Moreover, highly pure human neutrophils 
activated via TLR8 produce IL-23 and can subsequently promote Th17 polarization521. Both 
TGFb and IL-23 play important roles in Th17 development26. Furthermore, I have shown that 
mCRAMP boosts the generation of Th17 cells in a TGFb-dependent manner. One might 
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therefore speculate that neutrophils play a dual role in driving Th17 differentiation by 
simultaneously releasing mCRAMP and producing Th17-stimualting cytokines such as TGFb 
and IL-23.  
 
 
5.4.3 Neutrophils potentially promote Th17 differentiation in vitro 
 
I have shown that neutrophils are a potential source of mCRAMP within the lymph nodes 
that boost Th17 responses following inoculation with HKST. I therefore sought to determine 
whether neutrophils promoted Th17 differentiation in vitro, similarly to mCRAMP. 
Neutrophils from wildtype mice had no significant effect on IL-17A/IFNg production or 
RORgt/AHR expression. However, there was a trend indicating that culturing whole single cell 
splenic suspensions with WT neutrophils increased the percentage of CD4+ IL-17A+ T cells.  
 
The concentration of mCRAMP in neutrophil preparations was not determined and it is 
difficult to predict how much is released following activation and degranulation. Sørensen et 
al. determined that the concentration of hCAP-18 in human neutrophils is approximately 
0.627 µg/106 cells. Assuming mouse neutrophils are similar and that all neutrophils 
degranulated, I therefore predict that there was around 1.3 μM in my neutrophil 
suspensions. This is only half the amount of synthetic mCRAMP that I typically added to Th17 
cultures (2.5 μM).  
 
Moreover, hCAP-18 refers to the full length pre-peptide: cathelicidin requires proteolytic 
processing by proteinase-3 in order to release the biologically active fragment289. Proteinase-
3 is stored in primary, azurophilic granules, which prevents the unwanted intracellular 
processing of cathelicidin in resting neutrophils281. Neutrophil degranulation occurs in the 
reverse but ordered sequence of synthesis: secretory granules require minimal cellular 
stimulation for release, whereas azurophilic granules require a very powerful agonist159. In 
the present study, neutrophils were primed with cytochalasin B and stimulated with fMLF 
(N-formyl-Met-Leu-Phe). fMLF is a potent inducer of neutrophil degranulation and has been 
shown to stimulate the extracellular release of azurophilic granule contents508,522. 
Stimulation with fMLF therefore ensured the release of proteinase-3 and that the pre-pro-
peptide could be cleaved. However, it is also possible that not enough of the enzyme was 
CHAPTER 5: RESULTS 
 172 
released or that these neutrophil preparations contained too many immature PMN that had 
not yet fully undergone neutrophil granule formation. Future work will involve confirming 
neutrophil degranulation and the presence of biologically active mCRAMP. For example, a 
western blot could be performed on neutrophil supernatants, alongside samples of known 
concentration (e.g. synthetic CRAMP) to qualitatively assess how much is present.  
 
Previous Th17 cultures were treated with 2.5 µM synthetic mCRAMP, which is physiological 
in scenarios of inflammation where there is an influx of neutrophils. In the present study, 
neutrophils were added at a ratio of approximately 1:1. It is therefore likely that the amount 
of mCRAMP released did not equate to 2.5 µM. Future experiments will therefore include 
increasing the ratio of neutrophils to splenocytes (e.g. 5:1), which should be more 
physiologically relevant. In addition, purified CD4+ T lymphocytes will be used instead of 
whole single cell splenic suspensions, as it is possible that other cell types within the spleen 
could interfere.   
 
Neutrophils from mCRAMP-deficient mice did not significantly increase the frequency of IL-
17-producing CD4+ T lymphocytes, although the percentage of CD4+ IL-17A+ T cells was similar 
to that obtained following culture with WT neutrophils. However, a significant increase in 
the percentage of CD4+ IFNg+ T cells was observed compared to untreated samples. In 
addition, KO neutrophils significantly decreased the frequency of AHR- and RORgt-expressing 
CD4+ T lymphocytes. One possible explanation for this is that a currently unspecified 
neutrophil mediator promoted Th1 polarization due to the absence of mCRAMP, which 
normally counteracts its action in the presence of Th17-stimulating cytokines. For example, 
lactoferrin enhances Th1 differentiation in humans: Hwang et al. demonstrated that the 
addition of lactoferrin to the BCG vaccine boosted the generation of BCG-specific Th1 
responses and increased IFNg production523. To corroborate this, future experiments will 
involve examining the expression of other Th1 markers (e.g. T-bet) in T cell – neutrophil co-
cultures.  
 
It is important to note that there was a high degree of variability between experiments, 
particularly with regards to IFNg production. This could be an indication that several of the 
mice used were sick or infected with an unknown pathogen. Furthermore, the mCRAMP KO 
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mice used throughout the majority of this study were re-derived into a separate animal 
facility, which is considered ‘cleaner’. Differences in the microbiome of these mice could have 
profound effects on T helper cell differentiation and cytokine production524. For example, 
Ivanov and colleagues found that C57BL/6 mice obtained from different commercial vendors 
displayed significant differences in the proportion of Th17 cells in the gastrointestinal lamina 
propria90. They went on to demonstrate that colonization of the small intestine with 
segmented filamentous bacteria (SFB) induces Th17 development and that mice that have 
few Th17 cells lack this particular commensal microbe91.  
Nonetheless, taken together, these results suggest that neutrophils potentially promote 
Th17 differentiation in vitro, although it was not possible to conclude whether this is 
mCRAMP-dependent or not. Further investigation is therefore required.  
 
 
5.4.4 Neutrophil depletion does not impair the development of the Th17 response 
following inoculation with HKST 
 
To further examine the effects of neutrophils on the development of Th17 responses, I 
inoculated wildtype and neutrophil-depleted mice with HKST. I hypothesized that if 
neutrophil-derived mCRAMP is important for boosting Th17 differentiation, neutrophil-
depleted animals would display a similar phenotype to mCRAMP KO mice and fail to produce 
IL-17. However, the percentage of CD4+ IL-17A+ T cells within the draining popliteal lymph 
nodes was significantly increased in neutrophil depleted mice compared to the control 
group. Furthermore, cells from neutrophil-depleted mice produced significantly more IL-17A 
following re-stimulation with both aCD3 and HKST.  
 
There are several possible explanations for this. Firstly, the intraperitoneal injection of an 
anti-Ly6G antibody depletes neutrophils by targeting them for clearance by macrophages; 
Bruhn et al. found that anti-Ly6G-mediated neutrophil depletion is abrogated in the absence 
of this cell type509. Indeed, I observed a significant influx of SSC-Alo CD11b+ cells in the spleen 
following treatment. However, antibody-dependent cellular cytotoxicity (ADCC) has been 
suggested to also play a role525. ADCC refers to the immune mechanism through which Fc 
receptor-bearing effector cells recognize and kill antibody-coated targets526. One might 
therefore speculate that the lysis of a large number of neutrophils could lead to a sudden 
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release/burst of mCRAMP, which could in turn get taken up by other immune cells and 
transported to the lymph nodes where it enhances Th17 differentiation.  
 
On the other hand, Patel et al. recently demonstrated that chronic, systemic depletion of 
neutrophils results in the failure of apoptotic neutrophils to trigger the negative feedback IL-
23 – IL-17 – G-CSF regulatory axis in the periphery510. More specifically, during homeostasis, 
phagocytosis of transmigrated, apoptotic neutrophils by resident macrophages and DCs 
results in the suppression of their intrinsic IL-23 production510,527. IL-23 is important for the 
maintenance, stabilisation and pathogenicity of Th17 cells and is therefore a potent regulator 
of IL-17 expression510. An increase in the percentage of CD4+ IL-17A+ T cells could therefore 
be a result of sustained production of IL-23 from macrophages and DCs, whose inhibition 
normally prevents uncontrolled Th17 responses and the excessive production of harmful IL-
17.  
 
In order to overcome these issues and address the question as to whether neutrophil-derived 
mCRAMP is truly required for the development of a Th17 response following inoculation with 
HKST, it would be helpful to generate a mouse line that is deficient for mCRAMP specifically 
in neutrophils. However, efforts by the group thus far have proven unsuccessful. This is 
possibly due to the fact that mCRAMP is not synthesised by neutrophils de novo upon 
stimulation286. Instead, it is produced at the myelocyte and metamyelocyte stage of 
neutrophil maturation and stored as an inactive pre-pro-peptide in secondary granules286. It 
is therefore difficult to target due to how early it is expressed within the developing 





To summarize, I have provided evidence that suggests naïve CD4+ T cells sense mCRAMP in 
the lymph nodes during inflammation, which enhances Th17 responses in vivo. 
Immunofluorescent staining of lymph nodes taken from mice following HKST inoculation 
demonstrated shown that mCRAMP co-localised with Ly6G, indicating that neutrophils may 
be the cellular source.  
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However, culturing whole single cell splenic suspensions with WT neutrophils in vitro did not 
significantly increase RORgt or IL-17 expression, or at least not to the same extent as 
synthetic mCRAMP. On the other hand, mCRAMP-deficient neutrophils significantly 
increased IFNg production and downregulated RORgt expression compared to UT controls. 
This potentially reflects an increase in the development of Th1 lymphocytes as a result of the 
absence of mCRAMP, which normally skews T helper cell polarization away from this lineage.  
 
Further investigation is required in order to validate the role of neutrophil-derived mCRAMP 
in the development of Th17 responses during inflammation. A mouse line that is specifically 
deficient for neutrophil-mCRAMP would be highly beneficial but this has proven technically 
































































CD8+ T lymphocytes can be subdivided into different subsets, reminiscent of T helper cell 
classification528. Tc1 cells are considered canonical cytotoxic T lymphocytes (CTLs) that are 
capable of efficiently killing infected or malignant cells bearing their target antigen by 
releasing cytotoxic molecules into the immunological synapse528. Eomes and T-bet drive the 
CTL differentiation program by promoting the expression of IFNg and the cytolytic molecule 
granzyme B529. On the other hand, Tc17s express type 17 markers, such as RORgt, IL-23R and 
IL-17, display highly suppressed cytotoxic activity (diminished levels of IFNg and granzyme B) 
and therefore lack lytic function in vitro530–532.  
 
A lot of information regarding the differentiation of Tc17 cells stems from mouse studies: 
naïve CD8+ T cells activated in the presence of IL-6 and TGFb develop into IL-17-producing 
Tc17 cells, similarly to CD4+ T lymphocytes531,533. However, the exact conditions required for 
human Tc17 polarisation are still unclear533. A limited number of studies have been published 
that show only very low frequencies of CD8+ IL-17+ T cells or low levels of IL-17 production 
following induction533,534. For example, Kondo and colleagues demonstrated that human 
naïve CD8+ T cells cultured with TGFb, IL-6, IL-1b, IL-23 and anti-IFNg for 5 days, followed by 
the addition of IL-2 for another 4 days, induced the development of 0.11% CD8+ IL-17+ T 
cells534. It therefore remains to be seen whether human Tc17 cells require another inducing 
factor that is yet to be identified, or whether these low levels of polarization are simply due 
to technical challenges.  
 
Compared to CD4+ Th17 lymphocytes, Tc17s have received relatively little attention with 
regards to their role during inflammation. However, they have been detected in various 
chronic inflammatory disorders, suggesting that they contribute to immunopathology533. For 
example, Tc17 cells in psoriasis patients use CCR6 to home to a CCL20-enriched environment, 
where IL-17 synergistically acts with IFNg to promote keratinocyte proliferation535. 
Furthermore, myelin oligodendrocyte glycoprotein (MOG)-specific CD8+ T cells isolated from 
the lymph nodes and CNS of mice with EAE at the peak of disease express IL-17 ex vivo531,533. 
These cells do not express granzyme B, indicating that their potential pathogenicity is not 
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dependent on cytotoxic mechanisms and may rather be related to pro-inflammatory 
function531,533.  
 
Similarly to CD4+ Th17 cells, the presence and activity of CD8+ IL-17+ T lymphocytes in 
autoimmune disease can be associated with levels of cathelicidin. For instance, LL-37 acting 
as an autoantigen has been suggested to be one of the causes of Tc17 activation in psoriatic 
skin536. Furthermore, elevated levels of LL-37 have been measured in the synovial fluid of 





mCRAMP KO cannot produce IL-17 in response to inflammation induced by heat-killed S. 
typhimurium (HKST) and I have shown that mCRAMP enhances CD4+ Th17 differentiation in 
vitro. I therefore sought to determine whether mCRAMP influences CD8+ T cells in the same 
manner. The aims of this chapter were to examine the effects of synthetic mCRAMP on 





6.3.1 CD8+ T cells that develop in the absence of mCRAMP have normal cytokine 
responses  
 
mCRAMP KO mice could not produce IL-17 in response to inoculation with HKST (Chapter 1: 
Figure 1.10). I have shown that CD4+ T lymphocytes from naïve mCRAMP-deficient mice 
displayed similar cytokine responses to WT CD4+ T cells (Chapter 3: Figure 3.1). However, IL-
17-producing CD8+ T lymphocytes can also contribute to a type-17 response. I therefore 
sought to determine whether CD8+ T cells that developed in the absence of mCRAMP 
possessed an underlying defect that could contribute to the failure of IL-17 production in 
mCRAMP KO mice during inflammation induced by HKST.  
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I compared CD8+ T lymphocyte cytokine production ex vivo in cells from the liver, lungs, 
spleen, mesenteric lymph nodes and Peyer’s patches from naïve WT and mCRAMP KO mice 
by intracellular flow cytometry, in order to assess baseline cytokine responses (Figure 6.1).  
 
There were no significant differences in the production of IL-17A, IL-17F, IFNg, IL-22 or GM-
CSF between the two genotypes in any of the tissues tested. However, there was a significant 
increase in the frequency of CD8+ TNFa+ T cells in the liver (45.48% +/- 3.59 compared to 
32.45% +/- 3.87) and mesenteric lymph nodes (32.58% +/- 2.81 compared to 23.20% +/- 1.27) 
of mCRAMP KO mice. Despite this, these data suggest that like CD4+ T lymphocytes, CD8+ T 
cells that develop in the absence of mCRAMP do not have drastically different cytokine 






































Figure 6.1: CD8+ T cells that develop in the absence of mCRAMP have relatively normal 
cytokine responses. CD8+ T cell cytokine production was assessed in the liver, lungs, mesenteric 
lymph nodes, Peyer’s patches and spleen from naïve WT and mCRAMP KO mice (A) Percentages 
of CD8+ IL-17A+ T cells in WT and KO mice (B) Percentages of CD8+ IL-17F+ T cells in WT and KO 
mice (C) Percentages of CD8+ TNFα+ T cells in WT and KO mice (D) Percentages of CD8+ IFNɣ+ T 
cells in WT and KO mice (E) Percentages of CD8+ IL-22+ T cells in WT and KO mice (F) Percentages 
of CD8+ GM-CSF+ T cells in WT and KO mice. Data shown is mean +/- standard error. N = 4. 
Statistical significance (where * represents < 0.05) was determined using an unpaired t-test. 
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6.3.2 CD8+ T cells from mCRAMP knockout mice are capable of producing IL-17 in 
response to exogenous cytokines 
 
Next, I sought to determine whether CD8+ T cells from mCRAMP KO animals were capable of 
producing IL-17 in vitro in response to exogenous IL-17-inducing cytokines. Whole single cell 
splenic suspensions from WT and mCRAMP KO mice were cultured with IL-6, IL-23 and TGFb 
for 2 days, using the same protocol as for the differentiation of CD4+ Th17 lymphocytes. IL-
17A production was assessed by intracellular flow cytometry on day 2 (Figure 6.2).  
 
There was no significant difference in the percentage of CD8+ IL-17A+ T cells between WT and 
KO mice. However, there was a trend suggesting that the frequency of IL-17-producing CD8+ 
T lymphocytes generated in Tc17 cultures was reduced when using cells from mCRAMP KO 
mice. These results indicate that CD8+ T lymphocytes from mCRAMP-deficient mice are 
capable of producing IL-17A in vitro in response to exogenous cytokines, although perhaps 













WT KO FMO IL-17A A 
Figure 6.2: CD8+ T cells from mCRAMP knockout mice can produce IL-17A in response to 
exogenous cytokines. Whole single cell splenic suspensions from WT and mCRAMP KO mice were 
cultured under Tc17-driving conditions (20 ng/mL IL-6, 20 ng/mL IL-23, 3 ng/mL TGFβ) for 2 days 
(A) Representative plots of IL-17A production by CD8+ T cells from WT and mCRAMP KO mice on 
day 2, assessed by flow cytometry (B) Percentages of WT and mCRAMP KO CD8+ IL-17A+ T cells on 
day 2 following culture under Tc17-driving conditions. Data shown is mean +/- standard error. N = 
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6.3.3 mCRAMP increases CD8+ T cell activation but has no effect on IL-17 production 
following culture under non-lineage-driving conditions 
 
CD8+ T lymphocytes that developed in the absence of mCRAMP could produce IL-17 in 
response to exogenous cytokines and had relatively normal cytokine responses at resting 
state. I previously hypothesised that mCRAMP enhances the development of T cell immunity. 
To examine the effects of this peptide on CD8+ T cells, I cultured whole single cell splenic 
suspensions under non-lineage-driving conditions with plate-bound aCD3, with or without 
synthetic mCRAMP.  
 
Figure 6.3 shows that no significant differences in the total number of CD8+ T lymphocytes 
were observed between untreated and mCRAMP-treated samples on days 1 and 2. However, 
mCRAMP increased the total number of CD8+ T cells in non-polarising cultures on day 3, from 
87,104 (+/- 18,290) to 110,723 (+/- 15,446). This is in contrast to observations made for CD4+ 









First, I sought to determine whether mCRAMP had any effect on CD8+ T cell activation. Under 
non-lineage driving conditions, mCRAMP had no effect on the percentage of CD8+ CD62L- 
CD44+ T cells (Figure 6.4 A) but significantly increased the geometric mean of PD1 on days 1 














Figure 6.3: mCRAMP increases the total number of CD8+ T cells cultured under non-lineage-
driving conditions. Whole single cell splenic suspensions from WT mice were cultured under non-
lineage-driving conditions (αCD3 only, 5 µg/mL), with or without 2.5 µM synthetic mCRAMP, for 
up to 3 days. N = 3. Statistical significance (where *** represents < 0.001) was determined using a 
two-way repeated measures ANOVA with a Bonferroni multiple comparison post-test. UT: 
untreated.   
UT
mCRAMP
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and 3 (Figure 6.4 B). For example, this rose from 5033 (+/- 614) to 8586 (+/- 787) on day 1. 
There also appeared to be a trend indicating that PD1 expression was increased on day 2 (P 
= 0.08). These results are similar to those obtained for CD4+ T helper cells exposed to 
mCRAMP, which also displayed an increase in PD1, even in the absence of polarizing 
cytokines. 
 
Next, I sought to determine whether mCRAMP had any effect on cytokine production. The 
addition of mCRAMP to cells cultured in the absence of IL-17-inducing cytokines did not have 
any effect on IL-17A production by CD8+ T lymphocytes (Figure 6.4 C). However, cytotoxic 
CD8+ T cells produce large quantities of IFNg and a significant decrease in the percentage of 
CD8+ IFNg+ T cells was observed on day 3 following exposure to mCRAMP: this dropped from 








Figure 6.4: mCRAMP increases PD1 expression by CD8+ T cells cultured under non-lineage driving 
conditions. Whole single cell splenic suspensions were cultured under non-lineage-driving 
conditions (αCD3 only, 5 µg/mL), with or without 2.5 µM synthetic mCRAMP, for up to 3 days (A) 
Percentages of CD8+ CD62L- CD44+ T cells, ex vivo and days 1-3 (B) Geometric mean of PD1 
expression by CD8+ T cells, ex vivo and days 1-3 (C) Percentages of CD8+ IL-17A+ T cells, ex vivo and 
days 1-3 (D) Percentages of CD8+ IFNɣ+ T cells, ex vivo and days 1-3. Data shown is mean +/- 
standard error. N = 6. Statistical significance (where * represents < 0.05 and *** < 0.001) was 
determined using a two-way repeated measures ANOVA with a Bonferroni multiple comparison 
post-test. UT: untreated.  
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6.3.4 mCRAMP increases the activation status of CD8+ T cells cultured under Tc17-
driving conditions 
 
The cytokine and molecular requirements for Tc17 differentiation are highly similar to those 
of CD4+ Th17 cells531. For instance, culturing CD8+ T lymphocytes in the presence of IL-6 and 
TGFb induces the transcription of Rorc and the subsequent expression of IL-17531.  
 
mCRAMP increased PD1 expression by CD8+ T lymphocytes in the absence of polarizing 
cytokines but had no effect on IL-17 production, similarly to CD4+ T cells. However, mCRAMP 
increased the activation status and frequency of IL-17-producing CD4+ T cells cultured under 
Th17-driving conditions. I therefore sought to determine whether this host defence peptide 
had similar effects on CD8+ T lymphocytes in IL-17-inducing cultures in vitro. Whole single cell 
splenic suspensions were cultured under Tc17-polarizing conditions (IL-6, IL-23, TGFb), as 
previously described, with or without 2 synthetic mCRAMP.  
 
Figure 6.5 shows that mCRAMP had no significant effect on the total number of CD8+ T 








Almost 100% of CD8+ T cells were PD1+ by day 1 (data not shown). However, the geometric 
mean of PD1 expression was significantly increased following treatment with mCRAMP on 
days 1 to 3 (Figure 6.6 C). For example, on day 2, this rose by 72% from 7732 (+/- 713) to 













Figure 6.5: mCRAMP has no effect on the total number of CD8+ T cells cultured under Tc17-
driving conditions. Whole single cell splenic suspensions from WT mice were cultured under Tc17-
driving conditions (20 ng/mL IL-6, 20 ng/mL IL-23 and 3 ng/mL TGFβ), with or without 2.5 µM 
synthetic mCRAMP, for up to 3 days. N = 3.  
UT
mCRAMP
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13293 (+/- 614). Furthermore, the percentage of activated CD8+ CD62L- CD44+ T cells was also 
significantly increased following exposure to mCRAMP (Figure 6.6 D: day 2 UT: 44.37% +/- 
8.39; day 2 mCRAMP: 55.12% +/- 8.43).  
 
This indicates that mCRAMP increases the activation status of CD8+ T cells cultured under 















Ex Vivo UT mCRAMP FMO CD44 FMO CD62L 




Figure 6.6: mCRAMP increases the activation status of CD8+ T cells cultured under Tc17-driving 
conditions. Whole single cell splenic suspension from WT mice were cultured under Tc17-driving 
conditions, with or without 2.5 µM synthetic mCRAMP, for up to 3 days (A) Representative plots 
of CD44 and CD62L expression by CD8+ T cells on day 2, assessed by flow cytometry (B) 
Representative plots of PD1 expression by CD8+ T cells on day 2, assessed by flow cytometry (C) 
Geometric mean of PD1 expression by CD8+ T cells, ex vivo and days 1-3 (D) Percentages of CD62L- 
CD44+ T cells, ex vivo and days 1-3. Data shown is mean +/- standard error. N = 6. Statistical 
significance (where *** represents < 0.001 and **** < 0.0001) was determined using a two-way 
repeated measures ANOVA with a Bonferroni multiple comparison post-test. UT: untreated.   
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6.3.5 mCRAMP enhances the development of IL-17-producing CD8+ T cells in Tc17 
cultures 
 
mCRAMP had no effect on the frequency of CD8+ IL-17A+ T lymphocytes when the cells were 
cultured under non-lineage-driving conditions. However, I have shown that mCRAMP 
increased RORgt and IL-17 expression by CD4+ T lymphocytes when generated in the 
presence of IL-6, IL-23 and TGFb531. To determine whether the peptide induced similar 
changes in CD8+ T cells, I analysed the expression of RORgt and IL-17 by CD8+ T cells by 
intracellular flow cytometry (Figure 6.7). Whole single cell splenic suspensions from WT mice 
were cultured under Tc17-driving conditions, as previously described, with or without 
synthetic mCRAMP.  
 
Figure 6.7 demonstrates that mCRAMP promoted a significant increase, from 6.95% (+/- 
0.74) to 21.42% (+/- 7.51), in the percentage of CD8+ RORgt+ T cells on day 1 (Figure 6.7 C). 
By day 2, this translated into a 1.56-fold increase, from 15.31% (+/- 1.34) to 23.94% (+/- 1.47), 
in the frequency of IL-17-producing CD8+ T lymphocytes (Figure 6.7 E). Moreover, this 
increase in the proportion of CD8+ IL-17A+ T cells in response to mCRAMP was concentration-
dependent, similarly to CD4+ T lymphocytes (Figure 6.7 G). Interestingly, there was a 
significant decrease in the geometric mean of IL-17A of CD8+ IL-17A+ T cells, from 4115 (+/- 
335) to 3857 (+/- 301) (Figure 6.7 F).  
 
Taken together, these data indicate that mCRAMP increases the number of IL-17-producing 























Ex Vivo UT mCRAMP FMO IL-17A B 
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C D 
Figure 6.7: mCRAMP increases RORɣt expression and the frequency of IL-17A-producing CD8+ T 
cells cultured under Tc17-driving conditions. Whole single cell splenic suspensions from WT mice 
were cultured under Tc17-driving conditions, with or without 2.5 µM synthetic mCRAMP, for up 
to 3 days (A) Representative plots RORɣt expression by CD8+ T cells on day 1, assessed by flow 
cytometry (B) Representative plots of IL-17A production by CD8+ T cells on day 2, assessed by flow 
cytometry (C) Percentages of CD8+ RORɣt+ T cells, ex vivo and days 1-3 (n = 6) (D) Percentages of 
CD8+ IL-17A+ T cells, ex vivo and days 1-3 (n = 6) (E) Percentages of CD8+ IL-17A+ T cells on day 2 (n 
= 23) (F) Geometric mean of IL-17A expression by CD8+ IL-17A+ T cells on day 2 (n = 23) (G) CD8+ 
IL-17A+ vs. mCRAMP dose response (n = 3). Data shown is mean +/- standard error. Statistical 
significance (where * represents < 0.05, ** < 0.01 and **** < 0.0001) was determined using a two-
way repeated measures ANOVA with a Bonferroni multiple comparison post-test (C & D) or a 
paired t-test (E & F) or an ordinary one-way ANOVA with a Dunnett’s multiple comparison post-
test (G). UT: untreated.   
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In addition to IL-17A, several reports have shown that Tc17 cells also produce IL-17F and at 
percentages similar to CD4+ T lymphocytes126,540. Furthermore, I previously demonstrated 
that mCRAMP preferentially enhanced the development of IL-17F-producing CD4+ T cells in 
Th17 cultures. I therefore examined the effects of mCRAMP on IL-17F production by CD8+ T 
lymphocytes cultured under Tc17-driving conditions, to determine whether the peptide 
exerted similar effects on this cell type (Figure 6.8).  
 
Figure 6.8 shows that mCRAMP significantly increased the percentage of IL-17F single-
positive CD8+ T cells from 4.57% (+/- 0.98) to 7.92% (+/- 1.40) on day 2 (Figure 6.8 C). 
Moreover, mCRAMP significantly increased the percentage of IL-17A and IL-17F double-
producing CD8+ T lymphocytes from 5.83% (+/- 1.31) to 13.12% (+/- 2.08) (Figure 6.8 D). 
These observations were similar to those made for CD4+ T helper cells (Chapter 3: Figure 
3.9).  
 
The percentage of IL-17A single-positive CD8+ T lymphocytes was also significantly increased 
in mCRAMP-treated samples compared to untreated (Figure 6.8 B: 2.12% +/- 0.56 compared 
to 3.55% +/- 0.39). This was in contrast to CD4+ T cells, whose IL-17A expression was not 
significantly affected by the peptide (Chapter 3: Figure 3.9). These results therefore highlight 
a potential difference in the effects of mCRAMP on CD8+ T lymphocytes compared to CD4+ T 








































Figure 6.8: mCRAMP increases IL-17F production by CD8+ T cells cultured under Tc17-driving 
conditions. Whole single cell splenic suspensions from WT mice were cultured under Tc17-driving 
conditions, with or without 2.5 µM synthetic mCRAMP, for 2 days (A) Representative plots of IL-
17A and IL-17F expression by CD8+ T cells on day 2, assessed by flow cytometry (B) Percentages of 
CD8+ IL-17A+ IL-17F- T cells on day 2 (C) Percentages of CD8+ IL-17A- IL-17F+ T cells on day 2 (D) 
Percentages of CD8+ IL-17A+ IL-17F+ T cells on day 2 . Data shown is mean +/- standard error. N = 
6. Statistical significance (where * represents < 0.05. ** < 0.01 and *** < 0.001) was determined 
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6.3.6 mCRAMP acts via the aryl hydrocarbon receptor to enhance Tc17 
differentiation 
 
I have previously shown that mCRAMP upregulated the expression of AHR in CD4+ T 
lymphocytes and that this specifically promoted the development of CD4+ IL-17A+ IL-17F+ T 
cells (Chapter 4: Figures 4.6 & 4.7).  
 
To determine whether a similar AHR-dependent mechanism could be seen in CD8+ T cells, I 
cultured whole single cell splenic suspensions from WT mice under Tc17-driving conditions, 
as previously described, with or without synthetic mCRAMP, and examined the expression of 
AHR by intracellular flow cytometry (Figure 6.9).  
 
Figure 6.9 B shows that mCRAMP significantly increased the percentage of CD8+ AHR+ T cells 
on day 1, from 12.57% (+/- 0.73) to 18.73% (+/- 0.30), although no differences were observed 
on day 2. This is in contrast to CD4+ T cells, who displayed a significant and cumulative 
increase over time (Chapter 4: Figure 4.6).   
 
Hayes and colleagues suggested that the AHR pathway plays a greater role in Th17 
development compared to Tc17541. Nonetheless, to determine whether the effects of 
mCRAMP on the differentiation of Tc17 cells were AHR-dependent, I cultured whole single 
cell splenic suspensions under Tc17-driving conditions for 2 days, as previously described, 
with or without synthetic mCRAMP and/or an AHR antagonist (CH223191)447.  
 
mCRAMP significantly increased the proportion of IL-17A single-positive cells from 2.05% (+/- 
0.11) to 3.78% (+/- 0.38). However, this was abolished (2.27% +/- 0.29) following addition of 
the AHR antagonist (Figure 6.9 C). CH223191 also prevented the increase in the percentage 
IL-17A and IL-17F double-producing CD8+ T cells normally induced by mCRAMP (Figure 6.9 
D). Conversely, the AHR antagonist did not appear to have a significant effect on the 
frequency of CD8+ IL-17A- IL-17F+ T cells (Figure 6.9 E).  
 
These results indicate that mCRAMP acts via AHR to promote the development of CD8+ IL-
17A+ IL-17F+ T lymphocytes. However, unlike in CD4+ T helper cells, mCRAMP also acts via this 
transcription factor to boost the differentiation of IL-17A single-positive Tc17s.  















Ex Vivo UT mCRAMP FMO AHR A 
Figure 6.9: CH223191 prevents the increase in the percentage of CD8+ IL-17A+ IL-17F- and IL-17A+ 
IL-17F+ T cells induced by mCRAMP. Whole single cell splenic suspensions were cultured under 
Tc17-driving conditions for 2 days, with or without 2.5 µM synthetic mCRAMP and/or an AHR 
antagonist (CH223191, 10 µM) (A) Representative plots of AHR expression production by CD8+ T 
cells on day 1, assessed by flow cytometry (B) Percentages of CD8+ AhR+ T cells, ex vivo and days 
1-2 (n = 3) (C) Percentages of CD8+ IL-17A+ IL-17F- T cells on day 2 (n = 5) (D) Percentages of CD8+ 
IL-17A+ IL-17F+ T cells on day 2 (n = 5) (E) Percentages of CD8+ IL-17A- IL-17F+ T cells on day 2 (n = 
5). Data shown is mean +/- standard error. Statistical significance (where * represents < 0.05, ** < 
0.01 and **** < 0.0001) was determined using an ordinary one-way ANOVA with a Bonferroni 
multiple comparison post-test. UT: untreated.  
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6.3.7 mCRAMP acts directly on CD8+ T cells to enhance Tc17 differentiation in vitro 
 
I have shown that mCRAMP had no significant effect on the phenotype of differentiated DCs 
and that the peptide could act directly on CD4+ T cells to increase the frequency of CD4+ IL-
17A+ T lymphocytes in IL-17-inducing cultures (Chapter 3: section 3.3.8). To determine 
whether mCRAMP was capable of acting directly on CD8+ T lymphocytes, I cultured sorted 
splenic CD8+ T cells (DAPI- CD4- CD8+; purity > 97%) under Tc17-driving conditions, as 
previously described, with or without synthetic peptide (Figure 6.10).  
 
Figure 6.10 shows that mCRAMP significantly increased the proportion of CD8+ IL-17A+ T 
lymphocytes from 0.25% (+/- 0.09) to 1.46% (+/- 0.13) (Figure 6.10 B). The frequencies of IL-
17-producing CD8+ T lymphocytes generated were substantially lower than those obtained 
from culturing whole single cell splenic suspensions. This could indicate that CD8+ T cells 
require additional signals or growth factors that are provided by other cell types present 
within the spleen. Nonetheless, the concentration of IL-17A in cell culture supernatants 
measured by ELISA, rose 10-fold from 20 to 269 pg/mL, following exposure to mCRAMP 
(Figure 6.10 C).  
 
Taken together, these results suggest that mCRAMP can act directly on CD8+ T cells to 





Figure 6.10: mCRAMP acts directly on CD8+ T cells. Sorted CD8+ T cells were cultured under Tc17-
driving conditions for 2 days, with or without 2.5 µM synthetic mCRAMP (A) Representative plots 
of IL-17A production by CD8+ T cells on day 2, assessed by flow cytometry (B) Percentages of CD8+ 
IL-17A+ T cells on day 2 (C) Concentration of IL-17A in cell culture supernatants on day 2, 
determined by ELISA. Data shown is mean +/- standard error. N = 3. Statistical significance (where 
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 6.3.8 mCRAMP increases the frequency of CD8+ IL-23R+ and IL-6R+ T cells cultured 
under Tc17-driving conditions 
 
mCRAMP could act directly on CD8+ T cells to increase the development of IL-17-producing 
CD8+ T lymphocytes. One possible mechanism through which the peptide could achieve this 
is by upregulating the expression of receptors required for Tc17 differentiation, thereby 
increasing the sensitivity of CD8+ T cells to IL-17-inducing cytokines. I therefore analysed the 
expression of IL-23R and IL-6R by CD8+ T lymphocytes following culture under Tc17-driving 
conditions, with or without synthetic mCRAMP (Figure 6.11). The lack of a reliable antibody 
that can be used to detect TGFbR by flow cytometry prevented the analysis of CD8+ TGFbR+ 
T cells. 
 
Similarly to those obtained from CD4+ T helper cells, the results were highly variable. 
However, a significant increase in the percentage of CD8+ IL-23R+ (Figure 6.11 C: 19.39% +/- 
8.34 compared to 11.72% +/- 4.94) and CD8+ IL-6R+ T cells (Figure 6.11 D: 6.98% +/- 1.05 
compared to 3.46% +/- 0.39) was observed in response to mCRAMP on days 2 and 1, 
respectively.  
 
These results need to be confirmed by PCR (and should also include TGFbR) but they suggest 
that mCRAMP increases the expression of IL-6R and IL-23R by CD8+ T lymphocytes in Tc17 
cultures. This data is in contrast to CD4+ T lymphocytes, which did not display any significant 
differences in IL-6R or IL-23R, and therefore adds to the differential roles previously noted 

























Figure 6.11: mCRAMP increases the expression of IL-6R and IL-23R by CD8+ T cells cultured under 
Tc17-driving conditions. Whole single cell splenic suspensions from WT mice were cultured under 
Tc17-driving conditions, with or without 2.5 µM synthetic mCRAMP (A) Representative plots of IL-
23R expression by CD8+ T cells on day 2, assessed by flow cytometry (B) Representative plots of IL-
6R+ expression by CD8+ T cells on day 1, assessed by flow cytometry (C) Percentages of CD8+ IL-
23R+ T cell, ex vivo and days 1-3 (D) Percentages of CD8+ IL-6R+ T cell, ex vivo and days 1-3. Data 
shown is mean +/- standard error. N = 6. Statistical significance (where * represents < 0.05 and 
*** < 0.001) was determined using a two-way repeated measures ANOVA with a Bonferroni 
multiple comparison post-test. UT: untreated.   
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6.3.9 mCRAMP decreases T-bet expression and IFNg production by CD8+ T 
lymphocytes cultured under Tc17-driving conditions 
 
Gene expression analysis of CD4+ T cells cultured under Th17-driving conditions revealed that 
several Th1-related genes were significantly downregulated following exposure to mCRAMP 
(Chapter 4: Figure 4.1). I subsequently found that mCRAMP significantly decreased the 
frequency of CD4+ T-bet+ and CD4+ IFNg+ T cells, suggesting that the peptide skews T helper 
cell differentiation away from the Th1 lineage (Chapter 4: Figure 4.5).  
 
Like Th1 lymphocytes, Tc1 cells are significant producers of IFNg and their differentiation is 
driven, in part, by the master transcriptional regulator T-bet529. I therefore investigated the 
expression T-bet and IFNg by CD8+ T cells cultured under Tc17-driving conditions, with or 
without synthetic mCRAMP, to determine whether the peptide also skews cytotoxic CD8+ T 
cell differentiation (Figure 6.12).  
 
Figure 6.12 shows that mCRAMP significantly decreased T-bet expression on days 2 and 3 
(Figure 6.12 C). For example, the percentage of CD8+ RORgt- T-bet+ T cells dropped from 
48.97% (+/- 9.99) to 39.88% (+/- 9.12) on day 2.  
 
A subset of Tc17 cells has been shown to co-express T-bet and RORgt under certain 
conditions542–544. Similarly to CD4+ T lymphocytes, I observed a significant decrease in the 
frequency of CD8+ RORgt+ T-bet+ T cells on day 3 following exposure to mCRAMP, from 
29.92% (+/- 2.70) to 20.65% (+/- 3.79) (Figure 6.12 D).  
 
The reduction in T-bet expression by CD8+ T cells cultured in the presence of mCRAMP was 
associated with a significant decrease in IFNg production: the percentage of CD8+ IFNg+ T cells 
fell from 22.84% (+/- 1.90) to 16.58% (+/- 1.48) on day 2 (Figure 6.12 E). No differences in the 
geometric mean of IFNg of CD8+ IFNg+ T cells were observed (Figure 6.12 F) and no IL-17/IFNg 
double-producing lymphocytes were identified (data not shown).  
 
Taken together, these results support the hypothesis that like CD4+ T helper cells, mCRAMP 
skews cytotoxic T cell polarisation away from a Tc1 phenotype and towards the Tc17 lineage.  
 









Ex Vivo UT mCRAMP FMO IFNɣ B 
C D 
Figure 6.12: mCRAMP decreases T-bet expression and IFNɣ production in CD8+ T cells cultured 
under Tc17-driving conditions. Whole single cell splenic suspensions were cultured under Tc17-
driving conditions, with or without 2.5 µM synthetic mCRAMP (A) Representative plots of RORgt 
and T-bet expression by CD8+ T cells on day 2, assessed by flow cytometry (B) Representative plots 
of IFNɣ production by CD8+ T cells, assessed by flow cytometry (C) Percentages of CD8+ RORgt- T-
bet+ T cells, ex vivo and days 1-3 (n = 6) (D) Percentages of CD8+ RORgt+ T-bet+ T cells, ex vivo and 
days 1-3 (n = 6) (E) Percentages of CD8+ IFNɣ+ T cells on day 2 (n = 21) (F) Geometric mean of IFNg 
expression by CD8+ IFNg+ T cells. Data shown is mean +/- standard error. Statistical significance 
(where * represents < 0.05, ** < 0.01 and **** < 0.0001) was determined using two-way repeated 
measures ANOVA with a Bonferroni multiple comparison post-test (C & D) or a paired t-test (E). 
UT: untreated.  
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6.3.10 mCRAMP increases CD8+ T cell viability cultured under Tc17-driving 
conditions 
 
One of the potential mechanisms through which mCRAMP could increase Tc17 
differentiation is by promoting the survival of CD8+ IL-17+ T cells and/or the death of non-
Tc17 subsets. I therefore performed an annexin/PI apoptosis assay to examine cell death in 
non-lineage-driving and Tc17 cultures treated with or without synthetic mCRAMP (Figure 
6.13). As discussed previously, it was only possible to analyse the CD8+ T cell population as a 
whole using this method. 
 
Figure 6.13 D shows there was a trend suggesting that mCRAMP increased the percentage of 
CD8+ annexin- PI- (“alive”) T cells when they were cultured under non-lineage-driving 
conditions in the absence of polarising cytokines, similarly to CD4+ T lymphocytes. However, 
this was not statistically significant. On the other hand, mCRAMP significantly decreased the 
percentage of CD8+ annexin+ PI+ (“necrotic”) T cells on days 1, 2 and 3 (Figure 6.13 H). For 
instance, the frequency of CD8+ annexin+ PI+ T cells dropped from 19.73% (+/- 1.79) to 14.40% 
(+/- 0.62) on day 2. No differences in the percentage of apoptotic (annexin+ PI-) T cells were 
observed between untreated and mCRAMP-treated samples (Figure 6.13 F). It is important 
to note to that an increase in the total number of CD8+ T lymphocytes in non-polarising 
cultures exposed to mCRAMP was observed on day 3 (Figure 6.13 B). As a result, it is difficult 
to conclude whether or not these differences were responsible for the increase in the total 
number of CD8+ T cells, or simply a result of increased proliferation.  
 
mCRAMP had no effect on the total number of CD8+ T cells following culture under Tc17-
driving conditions (Figure 6.13 C). However, mCRAMP significantly increased the percentage 
of CD8+ annexin- PI- (Figure 6.13 E) and decreased the percentage of CD8+ annexin+ PI+ T cells 
(Figure 6.13 I), but only on day 2. More specifically, mCRAMP increased the proportion of 
CD8+ annexin- PI- T cells from 69.13% (+/- 4.51) to 74.32% (+/- 4.14), and decreased CD8+ 
annexin+ PI+ from 14.78% (+/- 2.74) to 9.79% (+/- 2.30). No differences in the percentage of 
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Figure 6.13: mCRAMP increases the viability of CD8+ T cells. Whole single cell splenic suspensions 
were cultured under non-lineage-driving or Tc17-polarizing conditions, with or without 2.5 µM 
synthetic mCRAMP (A) Representative plots of annexin/PI staining of CD8+ T cells on day 2, 
assessed by flow cytometry (B) Total numbers of CD8+ T cells in non-lineage driving cultures (C) 
Total numbers of CD8+ T cells in Th17 cultures (D) Percentages of CD8+ annexin- PI- T cells on days 
1-3 following culture under non-lineage-driving conditions (n = 3) (E) Percentages of CD8+ annexin- 
PI- T cells on days 1-3 following culture under Th17-driving conditions (n = 6) (F) Percentages of 
CD8+ annexin+ PI- T cells on days 1-3 following culture under non-lineage-driving conditions (n = 3) 
(G) Percentages of CD8+ annexin+ PI- T cells on days 1-3 following culture under Th17-driving 
conditions (n = 6) (H) Percentages of CD8+ annexin+ PI+ T cells on days 1-3 following culture under 
non-lineage-driving conditions (n = 3) (I) Percentages of CD8+ annexin+ PI+ T cells on days 1-3 
following culture under Th17-driving conditions (n = 6). Data shown is mean +/- standard error. 
Statistical significance (where * represents < 0.05 and *** < 0.001) was determined using a two-
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Next, I sought to examine the effects of mCRAMP on the viability of CD8+ IL-17A+ and CD8+ 
IFNg+ T lymphocytes by analysing the uptake of a fixable live/dead stain (Figure 6.14). Using 
this method, I observed a significant decrease, from 14.35% (+/- 1.14) to 8.30% (+/- 0.79), in 
the percentage of dead CD8+ T cells on day 2 (Figure 6.14 B). This supports the results 
obtained from the annexin/PI apoptosis assay (on day 2), as well as the hypothesis that 
mCRAMP protects the CD8+ T cell population as a whole from death.  
 
Furthermore, mCRAMP significantly decreased the percentage of dead CD8+ IL-17A+ T 
lymphocytes from 9.36% (+/- 1.15) to 4.75% (+/- 0.72) (Figure 6.14 D). Interestingly, the 
percentage of dead CD8+ IFNg+ T cells in Tc17 cultures was also significantly reduced following 
exposure to mCRAMP (Figure 6.14 F: 3.92% +/- 0.58 compared to 5.63% +/- 0.71). This was 
in contrast to CD4+ IFNg+ T helper cells who were not protected from death.  
 
The results obtained from the annexin/PI apoptosis assay do not provide a clear answer as 
to whether or not mCRAMP enhances the survival of CD8+ T lymphocytes similarly to CD4+ T 
helper cells. The fact that significant differences were only observed on day 2 could indicate 
that these effects are not biologically relevant. However, the data generated by looking at 
the uptake of a live/dead stain imply that mCRAMP acts as a survival factor to increase the 
viability of all CD8+ T cells, whether they be IL-17+ or not. Further investigation (such as using 



































Figure 6.14: mCRAMP promotes the survival of CD8+ IL-17+ and IFNɣ+ T cells. Whole single cell 
splenic suspensions were cultured under Tc17-driving conditions, with or without 2.5 µM synthetic 
mCRAMP (A) Representative plots of dead CD8+ T cells on day 2 (gated on single, CD8+ 
lymphocytes), assessed by flow cytometry (B) Percentages of dead CD8+ T cells on day 2 (C) 
Representative plots of dead CD8+ IL-17A+ T cells on day 2 (gated on single lymphocytes that are 
CD8+ IL-17A+), assessed by flow cytometry (D) Percentages of dead CD8+ IL-17A+ T cells on day 2 
(E) Representative plots of dead CD8+ IFNɣ+ T cells on day 2 (gated on single lymphocytes that are 
CD8+ IFNɣ+), assessed by flow cytometry (F) Percentages of dead CD8+ IFNɣ+ T cells on day 2. Data 
shown is mean +/- standard error. N = 22. Statistical significance (where **** represents < 0.0001) 
was determined using a paired t-test. UT: untreated.  
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6.3.11 mCRAMP increases the proliferation of CD8+ T cells cultured under Tc17-
driving conditions 
 
An apparent increase in Tc17 differentiation could be explained, in part, by an increase in the 
proliferation of CD8+ IL-17+ T lymphocytes. To address this, I monitored the proliferation of 
these cells in IL-17-inducing cultures by CFSE dye dilution (Figure 6.15).  
 
Figure 6.15 shows that there was a significant decrease in the geometric mean of CFSE of 
total CD8+ T lymphocytes, suggesting that mCRAMP increases the proliferation of the CD8+ T 
cell population as a whole (Figure 6.15 B). This was in contrast to CD4+ T helper lymphocytes, 
which did not display any differences in their proliferative capacity. 
 
Due to high levels of cell death in stimulated, intracellular cytokine- and CFSE-stained 
cultures, I analysed the division of CD8+ RORgt+ and T-bet+ T lymphocytes to monitor the 
proliferation of Tc1 and Tc17 cells. The proliferation of CD8+ RORgt+ T cells was not 
significantly different between untreated and mCRAMP-treated samples (Figure 6.15 D). 
However, there was a trend suggesting that the geometric mean of CFSE of CD8+ RORgt+ T 
cells was decreased following exposure to mCRAMP, similarly to the whole CD8+ population. 
Nonetheless, these results imply that mCRAMP does not increase the proliferation of CD8+ 
RORgt+ T cells to boost Tc17 differentiation.  
 
On the other hand, the geometric mean of CFSE of CD8+ T-bet+ T cells was significantly 
increased following exposure to mCRAMP (Figure 6.15 F). This was also in contrast to CD4+ T 
lymphocytes and suggests that mCRAMP inhibits the proliferation of CD8+ T-bet+ T cells, 
which could account, in part, for the decrease in their frequency.  
 
These results indicate that mCRAMP increases the proliferation of the CD8+ T cell population 
as a whole but that this is not a result of enhanced proliferation of CD8+ RORgt+ T 
lymphocytes. This insinuates that there must be another subset of CD8+ T cells (not Tc1/Tc17) 





















Figure 6.15: mCRAMP increases CD8+ T cell proliferation. Whole single cell splenic suspensions 
were cultured under Tc17-driving conditions for 2 days, with or without 2.5 µM synthetic mCRAMP 
(A) Representative CFSE plot of CD8+ T cells, assessed by flow cytometry (B) Geometric mean of 
CD8+ CFSE+ T cells on day 2 (C) Representative CFSE plot of CD8+ RORɣt+ T cells, assessed by flow 
cytometry (D) Geometric mean of CD8+ RORɣt+ CFSE T cells on day 2 (E) Representative CFSE plot 
of CD8+ T-bet+  T cells, assessed by flow cytometry (F) Geometric mean of CD8 T-bet+ CFSE T cells 
on day 2. Data shown is mean +/- standard error. N = 4. Statistical significance (where * represents 
< 0.05 and ** < 0.01) was determined using a paired t-test. UT: untreated.    
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6.3.12 mCRAMP requires TGFb to enhance Tc17 differentiation in vitro 
 
mCRAMP increased PD1 expression by CD8+ T lymphocytes when cultured under non-
lineage-driving and Tc17-polarising conditions. However, the peptide only increased the 
frequency of CD8+ IL-17A+ T cells when they were generated in the presence of Tc17-
polarizing cytokines. This suggests that, like CD4+ T cells, there are at least two, separate T 
cell signalling pathways induced by mCRAMP, one of which requires IL-6, IL-23 and/or TGFb.  
 
mCRAMP required TGFb to boost the differentiation of CD4+ Th17 cells (Chapter 3: Figure 
3.19). To examine the requirement for TGFb in CD8+ Tc17 responses, I cultured whole single 
cell splenic suspensions with each cytokine alone, or by systematically omitting each one at 
a time, with or without synthetic mCRAMP (Figure 6.16).  
 
Figure 6.16 shows that the geometric mean of RORgt expression was not significantly 
different between UT and mCRAMP-treated samples when the cells were cultured in the 
absence of TGFb (Figure 6.16 A). This suggests that mCRAMP requires TGFb to promote Tc17 
differentiation, similarly to CD4+ Th17 lymphocytes. 
 
Accordingly, mCRAMP failed to significantly increase the percentage of CD8+ RORgt+ T cells 
when the cells were cultured with IL-6 and IL-23 (in the absence of TGFb) or with IL-23 alone 
(Figure 6.16 B). Furthermore, mCRAMP increased the percentage of CD8+ RORgt+ T cells, from 
14.56% (+/- 1.80) to 28.19% (+/- 1.01), when generated in the presence of just TGFb. 
However, a significant increase in the percentage of CD8+ RORgt+ T cells was observed 
following exposure to mCRAMP when the cells were cultured with IL-6 alone. There was also 
a trend suggesting a similar increase in IL-23-stimulated cultures (p = 0.16) This could be 
explained by an increasing number of CD8+ T cells transiently expressing very low levels of 
RORgt, which is likely insufficient to have any downstream effects on IL-17 production.  
 
An increase in RORgt expression did not necessarily translate into IL-17 production (Figure 
6.16 C). Overexpression of RORgt in CD8+ T lymphocytes under non-polarizing conditions 
induces only low frequencies of IL-17-producing cells, indicating that RORgt is necessary but 
not sufficient for IL-17 expression531. Furthermore, similarly to in CD4+ T helper cells, several 
CHAPTER 6: RESULTS 
 204 
other transcription factors act cooperatively to promote Tc17 differentiation and IL-17 
production528. For example, IRF4 controls Tc17 development by balancing the levels of RORgt, 
Eomes and FOXP3532. It is therefore likely that all three Tc17-polarizing cytokines are required 














































































Figure 6.16: mCRAMP fails to increases RORɣt expression in CD8+ T cells in the absence of TGFβ. 
Whole single cell splenic suspensions were cultured with different combinations of IL-6 (20 ng/mL), 
IL-23 (20 ng/mL) and TGFβ (3 ng/mL), with or without 2.5 µM synthetic mCRAMP (A) Geometric 
mean of RORɣt expression by CD8+ T cells on day 1 (B) Percentages of CD8+ RORɣt+ T cells on day 
1 (C) Percentages of CD8+ IL-17A+ T cells on day 2. Data shown is mean +/- standard error. N = 6. 
Statistical significance (where * represents < 0.05, ** < 0.01 and *** < 0.001) was determined 
using a two-way repeated measures ANOVA with a Bonferroni multiple comparison post-test. UT: 











































































































Cytotoxic CD8+ T lymphocytes can be subdivided into different subsets, reminiscent of T 
helper cell classification528. Tc17s display highly suppressed cytotoxic function and express 
type 17 markers, such as RORgt, IL-23R and IL-17531. The polarising conditions required for 
the differentiation of Tc17 cells, as well as their cytokine profile, are similar to those of CD4+ 
Th17 lymphocytes531. More specifically, naïve CD8+ T cells can be induced to differentiate into 
an IL-17-producing subset in the presence of IL-6 and TGFb531. IL-6 is sufficient to activate 
STAT3 and induce the expression of IL-21 and IL-23R in differentiating CD8+ T cells531. 
However, IL-6 is also crucial for the development of cytotoxic potential545. The role of TGFb 
is therefore to target Eomes and T-bet to suppress IFNg/granzyme B expression and offset 
the pro-cytotoxic effects of IL-6546,547. Similarly to CD4+ T cells, IL-23 is not critical for Tc17 
differentiation: IL-23 alone only slightly induces IL-17A expression in naïve CD8+ T cell 
cultures548. Rather, IL-23 promotes the stabilisation, proliferation and pathogenicity of the 
CD8+ IL-17+ population126,549.  
 
Considering the numerous similarities with regard to their developmental regulation, it 
stands to reason that mCRAMP may exert similar effects on CD8+ T cells compared to CD4+. I 
have shown that mCRAMP is a CD4+ Th17 differentiation enhancing factor. I therefore sought 
to determine whether this host defence peptide exerts similar effects on CD8+ T cells. 
 
 
6.4.1 mCRAMP enhances Tc17 differentiation  
 
Preliminary data from the laboratory demonstrated that mCRAMP-deficient mice were 
incapable of producing IL-17 during inflammation induced by HKST (Chapter 1: Figure 1.10). 
CD8+ T cells can produce IL-17 in response to various stimuli and may therefore contribute to 
the type-17 response induced by HKST533. CD4+ T lymphocytes that developed in the absence 
of mCRAMP did not possess an obvious underlying defect that could be responsible for their 
inability to produce IL-17 during inflammation in vivo. I have shown that this is also true for 
CD8+ T cells: CD8+ lymphocytes from naïve mCRAMP KO mice displayed relatively normal 
cytokine responses at resting state and were capable of producing IL-17 following culture 
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with exogenous cytokines (IL-6, IL-23 and TGFb), although perhaps to a slightly less extent 
than WT cells.  
 
 
6.4.1.1 mCRAMP increases CD8+ T cell activation  
 
mCRAMP increased the percentage of activated CD8+ CD62L- CD44+ T cells, indicating that 
the peptide increases the activation status of CD8+ T lymphocytes cultured under Tc17-
polarizing conditions, similarly to CD4+ T cells.  
 
Furthermore, mCRAMP significantly upregulated the expression of PD1. As discussed 
previously, PD1 has long been associated with T cell exhaustion550–552. For example, Ma et al. 
demonstrated that CD8+ PD1hi T cells are significantly enriched in hepatocellular carcinoma 
tumours compared to adjacent non-tumour tissue and highly express exhaustion-related 
inhibitory markers such as TIM3 and CTLA4551. Intrahepatic hepatitis C virus (HCV)-specific 
CD8+ T cells from patients suffering from chronic HCV infection are also highly PD1 positive 
and profoundly dysfunctional552. However, my results do not suggest that mCRAMP increases 
CD8+ T cell exhaustion, as they do not display a compromised capacity to produce pro-
inflammatory cytokines and appear to proliferate more than their untreated counterparts. 
Nonetheless, future investigations will include long-term cultures (up to 14 days) in order to 
assess whether or not mCRAMP does indeed have any effect on T cell exhaustion.  
 
The above findings are in accordance with those published by Petrelli et al., who found that 
CD8+ PD1+ T lymphocytes that accumulate in the synovial fluid of patients with juvenile 
idiopathic arthritis are metabolically active effector cells that do not display an exhausted 
signature553. Gene expression profiling revealed that these CD8+ PD1+ T cells were enriched 
for pathways relating to cell cycle, proliferation, cytotoxicity and pro-inflammatory 
signalling553. The authors suggested that increased PD1 expression is in fact an indicator of 
functional T cell adaptation to the chronically inflamed milieu553. Moreover, Blackburn et al. 
found that while cytokine production did not strictly correlate with the amount of PD1 
expressed by CD8+ T cells, it was tightly linked to their ability to degranulate554. Tc17s display 
suppressed cytotoxic function531. It is therefore possible that increased PD1 reflects this and 
is an indicator of Tc17 potential.   
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On the other hand, the upregulation of PD1 could represent a mechanism through which 
mCRAMP reduces the pathogenic potential of CD8+ T cells. Zhang and Xu demonstrated that 
activated PDL1+ neutrophils inhibit the proliferation of PD1+ T cells and dampen T cell-
mediated responses in vitro555. By increasing the percentage of CD8+ PD1+ T lymphocytes, 
mCRAMP could consequently render them more vulnerable to suppression.  
 
 
6.4.1.2 mCRAMP increases the frequency of IL-17-producing CD8+ T lymphocytes   
 
The addition of mCRAMP to Tc17 cultures led to an increase in the expression of the RORgt 
master regulator. Similarly to during Th17 differentiation, RORgt plays an important role in 
Tc17 polarisation531. For instance, Huber and colleagues observed a significant induction of 
Rorc mRNA in CD8+ T cells cultured in the presence of TGFb and IL-6531. Furthermore, Rorc 
gene expression was increased in CD8+ IL-17+ T cells in psoriatic skin, unlike CD8+ IL-17- T 
lymphocytes which expressed high levels of Tbx21 (T-bet)556. Mechanistically, RORgt 
promotes IL-17 production by directly targeting the IL-17 conserved noncoding sequence 2 
(CNS-2) enhancer region in CD8+ T cells557.  
 
However, overexpression of RORgt in CD8+ T lymphocytes under non-polarizing conditions 
induces only low frequencies of IL-17-producing cells, indicating that RORgt is necessary but 
not sufficient for IL-17 expression531. This is likely due to the antagonising activity of Eomes 
on RORgt function: levels of this transcription factor negatively correlate with Tc17 
development531. Several other factors are therefore required to promote the suppression of 
Eomes and act cooperatively on the Il17 locus to effectively induce expression of this 
cytokine557. For example, STAT3 and IRF4 work together to function as a molecular switch for 
cell fate decisions in CD8+ T cells557. IRF4-deficient mice display enhanced expression of 
Eomes and impaired IL-17 production532.  
 
The increase in RORgt expression following exposure to mCRAMP was accompanied by a 
concentration-dependent increase in the percentage of CD8+ IL-17A+ T cells. More 
specifically, this rose 1.56-fold, which was around half that observed in CD4+ T helper cells 
(Chapter 3: Figure 3.8). There is very little published work that has tried to identify Tc17 
enhancing factors. For instance, while the AHR agonist FICZ increases IL-17 production by 
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CD4+ T cells, no such effect is seen in CD8+ T lymphocytes558. Pick and colleagues 
demonstrated that CTLA4 showcased a cell intrinsic ability to enhance Tc17 differentiation 
by sustaining the expression of IL-17-inducing factors such as STAT3, RORgt and IRF4559. 
However, to my knowledge, no other direct Tc17 endogenous or exogenous inducing factors 
have been identified541.  
 
IL-17A production was significantly increased when culturing sorted CD8+ T cells under Tc17-
polarizing conditions with mCRAMP, indicating that similarly to CD4+ T lymphocytes, the 
peptide can act directly on this cell type. However, the percentages of CD8+ IL-17A+ T cells 
obtained using pure CD8 cultures were substantially lower than those achieved when using 
whole single cell splenic suspensions. One possible reason for this is that DCs provide higher 
quality activation signals than aCD3/CD28 antibodies. CD8+ T lymphocytes may also require 
additional signals or growth factors that are provided by other cell types present within the 
spleen. To address this, multiplex cytokine profiling could be performed on supernatants 
from splenic cultures, similar to that performed by Lehmann et al., to identify potential 
mediators that could then be added to CD8+ T cells to boost Tc17 differentiation560.  
 
In steady state, Tc17 cells predominantly produce IL-17F, unlike CD4+ Th17 lymphocytes, 
which only express IL-17A398. This is in accordance with my data, which revealed greater 
frequencies of CD8+ IL-17F+ T cells in the liver, lungs, spleen, mesenteric lymph nodes and 
Peyer’s patches, compared to CD8+ IL-17A+. In addition, Chang and colleagues detected the 
presence of IL-17A and IL-17F double-producing CD8+ T cells in bronchoscopic biopsies from 
patients with chronic obstructive pulmonary disease (COPD), at percentages similar to CD4+ 
T cells540. I found that mCRAMP induced a similar IL-17A/IL-17F expression profile in CD8+ T 
cells compared to CD4+ when using a TGFb/IL-6 differentiation protocol, which is potentially 
due to their similar regulatory requirements557. More specifically, mCRAMP increased the 
percentages of IL-17F+ and IL-17A+ IL-17F+ T cells in Tc17 cultures. However, unlike CD4+ T 
lymphocytes, mCRAMP also significantly increased the frequency of CD8+ IL-17A single-
positive lymphocytes.  
 
mCRAMP upregulated the expression of AHR in CD4+ T cells and acted via this transcription 
factor to specifically promote the development of CD4+ IL-17A/IL-17F dual-producers 
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(Chapter 4: Figures 4.6 & 4.7). Hayes and colleagues demonstrated that Tc17s express 
baseline Ahr mRNA but do not upregulate its expression during polarisation (unlike CD4+ T 
lymphocytes), indicating that AHR ligands play a greater role in Th17 development compared 
to Tc17541. My results diverge from this: I found that the frequency of CD8+ AHR+ T cells 
increased during polarisation and that mCRAMP increased this further on day 1 (but not on 
day 2). Potential explanations as to the differences between my results and the Hayes study 
could include different cells (naïve CD8+ T lymphocytes vs. whole single cell splenic 
suspensions) and/or polarizing cocktail (Hayes: no IL-23, added IL-1b)558.  
 
Based on observations made for CD4+ T lymphocytes, I sought to determine what effects an 
AHR antagonist would have on IL-17 production by CD8+ T cells following exposure to 
mCRAMP. Similarly to CD4+ T lymphocytes, the addition of CH223191 abolished the increase 
in the percentage of CD8+ IL-17A+ Il-17F+ T cells normally induced by the peptide. 
Furthermore, the AHR antagonist also prevented an increase in the frequency of CD8+ IL-17A 
single-positive cells. This was in contrast to CD4+ T lymphocytes, who displayed no significant 
differences in the frequency of IL-17A+ IL-17F- cells. This highlights potential differences 
between CD4+ and CD8+ T lymphocytes and suggests that mCRAMP enhances the generation 
of CD8+ IL-17A+ IL-17F- and IL-17A/IL-17F co-expressers in an AHR-dependent manner. 
 
 
6.4.1.3 mCRAMP skews cytotoxic T cell differentiation away from the Tc1 lineage 
 
mCRAMP downregulated the expression of genes classically associated with the Th1 lineage 
in CD4+ T cells cultured under Th17-driving conditions (Chapter 4: Figure 4.1). Furthermore, 
mCRAMP decreased the frequency of CD4+ T-bet+ and CD4+ IFNg+ T cells in Th17 cultures 
(Chapter 4: Figure 4.5). Similar effects were observed in CD8+ T lymphocytes, suggesting that 
this host defence peptide also skews CD8+ T cell differentiation away from the Tc1 lineage to 
promote Tc17 development.  
 
Master regulators, such as T-bet, shape immune responses by activating one genetic program 
whilst simultaneously silencing the activity of factors that drive the differentiation of other 
subsets465,466. For example, T-bet and Eomes drive Tc1 polarization but have been shown to 
also suppress alternative CD8+ T cell fates (Tc2 and Tc17)529,561. Indeed, Zhu and colleagues 
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demonstrated that 2 to 3-fold more T-bet-deficient CD8+ T lymphocytes became IL-17 
producers when cultured under Tc17-polarizing conditions, compared to WT cells561. Tc17s 
therefore express diminished levels of T-bet and Eomes126. To confirm these results, future 
investigations should explore changes in the expression of Eomes, as this transcription factor 
is also crucial for the development of Tc1 lymphocytes529. 
 
Tc1 lymphocytes produce large quantities of IFNg528. mCRAMP significantly decreased the 
percentage of CD8+ IFNg+ T cells when cultured under Tc17-driving conditions, reflecting the 
downregulation of T-bet expression and the skewing of cytotoxic T cell differentiation. IFNg 
is a well-known suppressor of type-17 immune responses39. Similarly to CD4+ T cells, the 
downregulation of T-bet and subsequent reduction in IFNg production therefore supports 
the hypothesis that mCRAMP skews CD8+ T cell differentiation away from the Tc1 lineage and 
in doing so, also promotes Tc17 development.  
 
Tc17 effector cells are highly plastic and can convert into cytotoxic IFNg-producing cells that 
express both RORgt and T-bet542. For instance, IL-12 induces the conversion of Tc17 
lymphocytes into IL-17/IFNg dual-producers542. Satoh et al. demonstrated that this is driven 
by the epigenetic suppression of the Socs3 gene promoter543. In the present study, I did not 
detect any CD8+ IL-17A+ IFNg+ T cells in vitro but a significant proportion of CD8+ T 
lymphocytes expressed both RORgt and T-bet. Similarly to CD4+ T cells, the addition of 
mCRAMP decreased their frequency following 3 days of culture under Tc17-driving 
conditions. CD8+ T cells that co-express RORgt and T-bet are expanded in patients with distal 
bile duct cancer: they display a hyperactivated TCR signalling signature, which results in 
enhanced proliferation and a strong pro-inflammatory phenotype but impaired ability to 
sustain cytotoxic immune responses544. The reduced frequency of this cellular subset could 
indicate that mCRAMP does not increase Tc17 pathogenicity, or at least not by upregulating 
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6.4.2 Mechanism of action  
 
6.4.2.1 mCRAMP increases the expression of receptors required for Tc17 differentiation 
 
CD4+ T lymphocytes did not upregulate their expression of IL-23R or IL-6R following exposure 
to mCRAMP (Chapter 3: Figure 3.3.13). However, I observed a significant increase in the 
percentage of CD8+ IL-6R+ T lymphocytes on day 1 when cultured under Tc17-driving 
conditions and in the presence of mCRAMP. Signalling via IL-6R induces the activation of 
STAT3, which promotes the transcription of signature Tc17 genes such as Rorc, Il21 and 
Il23r531. Yang et al. found that IL-6R was expressed by naïve (CD44lo), but not activated 
(CD44hi), CD8+ T cells, and that the frequency of IL-6R-expressing CD8+ T cells was lower than 
in CD4+ T lymphocytes562. This is in accordance with the data presented here. Furthermore, 
the authors suggested that the expression of IL-6R defines a subset of CD8+ T cells that are 
capable of producing IL-21, an important cytokine required for the expansion of Tc17 
lymphocytes562. The early upregulation of IL-6R by mCRAMP could therefore increase Tc17 
potential.  
 
In addition, IL-23R is not expressed by naïve CD8+ T cells and is upregulated following IL-6 
induction556. Ciric and colleagues demonstrated that IL-23 drives the development of 
pathogenic IL-17-producing CD8+ T cells549. More specifically, Tc17s generated with TGFb and 
IL-6 were not diabetogenic, unlike those treated with IL-23, which specifically upregulated IL-
17F and potently induced disease549. Furthermore, CD8+ IL-17+ T lymphocytes from EAE mice 
display elevated levels of IL-23R, which increases their pathogenicity532. I have shown that 
mCRAMP significantly increased the percentage of CD8+ IL-23R+ T cells on day 2. This could 
increase the sensitivity of CD8+ T lymphocytes to IL-23 and subsequently promote the 
generation of a more pathogenic population of IL-17-producing cells.  
 
On the other hand, I have provided evidence suggesting that mCRAMP requires TGFb to 
increase RORgt expression and thereby enhance Tc17 differentiation. It is therefore not clear 
how an increase in the expression of IL-6R and IL-23R could help the peptide achieve this. In 
the future, it will therefore be necessary to also examine the expression of TGFbR.  
 
Nonetheless, the changes observed in the expression of IL-6R and IL-23R by CD8+ T cells were 
contrary to those found for CD4+ T lymphocytes, which displayed no significant differences 
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following exposure to mCRAMP. This supports the hypothesis that mCRAMP exhibits 
differential effects on CD4+ and CD8+ T cells and suggests that the mechanism it employs to 
promote Tc17 differentiation differs from that which amplifies Th17 responses. However, it 
is also possible that, due to high variability, the observations made in the present study are 
inaccurate. It will therefore be beneficial to repeat the above experiments and analyse the 
expression of IL-6R, IL-23R and TGFbR by PCR, instead of flow cytometry.  
 
 
6.4.2.2 mCRAMP is a CD8+ T cell survival factor  
 
mCRAMP increased the viability of the whole CD8+ T cell population when cultured with IL-
6, IL-23 and TGFb, as determined by annexin/PI staining; although, unlike CD4+ T 
lymphocytes, this was only statistically significant on day 2 and therefore may not be 
biologically relevant. However, examining the survival of CD8+ T cells (also on day 2) by 
analysing the uptake of a fixable live/dead stain revealed that mCRAMP significantly 
decreased the percentages of ‘dead’ total CD8+, IL-17A+ and IFNg+ T lymphocytes. This 
suggests that mCRAMP is a CD8+ T cell survival factor. These results are in contrast to those 
published by Mader and colleagues, who demonstrated that human cathelicidin (LL-37) 
induced granzyme-mediated apoptosis in cytotoxic CD8+ T lymphocytes378. However, the 
concentration of LL-37 used in the Mader study (40 µg/mL) was substantially larger than what 
I typically add to my cultures (2.5 µM, approx. 10 µg/mL)378. It is therefore possible that the 
observations made by Mader et al. are a result of the cytotoxic side effects of the peptide, 
which have frequently been noted at high concentrations. 
 
Unlike for CD4+ T helper cells, there appeared to be a small but significant increase in the 
proliferation of total CD8+ T cells. This could account for enhanced CD8 survival and supports 
observations made by Mihailovic and colleagues, who demonstrated that the immunization 
of ApoE-/- mice with synthetic mCRAMP increased the proliferation of cytotoxic CD8+ T 
cells563. However, mCRAMP did not increase the proliferation of CD8+ RORgt+ T cells, 
suggesting that there must be another subset that are proliferating more in response to 
mCRAMP.   
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TGFb alone inhibits CD8+ T cell proliferation but this is abrogated in the presence of IL-6, 
which instead promotes expansion546. An increase in proliferation in response to mCRAMP 
could therefore represent one of the downstream effects of boosting TGFb signals. However, 
mCRAMP also decreased the percentage of necrotic CD8+ T cells in the absence of Tc17-
stimualting cytokines, indicating once again that there are at least two, different T cell 
signalling pathways induced by mCRAMP, one of which is non-specific and does not require 
TGFb to protect CD8+ T lymphocytes from death.  
 
Liu et al. found that Tc17 cells are more resistant than Tc1s to activation-induced cell 
death564. Furthermore, terminally differentiated or senescent T cells are more prone to 
apoptosis565. Flores-Santibáñez and colleagues demonstrated that Tc17 cells present high 
levels of the CD73 ectonucleotidase and produce significant quantities of adenosine, which 
arrests CD8+ T cell differentiation, favours IL-17 production and promotes stem cell-like 
properties565. Tc17 lymphocytes therefore display a less differentiated status and 
consequently suffer significantly lower apoptosis-induced cell death than Tc1 cells565. 
mCRAMP could therefore increase overall T cell viability simply by skewing cytotoxic T cell 
differentiation towards the Tc17 lineage.  
 
mCRAMP decreased the percentage of dead CD8+ IL-17A+ T cells but had no significant effect 
on the proliferation of CD8+ RORgt+ T lymphocytes, indicating that the peptide does not boost 
Tc17 differentiation by increasing the proliferative capacity of these subsets. In vitro-
generated Tc17s present a memory phenotype566. Nanjappa et al. observed that memory 
Tc17 cells display higher levels of basal homeostatic proliferation and were more resistant to 
apoptosis than Tc1s, despite expressing lower levels of anti-apoptotic molecules such as BCL2 
and BCL-XL567. Moreover, another study has shown that, unlike naïve CD8+ T cells, memory 
CD8+ T lymphocytes stimulated in the presence of TGFb display enhanced survival and 
increased production of IL-17568. One might therefore conclude that, by boosting TGFb and 
its downstream effects, mCRAMP increases this memory phenotype, which protects Tc17 
cells from death and amplifies Tc17 differentiation.  
 
On the other hand, mCRAMP also significantly increased the viability of CD8+ IFNg+ T 
lymphocytes. This was in contrast to CD4+ IFNg+ T helper cells, who were not protected from 
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death. Interestingly, mCRAMP decreased the proliferation of CD8+ T-bet+ T lymphocytes in 
Tc17 cultures. These cells likely represent those producing IFNg and a reduction in their 
proliferative capacity may account for, in part, the decrease observed in their frequency but 
not an increase in their survival. Nonetheless, this highlights a clear difference in the effects 
of mCRAMP on CD8+ T lymphocytes compared to CD4+ and taken together, suggests that the 
peptide does not increase Tc17 polarization by simply protecting CD8+ IL-17 producers and/or 
by promoting the death of non-Tc17 cell types.  
 
 
6.4.2.3 mCRAMP requires TGFb to enhance Tc17 differentiation in vitro 
 
Similarly to CD4+ T lymphocytes, mCRAMP significantly upregulated the expression of PD1 by 
CD8+ T cells when the cells were cultured under non-lineage-driving conditions. However, the 
peptide had no effect on the percentages of CD8+ IL-17+ T lymphocytes in the absence of 
Tc17-polarizing cytokines. This suggests that at least two, separate T cell signalling pathways 
are induced by mCRAMP, which are likely shared between CD4+ and CD8+ T lymphocytes.  
 
More specifically, my results indicate that the pathway responsible for increasing the 
development of IL-17-producing CD8+ T cells cultured under Tc17-driving conditions requires 
IL-6, IL-23 and/or TGFb. mCRAMP failed to increase RORgt expression by CD8+ T lymphocytes 
when they were generated in the absence of TGFb. This supports the hypothesis that, 
similarly to CD4+ T cells, mCRAMP specifically requires TGFb to promote Tc17 differentiation. 
TGFb helps maintain an IL-17 producing subset by repressing IL-6-induced cytotoxic 
differentiation via STAT3 and RORgt, which could be enhanced by mCRAMP557.  
 
However, the contribution of TGFb to Tc17 skewing may not be as important as for Th17 
differentiation, at least in vivo. For example, TGFb neutralisation in mice does not have a 
considerable effect on the frequency of CD8+ IL-17+ T cells569. Furthermore, transgenic 
TGFbRIIDN mice that express a dominant negative TGFb receptor and in which TGFb 
signalling is ultimately impaired, cannot produce CD4+ Th17 cells but CD8+ IL-17+ lymphocytes 
are still present570.  The physiological relevance of the effects of mCRAMP on CD8+ Tc17 cells 
therefore remains unclear.  
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6.4.3 Are Tc17 cells generated in the presence of mCRAMP more or less pathogenic?  
 
Ciric and colleagues demonstrated that IL-23 promotes the pathogenicity of CD8+ Tc17s by 
upregulating their expression of IL-17F and not IL-17A549. I have shown that mCRAMP 
significantly increased the frequency of CD8+ IL-17F single-positive cells, as well as IL-17A/IL-
17F dual-producers. Unlike CD4+ T cells, mCRAMP may therefore promote the development 
of a more pathogenic population of Tc17 lymphocytes, which could promote autoimmunity 
in certain conditions such as multiple sclerosis, where this cytotoxic T cell subset is 
enriched532.   
 
Furthermore, mCRAMP significantly increased the frequency of CD8+ IL-17A single-positive T 
cells. Huber and colleagues demonstrated that IL-17A produced by Tc17 lymphocytes 
contributes to the initiation of CNS autoimmunity532. More specifically, surface-bound IL-17A 
promoted the generation of CD4+ Th17 cells and rendered them more encephalitogenic 
during induction of EAE532. An increase in the proportion of CD8+ IL-17A+ IL-17F- T cells could 
therefore be another indicator of a potentially more pathogenic population of Tc17s.  
 
In addition, increasing the longevity of CD8+ IL-17+ T cells could result in a prolonged period 
where they are able to produce inflammatory cytokines, which could in turn lead to greater 
immunopathology if left unchecked. Frohm et al. reported that human cathelicidin (LL-37) is 
upregulated in the psoriatic epidermis284. Moreover, IL-17-producing CD8+ T cells accumulate 
in psoriatic skin lesions and have been implicated in driving disease pathology: neutralization 
of Tc17 lymphocytes effectively prevents psoriasis development in vivo571,572. Cathelicidin 
could therefore contribute to disease activity by increasing the survival of pathogenic CD8+ 
Tc17 cells.  
 
On the other hand, human Tc17s have been shown to harbour potent immune suppressive 
potential compared to other cytotoxic CD8+ subsets573. As a result, Tc17s may play an 
important regulatory function against effector CD4+ cells. Indeed, acute relapses of multiple 
sclerosis are characterised by a deficit of CD8+ T cell-mediated immune suppression574. It is 
therefore possible that by enhancing Tc17 differentiation, mCRAMP promotes the 
development of a less pathogenic and more regulatory subset of CD8+ T cells.  
 




To summarize, I have shown that mCRAMP acts directly on CD8+ T lymphocytes in vitro to 
increase their activation status, upregulate RORgt expression and boost Tc17 polarization. 
My results also indicate that, similarly to CD4+ T helper cells, mCRAMP downregulates T-bet 
expression and decreases IFNg production, suggesting that the peptide skews cytotoxic CD8+ 
T cell differentiation away from the Tc1 lineage. Furthermore, at least two, separate T cell 
signalling pathways are induced by mCRAMP, one of which requires TGFb in order to amplify 
IL-17 production and one which increases PD1 expression even in the absence of polarizing 
cytokines.   
 
However, I have also provided evidence that suggests mCRAMP exerts differential effects on 
CD4+ and CD8+ T cells. For example, mCRAMP significantly increases the percentage of CD8+ 
IL-17A+ IL-17F- T cells, upregulates their expression of IL-6R and IL-23R and increases the 
proliferation of the CD8+ T cell population as a whole, none of which was the case for CD4+ T 
lymphocytes. In addition, I observed several differences in the viability of CD8+ T cells 
exposed to mCRAMP. More specifically, mCRAMP failed to protect CD4+ IFNg+ T helper cells 
from death but the peptide significantly increased the survival of CD8+ IFNg+ Tc17s, despite 







































CHAPTER 7: CONCLUDING REMARKS 
 219 
I have shown that mouse cathelicidin (mCRAMP) acts directly on CD4+ and CD8+ T 
lymphocytes to enhance the development of IL-17-producing cells and skew differentiation 
away from the Th1/Tc1 lineage. Furthermore, I have provided evidence suggesting that 
mCRAMP induces at least two, different signalling pathways in T lymphocytes. More 
specifically, mCRAMP required TGFb to increase RORgt expression. However, mCRAMP also 
upregulated PD1 and promoted the survival of both CD4+ and CD8+ T cells when they were 
cultured under non-lineage-driving conditions in the absence of polarizing cytokines.  
 
I have also highlighted a requirement for T cells to sense mCRAMP during the first 24 hours 
of activation in order to amplify type-17 responses, implying that this interaction takes place 
in the lymph nodes in vivo. In addition, my results suggest that neutrophils are the likely 
cellular source of this host defence peptide during inflammation induced by heat-killed S. 









(IL-17A+ IL-17F+: AHR-dependent) 








↓ Th1 genes 
(e.g. IL2, BCL3,  
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Figure 7.1: mCRAMP is a Th17 differentiation enhancing factor. During inflammation induced by heat-
killed Salmonella typhimurium, neutrophils are recruited to the draining lymph nodes where they release 
the host defence peptide, mCRAMP. mCRAMP acts directly on naïve T cells during the first 24 hours of 
activation to increase their activation status and viability. mCRAMP downregulates the expression of 
Th1-related and anti-Th17 genes to decrease T-bet and increase RORɣt expression, thereby skewing T 
helper cell differentiation away from the Th1 lineage and towards a Th17 phenotype. mCRAMP 
specifically promotes the development of IL-17A/IL-17F dual producers in an AHR dependent manner, 
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7.1 mCRAMP is a novel Th17 and Tc17 differentiation enhancing factor 
 
In addition to cytokines such as IL-23, which enhances IL-17 production by CD4+ Th17 (and 
CD8+ Tc17) cells, a number of other exogenous and endogenous Th17 inducers of varying 
potency have previously been identified. For example, Song et al. demonstrated that vitamin 
C increased the percentage of CD4+ IL-17+ T lymphocytes in vitro following three days of 
culture under Th17-driving conditions, although it did not increase RORgt expression or have 
any effect on IFNg production (unlike mCRAMP)575. Furthermore, as discussed previously, 
Duarte et al. reported that culturing sorted naïve CD4+ T cells under Th17-driving conditions 
with AHR agonists, such as FICZ, TCDD, ITE (2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic 
acid methyl ester) and 3-MC (3-methylcholanthrene), increased IL-17 production around 2-
fold474. Neutrophil elastase has also been shown to promote human Th17 differentiation by 
processing DC-derived CXCL8 into a truncated, potent Th17-inducing form234. 
 
However, there is very little published work that has tried to identify CD8+ Tc17 enhancing 
factors. For instance, while AHR agonists increase IL-17 production by CD4+ T lymphocytes, 
Hayes and colleagues demonstrated that CD8+ Tc17 cells were largely refractory to 
exogenous FICZ541. They suggested that this was because Tc17s express baseline Ahr mRNA 
but do not upregulate its expression during polarisation (unlike CD4+ T lymphocytes), 
indicating that AHR ligands and the activation of the AHR pathway may play a greater role in 
Th17 development compared to Tc17541.  
 
I have shown that mCRAMP significantly increased the frequency of CD4+ IL-17+ T cells in 
Th17 cultures. The fold change in the number of IL-17-producing CD4+ T lymphocytes (6.5-
fold in sorted CD4+ T cells; 1.99-fold in splenic cultures) suggests that mCRAMP is of equal or 
superior potency compared to previously identified Th17 enhancers. Moreover, mCRAMP 
also amplified the differentiation of CD8+ Tc17 cells. mCRAMP therefore represents a novel, 
potent, locally produced Th17 and Tc17 differentiation enhancing factor that contributes to 
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7.2 mCRAMP is a T cell survival factor  
 
The present study has uncovered several novel findings. Cathelicidin has been shown to 
suppress apoptosis of several cell types, including cardiomyocytes, endothelial cells, 
keratinocytes and dermal fibroblasts358,414,415,576. I have shown that mCRAMP increases CD4+ 
and CD8+ T cell viability, which is contrary to published work by Mader et al., who 
demonstrated that human cathelicidin (LL-37) induces granzyme-mediated apoptosis of 
regulatory and CD8+ cytotoxic T lymphocytes359,360. To my knowledge, this is the first 
demonstration of a neutrophil peptide increasing the survival of T cells. 
 
Interestingly, mCRAMP protected CD4+ IL-17A+ T cells from death, but not those that 
produced IFNg. The fact that this host defence peptide appears to protect one T helper cell 
subset from death over another is quite unusual, although several factors have been shown 
to selectively promote apoptosis of specific CD4+ T lymphocytes. For example, galectin-1 
functions as a Th2 cytokine that preferentially induces Th1 apoptosis577. Similarly, IL-10 
controls Th2 cell survival by upregulating granzyme B expression during allergic airway 
inflammation578. On the other hand, Elyaman and colleagues suggested that IL-9 could act as 
a survival factor for regulatory T lymphocytes, as this cytokine rescued Tregs from apoptotic 
cell death in vitro579.  
 
These differences in survival were not a result of changes in the proliferative capacity of CD4+ 
RORgt+ or T-bet+ T cells. This is similar to findings by Coccia et al., who demonstrated a key 
role for IL-1b and IL-1R in the survival of pathogenic Th17 cells in the colon: the authors 
showed that reduced accumulation of naïve CD4+ T lymphocytes from IL-1R-deficient mice 
following adoptive transfer to RAG-/- animals was not caused by impaired proliferation or 
migration of these cells; instead, the authors suggested that IL-1b promoted Th17 survival by 
upregulating the expression of anti-apoptotic proteins such as BCL2 and BCL-XL580.  
 
 
7.3 The potential importance of mCRAMP-induced IL-2 suppression   
 
mCRAMP significantly decreased the expression of IL-2 in CD4+ T lymphocytes cultured under 
Th17-driving conditions. This was confirmed by measuring the concentration of IL-2 in cell 
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culture supernatants, which showed an almost complete suppression of production 
following exposure to mCRAMP.  
 
IL-2 is a potent Th17 antagonist and I have highlighted multiple pathways that are potentially 
modulated by mCRAMP, which regulate the inhibitory effects of this cytokine442. For 
example, mCRAMP requires TGFb to increase RORgt expression and has previously been 
shown to suppress IL-2462. In addition, mCRAMP upregulates the aryl hydrocarbon receptor 
(AHR), which cooperates with STAT3 to induce the expression of Aiolos; Aiolos binds to the 
Il2 promoter and induces chromatin modifications that result in IL-2 silencing478. mCRAMP 
also downregulates the expression of EOS, which is required for IL-2 production by CD4+ T 
cells461. Due to the multitude of pathways influenced by mCRAMP which affect IL-2 
production, one might speculate that the downregulation of this cytokine is one of the key 
mechanisms through which it acts to enhance Th17 (and Tc17) differentiation. It would 
therefore be interesting to determine whether the addition of recombinant IL-2 to Th17 
cultures abolishes the increase in IL-17-producing T lymphocytes normally induced in 
response to mCRAMP.  
 
IL-2 is a key factor that drives the clonal proliferation of activated T lymphocytes581. One 
might therefore predict that the suppression of IL-2 production by mCRAMP would result in 
reduced T cell proliferation. For example, this could account for a decrease in the number of 
T-bet/IFNg-expressing cells. However, this was not the case. Nonetheless, neutrophils are 
prominent producers of mCRAMP and have been shown to strongly inhibit T cell proliferation 
under certain conditions249,582. One might therefore speculate that the release of neutrophil-
derived cathelicidin and the subsequent suppression of IL-2, is one of the mechanisms by 
which neutrophils potentiate T cell responses.  
 
In addition, IL-2 is a recognised T cell survival factor: Kelly et al. demonstrated that this 
cytokine activates the protein kinase AKT, which protects T lymphocytes from apoptosis 
following growth factor withdrawal583. However, I have shown that despite the fact that 
mCRAMP downregulated IL-2 expression by CD4+ T cells cultured under Th17-driving 
conditions, it also increased their viability. This could be explained, in part, by the fact that 
Th17 lymphocytes are significant producers of IL-21, which has been shown to be a critical 
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7.4 Differential effects of mCRAMP on CD4+ T helper and CD8+cytotoxic 
T cells 
 
I have shown that mCRAMP enhances both CD4+ Th17 and CD8+ Tc17 differentiation. 
However, several differences were observed between the two cell types. For example, 
mCRAMP had no effect on the percentage of IL-17A single-positive CD4+ T cells in IL-17-
inducing cultures but significantly increased the frequency of CD8+ IL-17A+ IL-17F- T 
lymphocytes (in an AHR-dependent manner). This suggests that mCRAMP exerts differential 
effects on CD4+ and CD8+ T cells.  
 
Furthermore, mCRAMP increased the proportions of CD8+ IL-6R+ and IL-23R+ T lymphocytes 
but had no effect on the expression of these receptors in CD4+ T cells. This could indicate that 
CD8+ T cells cultured under Tc17-driving conditions are more sensitive to IL-6 and IL-23. 
However, this does not explain the requirement for TGFb and analysing these receptors by 
flow cytometry may not provide the most reliable readout: the quality of staining was highly 
variable and must therefore be confirmed by PCR.  
 
Differences were also observed in the proliferative capacity of CD4+ and CD8+ T cells following 
exposure to mCRAMP: CD8+ T lymphocytes treated with mCRAMP appeared to proliferate 
more than their untreated counterparts, whereas the peptide did not have any significant 
effect on the proliferation of CD4+ T cells. However, it is important to note that mCRAMP did 
not increase the proliferation of CD8+ RORgt+ T cells (and decreased that of CD8+ T-bet+ T 
lymphocytes), which suggests that the peptide exerts effects on another Tc subset.  
 
I have shown that mCRAMP skews both CD4+ and CD8+ T cell differentiation away from the 
Th1/Tc1 lineage, demonstrated by a significant decrease in T-bet expression and IFNg 
production. mCRAMP increased the viability of CD4+ IL-17+ T cells but did not decrease the 
percentage of dead CD4+ IFNg+ T lymphocytes. This lack of protection could be responsible 
for the decrease in the frequency of CD4+ IFNg+ T cells, which is normally seen in Th17 cultures 
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following exposure to mCRAMP. Conversely, while CD8+ IL-17+ T lymphocytes were also 
protected from death, so too were CD8+ IFNg+ T cells. T-bet-expressing CD8+ T cells that had 
been cultured in the presence of mCRAMP exhibited impaired proliferation compared to 
their untreated counterparts. This suggests that mCRAMP skews cytotoxic CD8+ T cell 
differentiation away from the Tc1 lineage by suppressing their proliferation (as opposed to 
failing to protect them from cell death).  
 
 
7.5 Neutrophils, cathelicidin and type-17 responses 
 
There is a limited amount of published data suggesting that neutrophils can promote the 
differentiation of IL-17-producing T lymphocytes. For example, Thewissen et al. found that 
neutrophils dose-dependently increase IL-17 production by CD4+ T cells in an in vitro-co-
culture model492. In addition, neutrophils have been shown to assist in the induction of Th17-
specific responses during vaccination against Mycobacterium tuberculosis493. Neutrophil 
cytoplasts, the remnants of NETs following expulsion of their nuclear DNA, also induce Th17 
differentiation in severe asthma233. However, the exact mechanisms through which they 
achieve this remain unknown.  
 
I have speculated that neutrophils are the cellular source of mCRAMP, which amplifies Th17 
and Tc17 differentiation following release in the lymph node during inflammation induced 
by HKST. My results suggest that mCRAMP requires TGFb in order to enhance the 
development of IL-17-producing CD4+ and CD8+ T lymphocytes. Both mouse and human 
neutrophils can produce TGFb195,242. It is therefore possible that neutrophils play a dual role 
in driving Th17 differentiation by simultaneously releasing mCRAMP and producing Th17-
polarizing cytokines.  
 
Furthermore, I have highlighted a potentially novel role for mCRAMP in promoting the 
survival of T lymphocytes. Neutrophils increase the survival of B cells and plasma cells via 
their expression of BAFF and APRIL, as well as preventing NK cells from undergoing 
activation-induced cell death in tumours585–587. However, there is little evidence suggesting 
that neutrophils protect T lymphocytes from apoptosis, although the inverse has been 
shown: production of GM-CSF by Th17 cells enhances neutrophil survival by increasing the 
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expression of anti-apoptotic BCL2 and preventing caspase activation588. My results therefore 
point towards an additional unique pathway by which neutrophils can modulate the 
development of the adaptive T cell response with some sophistication.  
 
 
7.6 Future directions 
 
There are several avenues of research that can be pursued to further explore the role of 
mCRAMP in the development of Th17 and Tc17 responses. For example, the IL-17-inducing 
differentiation protocol used throughout this study (IL-6, IL-23 and TGFb) has been shown to 
preferentially promote the expression of IL-17F398. I have shown that mCRAMP significantly 
increased the proportions of IL-17F single-positive and IL-17A/IL-17F co-expressing CD4+ T 
lymphocytes in a TGFb-dependent manner. Wanke et al. demonstrated that culturing CD4+ 
T lymphocytes with IL-1b leads to the development of predominately IL-17A-expressing 
cells398. It would therefore be interesting to establish whether mCRAMP exhibits similar 
effects on CD4+ (and CD8+) T cells when stimulated with IL-1b. This would help clarify whether 
the effects of mCRAMP described in this study are simply a by-product of the cell culture 
conditions used.  
 
Furthermore, it remains to be seen whether CD4+ Th17 and CD8+ Tc17 cells generated in the 
presence of mCRAMP in vitro are more or less pathogenic than those cultured without. My 
Nanostring data indicated that the expression of certain effector molecules, such as IL-2, 
CXCR3 and IL-22, which are known to identify a population of damaging, pro-inflammatory 
lymphocytes, was either downregulated or unaffected by mCRAMP479. Moreover, the 
upregulation of immunomodulatory genes, such as Ahr and Maf, suggest that they possess a 
more regulatory phenotype. To address this, one could perform a T cell transfer model of 
colitis, in which T cells cultured under IL-17-inducing conditions, with or without mCRAMP, 
are injected intraperitoneally into immunodeficient RAG-/- mice406. If IL-17+ lymphocytes 
generated in the presence of mCRAMP are indeed less pathogenic, I would hypothesise that 
animals receiving mCRAMP-treated cells would display delayed onset of colitis and 
potentially lower disease scores than controls.  
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mCRAMP also increased the expression of the aryl hydrocarbon receptor (AHR) in CD4+ T cells 
in Th17 cultures. The addition of an AHR antagonist abolished the increase in the percentage 
of CD4+ IL-17A+ IL-17F+ T cells but had no effect on the increase in IL-17F single-positive 
lymphocytes. This suggests that there are at least two pathways induced by mCRAMP, one 
of which is AHR-dependent and one which is AHR-independent. To further explore this 
possibility, single-cell transcriptome and signalling pathway analysis could be used to dissect 
the differences between IL17A and IL-17F single- or double-producing lymphocytes following 
exposure to mCRAMP.  
 
Finally, I have suggested that it is unlikely that mCRAMP is an endogenous AHR ligand due to 
the fact that other small, structurally different peptides (e.g. hBD2) also enhance Th17 
differentiation. However, further studies can be undertaken to confirm this. For example, 
bioinformatic and molecular modelling approaches could be employed to establish whether 
mCRAMP and/or LL-37 are capable of potentially interacting with the AHR ligand binding 
domain based on their sequence and structure.  
 
 
7.7 Targeting cathelicidin as a therapy for autoimmune disease 
 
To conclude, I have shown that mouse cathelicidin (mCRAMP) is a novel Th17 and Tc17 
differentiation enhancing factor and suggested that neutrophils may be the cellular source 
of this peptide in vivo during inflammation induced by HKST. IL-17-producing T cells have 
been heavily implicated in driving the pathogenesis of numerous chronic, pro-inflammatory 
and autoimmune disorders, including rheumatoid arthritis (RA) and psoriasis589. The 
presence of neutrophils and increased levels of cathelicidin have been correlated with many 
of these diseases. For example, neutrophils migrate to the articular cavity during the early 
stages of RA, where they become activated and prone to NETosis495. Elevated levels of LL-37, 
as well as IL-17, have been detected in the synovial fluid of RA patients365,590. Moreover, the 
abundant presence of neutrophils in psoriatic lesions serves as a typical histopathologic 
hallmark of disease591. Frohm et al. found that LL-37 is increased in the psoriatic epidermis, 
which acts as an autoantigen to induce Th17 and Tc17 activation284,334. Taken together, one 
might therefore suggest that cathelicidin could be considered as a potential therapeutic 
target.  
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However, cathelicidin is a host defence peptide that possesses anti-bacterial, anti-viral and 
anti-fungal activity, as well as immunomodulatory properties277,285. Blocking its function may 
well dampen the pathogenic, autoimmune type-17 response, however in doing so, patients 
could be rendered more susceptible to opportunistic infection. For example, individuals with 
morbus Kostmann syndrome, whose neutrophils are deficient for LL-37, are vulnerable to 
recurrent infections and often present with severe periodontal disease311. On the other hand, 
one could argue that the host defence system has evolved families of peptides and proteins 
with overlapping functions, which could be indicative of biological redundancy592,593. Other 
antimicrobial peptides, such as the defensins, could therefore potentially take over such a 
role in the absence of cathelicidin. Morbus Kostmann neutrophils display reduced 
concentrations of a-defensins, which could explain why this redundant protection is not 
observed in patients with this form of severe congenital neutropenia311.   
 
Conversely, using cathelicidin as a treatment for microbial infections may have unexpected 
consequences, such as increased Th17/Tc17 differentiation and uncontrolled IL-17 
production, which could lead to autoimmune inflammation. Specificity of targeting would 
therefore be of paramount importance to avoid any unintended side effects.  
 
Another important question that remains to be answered is whether or not blocking the 
amplification of Th17/Tc17 development by cathelicidin would ameliorate or worsen disease. 
I have shown that mCRAMP increases IL-17F production and the expression of 
immunoregulatory genes such as Ahr in CD4+ T cells cultured under Th17-driving conditions 
in vitro, which suggests that they may be less pathogenic than their untreated counterparts. 
It is therefore possible that suppressing the IL-17-boosting effects of cathelicidin could 
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